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SUMMARY
The aim of the study presented in this thesis was to 
characterise two herpes simplex virus type 1 (HSV-1) DNA
positive temperature sensitive (ts) mutants, tsl233 and 
tsl201, and the genes in which their mutations lie.
Electron microscopic examination of thin section 
preparations of tsl233-infected cells revealed that at the 
non-permissive temperature (NPT) the nuclei contained large 
numbers of partially-cored capsids. In contrast to wt 
virus-infected cells, no dense capsids or empty capsids 
were detected in the nuclei of tsl233-infected cells at the 
NPT. This result suggests that the mutant has a block in 
the assembly of full nucleocapsids. The effect of the 
tsl233 mutation could not be reversed when mutant virus- 
infected cells were shifted from the NPT to the permissive 
temperature (PT) in the presence of a protein synthesis 
inhibitor. Southern blot analysis of total and 
encapsidated DNA confirmed that tsl233 failed to 
encapsidate DNA at the NPT, and showed that the DNA 
synthesized by tsl233 at the NPT was in an endless state. 
This information suggested that most of the mutant DNA was 
in the form of high moleculer weight (mw) concatemers at 
the NPT. Previous work had located the ts mutation of 
tsl233 within EcoRI o. Complementation experiments between 
tsl233 and another HSV-1 mutant tsN20, which also had a 
lesion in HSV EcoRI o, showed that tsl233, belonged to a 
different cistron from fcsN20.
The polypeptide profile of tsl233-infected cells was
iv
similar to that of wt virus-infected cells. In contrast to 
the mutant tsl201, tsl233 processed the structural protein 
UL26 gene product normally and therefore, the gene in 
which tsl233 maps is not required for the processing of 
UL26 gene product.
Marker rescue experiments localised the lesion in 
tsl233 within a 150bp fragment which contains the 5' ends 
of two genes, UL32 and UL33 oriented in opposite 
directions. UL32 encodes a 64,000 mw polypeptide and UL33 
encodes a 14,000 mw polypeptide. The nucleotide sequence 
of a 392 base pair (bp) fragment from tsl233 and two ts* 
revertants for growth, isolated during this study, was 
determined. Sequence analysis revealed that tsl233 had a 
single bp change at residue 69210 of HSV-1 DNA nucleotide 
sequence within gene UL33. The alteration resulted in the 
substitution of an isoleucine by an asparagine codon. The 
nucleotide sequence of the revertants in this region was 
identical to that of wt virus DNA. The nature of the 
mutation in tsl233 is consistent with the use of UV-light 
as a mutagen.
Two oligopeptides, one representing a portion of the 
amino-terminus and the other representing a portion of the 
carboxy-terminus of UL33 amino acid sequence were 
synthesised and coupled either to bovine serum albumin 
(BSA) or to p-galactosidase and injected into rabbits. 
Antibodies against the peptides were detected by radio­
immunoassays. No virus specific bands were detected when 
the antisera were reacted with virus infected cell extracts 
on western blots, however, immunoprecipitation experiments
Vwith virus-infected cell extracts and the antisera gave a
very weak specific reaction with a polypeptide of the
apparent mw predicted for UL33 gene product.
Attempts to express the UL33 gene product in bacterial
expression vectors were unsuccessful. The UL33 gene
product was also placed under immediate-early (IE) gene
regulation. The IE promoter and upstream regulatory
iV\e
sequence of Vm w 175 were inserted in front of/UL33 gene and
the UL33 gene containing IE promoter recombined into TK
gene of tsK virus, which has a defect in Vm w 175. Although
novel bands were detected in cells infected with tsK
recombinant virus at the NPT, further work is required to
•foe
determine whether any of these bands are/uL33 gene product.
Tsl201, like tsl233 fails to encapsidate DNA at the 
NPT. Sequence analysis of the 673bp fragment in which the 
tsl201 lesion mapped revealed that the mutation lies 89bp 
upstream from the amino terminus of UL26. A single bp 
change was found at a position corresponding to residue 
50897 of HSV-1 11 syn* nucleotide sequence. This resulted 
in the substitutioijbf tyrosine with phenyl alanine codon. 
Both the ts* revertants analys ed retained the tsl201 
mutation and had second site reversions elsewhere within 
UL26 gene.
Three oligopeptides, one representing 9 amino acids at 
the amino terminus of UL26, one representing 12 amino acids 
from the second potential AUG, and one representing 14 
amino acids of the carboxy terminus were synthesised, 
coupled to 3-galactosidase and injected into rabbits. The
vi
antisera all contained oligopeptide antibodies that 
recognised the peptides which they were raised
against. However, in western blot experiments only 
antibodies against the carboxy terminus of UL26 gene 
product reacted with a specific virus band in virus 
infected cell extracts. In immunoprecipitation reactions, 
only antisera raised against the oligopeptide specific for 
the carboxy terminus of UL26 gene product gave a strong 
reaction with a virus specific band with an apparant mw of 
about 40,000. The ability of the oligopeptide to 
competitively inhibit immunoprecipitation of this band 
strongly suggested that antibodies raised against the 
carboxy terminus were specific to UL26 gene product. The 
processing of UL26 gene product was further investigated in 
tsl201 and wt virus-infected cells at the PT and the NPT 
using the antibody raised against the carboxy terminus. 
The oligopeptide antisera reacted only with the high mw 
forms of UL26 gene products suggesting that the conversion 
of the UL26 gene product to its lower mw forms was due to 
processing, probably proteolytic cleavage at the carboxy 
terminal end of the protein.
A adenine
APS ammonium persulphate
ATP adenosine-5'-triphosphate
BCIG (X-Gal) 5-bromo-4-chloro-3-indolyl-p-D-
galactoside 
BCdR 5-bromo-2'-deoxycytidine
BHK baby hamster kidney
bp base pair
BSA bovine serum albumin
BPB bromophenol blue
BUdR 5-bromo-2'-deoxyuridine
C cytosine
Ci Curies
cm centimeters
CMV cytomegalovirus
CO2 carbon dioxide
CPE cytopathic effect
cpm counts per minute
dATP deoxyadenosine triphosphate
dCTP deoxycytidine triphosphate
ddATP dideoxyadenosine triphosphate
ddCTP dideoxycytidine triphosphate
ddGTP dideoxyguanosine triphosphate
ddNTP dideoxynucleoside triphosphate
ddTTP dideoxythymidine triphosphate
dGTP deoxyguanosine triphosphate
DMSO dimethyl sulphoxide
DNA deoxyribonucleic acid
DNase deoxyribonuclease
Vlll
ds double strand
DDT dithiothreitol
dTTP deoxythymidine triphosphate
E early
EBV Epstein-Barr virus
E.coli Escherichia coli
EDTA sodium ethylen-diamine tetra-acetic acid
EHV equin e herpesvirus
em electron microscope
eop efficiency of plating
EtBr ethidium bromide
G guanine
%GC moles percent deoxyguanosine and deoxycytidine
h hour
HC1 hydrochloric acid
HFL human foetal lung
hpi hours post infection
HSV herpes simplex virus
HU human serum
HVS herpesvirus saimiri
ICP infected cell polypeptides
IE immediate early
IgG immunoglobulin G
IP immunoprecipitation
IPTG isopropyl-beta-D-thio-galactopyranoside
Kb kilobase
1 litre
L late
M molar
MI mock-infected
min minute
ml millilitre
mm millimetre
moi multiplicity of infection
mRNA messenger ribonucleic acid
mu map units
MW molecular weight
NA nitrous acid
ng nanograms
nm nanometer
NP40 nonidet p40
NPC nucleoprotein complex
NPT non permissive temperature
OD optical density
ori origin of replication
PAA phosphonoacetic acid
PAGE polyacrylamide gel electrophoresis
PBS phosphate buffer saline
pfu particle forming unit
pi post infection
PMSF phenylmethylsulphonyl fluoride.
PRV pseudorabies virus
PT permissive temperature
RNA ribonucleic acid
RNase ribonuclease
rev revertant
rpm revolutions per minute
RT room temperature
SDS sodium dodecyl sulphate
sec second
syn syncytial
syn* non-syncytial
T thymidine
TEMED N ,N ,N '- N '-tetramethylethylenediamine
TK thymidine kinase
TK+ thymidine kinase-positive
TK" thymidine kinase-negative
ts temperature sensitive
ts* wild-type for temperature sensitivity
Tween 20 polyoxyethylene sorbitan monolaurate 
UV ultra violet
V volts
v/v volume per volume
Vmw molecular weight of virus-induced protein
VP virion protein
VZV varicella zoster virus
wt wild type
w/v weight per volume
w/w weight per weight
pCi microcuries
pg microgram
pi microlitre
unit unit
% percentage
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1INTRODUCTION
The project presented in this thesis concerns the 
characterisation of two herpes simplex virus (HSV) 
temperature sensitive (ts) mutants, tsl233 and tsl201, and 
the genes in which the mutations lie. Tsl233 and tsl201 
both have structural defects and fail to package virus DNA 
at the non permissive temperature (NPT) . The aim of the 
following chapter is to provide a review on the biology of 
HSV, with particular emphasis on the assembly of the virion 
and encapsidation of HSV DNA.
1.1 DEFINITION AND CLASSIFICATION OF HERPESVIRUSES
Members of the family herpesviridae have been 
isolated from a wide variety of vertebrates and 
invertebrates (Roizman, 1982) . The virion is 150-200nm in 
diameter and contains a double stranded (ds) linear DNA 
genome which is enclosed within an icosahedral capsid. A 
lipid envelope surrounds the capsid (Wildy et al., 1960;
Furlong et al., 1972). Viruses of this family replicate in 
the nucleus, and acquire their envelopes by budding through 
the nuclear membrane (Morgan et al., 1954; Wildy et 
al,.1960; Darlington et al,. 1968).
The members of herpesviridae family have been 
classified into three sub-families, according to their 
biological and pathogenic properties which include host 
range, duration of the lytic cycle, cytopathology, and 
characteristics of the latent infection (Roizman et al. ,
21981; 1982; Matthews, 1982).
1.1.1 Sub-family alphaherpesvirinae
Although members of this sub-family have a narrow
host range in nature some, for example HSV, can infect a
variety of experimental animals and tissue culture cells.
In vitro, the reproductive cycle is short, usually less
than 24h, and results in destruction of susceptible cells.
Latency frequently occurs in the ganglia (Stevens and Cook,
1971; 1972). HSV type-1 (HSV-1) is the prototype virus of
this group. Primary virus infection can be inapparent, but
is sometimes manifested as acute gingivo-stomatitis.
Occasionally the virus causes ocular keratitis and, in very
rare cases, acute necrotising encephalitis. HSV-1 is
normally spread by direct contact or by droplets from an
infected person. HSV type 2 (HSV-2), another member of
this sub-family, which is closely related to HSV-1 causes
genital lesions in man and is venerally transmitted.
Exposure of neonates to this virus results in a
disseminated, frequently fatal infection. Although HSV-1
normally causes oral lesions and HSV-2 genital lesions, the
distinction is not absolute, since HSV-1 can cause genital
lesions, and likewise HSV-2 can infect other parts of the
body. Another human alphaherpesvirus is varicella zoster
usually
virus (VZV) which causes varicella or chicken pox A an 
childhood and zoster or shingles after latent virus 
reactivation in adults. Other members include pseudorabies 
virus (PRV) which causes Aujeszky's disease in pigs and B 
virus, a monkey virus which causes a fatal illness in
3humans.
1.1.2 Sub-family betaherpesvirinae
Members of this sub-family are known as 
cytomegaloviruses and are characterised by restricted host 
range in vivo and in vitro. In tissue culture the 
infection progresses slowly and infected cells become 
enlarged. Cell types responsible for harbouring latent 
viruses are unknown. The prototype virus is the human 
cytomegalovirus (HCMV). Although most infections with HCMV 
are asymptomatic, HCMV is a major cause of congenital 
disease. The virus can also cause severe problems in 
immunocompromised individuals, principally those undergoing 
transplant surgery {Alford and Britt, 1985), and more 
recently those with AIDS.
1.1.3 Sub-family gammaherpesvirinae
Members of this group are lymphoproliferative 
viruses. They normally exhibit a narrow host range in 
vivo. In vitro, viruses can infect lymphoblastoid cells, 
which are usually non-permissive or semi-permissive for 
virus replication. Viruses are generally specific for 
either T or B lymphocytes but some, for example herpes 
virus sylvilagis can infect both types. Although viruses 
usually have restricted growth in lymphoblastoid cells, 
many viruses in this sub-family, will productively infect 
fibroblasts. Epstein-Barr Virus (EBV) is the prototype of 
this group and has been associated with Burkitt's lymphoma. 
This virus is the causative agent of infectious
mononucleosis. Other members of this group include Gallid 
herpesvirus 1 (MDV) which causes Marek’s disease in 
chickens, and herpesvirus saimiri (HVS) which infects 
primates.
Classification into various families is somewhat 
arbitrary and subjective, and as a consequence some 
herpesviruses have been incorrectly assigned, for example 
MDV. In general, however, the classification system has 
proved to be reasonably satisfactory.
1.2 THE STRUCTURE OF HERPESVIRUS GENOME
The HSV-1 genome is a linear ds DNA molecule 
(Becker, et al. ,1968; Graham et al.,1972) with a molecular 
weight (mw) of about 95-100X106 (Kieff, et al. , 1971). It 
has a high overall guanine and cytosine (G+C) content of 
68.3%. Different regions of the genome, however, vary in 
their G+C content, most notably the short repeat region 
which has a very high G+C value of 79.5% (Davison and 
Wilkie, 1981; Murchie and McGeoch, 1982; McGeoch et al., 
1986) .
The HSV genome can be divided into two covalently 
linked regions, designated L (long), and S (short), 
representing 77% and 23% of the virus DNA respectively. 
Each component consists of unique sequences (as shown in 
fig 1A) , flanked by inverted repeat sequences (Sheldrick 
and Berthelot, 1974; Wadsworth et al., 1975). A direct 
repeat known as the a sequence is present at the genomic 
termini and also in an inverted orientation at the L-S 
junction (Grafstrom et al., 1974; 1975; Wadsworth et al.,
A)
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A) HSV-1 genome arrangement.
The genome is divided into two regions. The long 
region (L) consists of a long unique sequence (Ul) 
flanked by a terminal sequence (TRl) which is repeated 
internally in an inverted orientation (IRl ) . The short 
(S) region consists of a short unique sequence (Us) 
flanked by a terminal sequence (TRs ) whitrh is repeated 
internally (IRs) in an inverted orientation. The 
direct repeat at the genomic termini is known as the a 
sequence. The remaining sequence within TRl/IRl and 
TRs/IRs are referred to as b/b' and c/c' respectively.
B) Genome isomerisation
P : prototype orientation
Is : inversion of the short region
IL : inversion of the long region
Isl : inversion of the short and long regions
1976; Wagner and Summer, 1978; Davison and Wilkie, 1981; 
Mocarski and Roizman, 1981). As a consequence of the 
genome arrangement of HSV, the L and S components can 
invert relative to each other (Fig. IB). Thus, DNA 
extracted from virions or from cells infected with wt virus 
consists of four equimolar populations differing with 
respect to the orientation of L and S unique regions 
(Sheldrick and Berthelot, 1974; Hayward et al., 1975;
Clements et al., 1976; Delius and Clements, 1976).
1.2.1 Gene organisation in HSV-1 genome
The complete sequence of HSV-1 strain 17 genome 
contains 152,260 residues in each strand and specifies at 
least 72 genes encoding 70 distinct proteins (McGeoch et 
al., 1985; 1986; 1988a; 1988b). From the sequence analysis 
of Ul it was concluded that 89% of the sequence,
representing 56 genes, encoded for proteins (fig. 2). 
Thus, genes are compactly arranged within Ul . Overlaps of 
coding sequences in UL occur in two major clusters at genes 
UL5 to UL14, and UL30 to UL33. In many cases the 
transcriptional control elements overlap the polypeptide 
coding regions of the adjacent gene. The largest non­
protein coding region of 754bp lies between genes UL29 and 
UL 30 and contains orii. . The overall G+C content of Ul is 
67% (McGeoch et al., 1988).
The Us region, which is 12,979 bp in length,
contains 12 genes compactly arranged (McGeoch et al., 1985; 
Rixon and McGeoch, 1985) . Although all the genes have 
separate promoters, most of the genes share 3' termination
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Figure 2
Layout of genes in the genome of HSV-1.
The HSV-1 genome is shown in four successive lines, with 
unique regions represented by solid lines and major repeat 
elements as open boxes. The lower scale represents 
kilobases, numbered from the left terminus, and the upper 
scale represents fractional map units. The sizes and 
orientations of proposed functional ORFs are shown by 
arrows. Overlaps of adjacent, similarly oriented ORFs are 
not shown explicitly. Locations of proposed transcription 
polyadenylation sites are indicated as short vertical bars. 
Locations of origins of DNA replication are shown as X. In 
the Ul region, on the first three lines, genes UL1 to UL56 
are labelled. In the Us region, on the bottom line, genes 
US1 to US12 are labelled. The locations of introns in the 
coding regions of gene UL15 and the two copies (TRl and 
IRl ) of the IE110 gene are indicated (taken from McGeoch et 
al., 1988).
6sites. In fact all but 2 mRNAs belong to one of four 3* 
coterminal families. Only genes Us 10 and Us 11 have 
overlapping coding sequences but in different reading 
frames. The promoter of Us 10, however, lies within Us 11 
coding sequences. The overall G+C is 64%, which is 
considerably lower than the G+C content of adjacent DNA 
(IRs/TRs) (Rixon and McGeoch, 1984; McGeoch et al., 1985; 
McGeoch et al., 1988).
The short repeat sequence (TRs/IRs), which is 6,633 
bp in length, contains only one gene, the immediate early 
(IE) gene 3 which encodes IE175. The a sequence is present 
at the 3' end of this gene, while at 5' end of IE175 map 
sequences representing an origin of replication (oris) and 
the promoter of IE68 (gene Usl) and IE12 (gene Us 12). The 
coding sequences of the latter two genes lie within 
Us (Murchie and McGeoch, 1982; McGeoch et al., 1985; 1986).
The long repeat region in HSV-1 17syn* , which has 
a G+C content of 71.6% and spans some 9,215 bp, contains a 
spliced gene encoding IE110 (Perry et al., 1986; Perry and 
McGeoch, 1988). In addition, the IRl/TRl sequence contains 
six families of tandemly reiterated sequences, ranging from 
3 to 55bp, present in different regions of the repeat, and 
the a sequence. Two open reading frames (ORF) have also 
been described in the long repeat of other HSV-1 strains. 
The first ORF, which is proposed to encode ICP 34.5, is 
situated upstream of 5' end of IE110 in strain F (Chou and 
Roizman, 1986; Ackermann et al., 1986). In HSV-1 strain 17 
syn* this region contains multiple stop codons. The other 
ORF lies at the 3 ’ end of IE110 gene and overlaps IE110
7coding sequences. Recently it has been shown that this 
region is transcribed in latently infected neurons. It has 
not been shown, however, that these latency-associated 
transcripts (LAT), encode proteins (Stevens et al. , 1987; 
Rock et al., 1987; Spivack and Fraser, 1987; Wagner et 
al.,1988) .
1.3 THE STRUCTURE OF HERPESVIRION
1.3.1 Morphology
The herpesvirion is generally considered to be 
composed of four complex concentric substructures, referred 
to as the core, capsid, tegument, and envelope (fig. 3).
1.3.1.a The core
This is the central component of the virion and is 
thought to consist of a cylindrical protein plug around 
which the viral DNA is tightly spooled in the form of a 
torus (Furlong et al., 1972). Studies on infectious 
rhinotracheitis virus, MDV, and HCMV suggest that the core 
is attached to the inner surface of the capsid (Nazerian, 
1974; Haguenau and Michelson-Fiske 1975).
1.3.1.b The capsid
This structure has a diameter of approximately 
120nm, and it is calculated to be composed of 150 hexameric 
and 12 pentameric units in the form of an icosahedron 
(Wildy et al., 1960; Furlong, 1978). Until recently it 
was thought that HSV had a single icosahedral capsid shell, 
however, data obtained from computer analysis of low dose

Figure 3
Cryo-electron micrograph of HSV-1 virion.
The virion is suspended in vitreous ice. Visible in the 
enveloped particle is the nucleocapsid (long arrow), 
tegument, and envelope with associated glycoprotein spikes 
(short arrow) . The micrograph was kindly provided by Dr. 
Frazer J. Rixon.
cryo-electron images of ice embedded capsids revealed that 
full capsids structure are organised into an outer, 
intermediate and inner structural layers. The outer layer 
is arranged according to T=16 icosahedral symmetry. This 
structure has a diameter of approximately 120nm and is 
composed of 150 hexameric and 12 pentameric units (Wildy et 
al. , 1960). Adajacent capsomeres are connected by a mass
density (Schrag et al., 1989), previously referred to as
intercapsomeric fibrils (Palmer et al., 1975; Vernon et
al. , 1974). The intermediate layer lies on a T=4
icosahedral lattice (Schrag et al., 1989). The inner most 
layer contains the genomic DNA, which is connected to the 
external environment by channels through the outer and 
intermediate layers which coincide along their icosahedral 
two-fold axis.
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1.3.1.C The tegument
This is defined as an amorphous structure which 
lies between the capsid and the envelope (Wildy et al. , 
1960; Morgan et al., 1968; Roizman and Furlong, 1974). The 
thickness of the tegument varies between different 
herpesviruses and is genetically determined by the virus 
(McCombs et al., 1971). According to Vernon et al. (1982), 
the tegument is attached to the vertices of the capsid and 
the inner surface of the envelope, and may have a function 
in envelopment of the virus particle. It has been 
suggested that the tegument of EHV-1 virions is composed of 
granular particles of varying size which form a shell 
surrounding the capsid. This observation implies that the
9tegument might possess some form of structural integrity. 
In addition it has been concluded that this structure 
probably has a high water content (Vernon et al., 1982).
1.3.1.d The envelope
This is a trilaminar membrane which is thought to 
be derived from the inner nuclear membrane, acquired during 
budding of the virus particles through the nuclear membrane 
(Darlington and Moss, 1968). The envelope tightly adheres 
to the tegument and contain spikes 8-10nm long spaced 5nm 
apart over the surface (Wildy et al., 1960). In a recent 
electron microscopic study of disrupted virus particles, 
using monoclonal antibodies to identify individual 
glycoproteins, it was shown that glycoprotein gB, gC, and 
gD each form separate spikes that are different in size, 
morphology and distribution in the envelope (Stannard et 
al., 1987) .
1.4 EARLY STAGES OF HSV INFECTION
The initial stages of the lytic cycle can be
divided into three parts: adsorption of the virus particle
to the cell, penetration of the capsid into the cytoplasm, 
and release of viral DNA from the capsid (uncoating).
1.4.1 Adsorption
Attachment of the HSV particle to the cell surface
is a rapid process (Hochberg and Becker,1968) , and occurs
over a wide range of temperatures (Farnam and Newton,
1959). The results of early studies by Hochberg and Becker
(1968) showed that heparin, a negatively charged 
polysaccharide, prevented the adsorption of the virus to 
cells and released the virus already attached to the cell 
surface. On the basis of these experiments it was 
suggested that the first step in virus adsorption involved 
an electrostatic interaction. These results were supported 
and extended by the recent findings of WuDunn and Spear 
(1989), who demonstrated that virions could bind to heparin 
in affinity chromatography experiments, and that removal of 
heparan sulphate from cells reduced the ability of the cell 
to bind virus. It was concluded that both HSV-1, and HSV-2
normally initiate infection by binding first to heparan
sulfate on the cell surface, which serves as a receptor for 
HSV (WuDunn and Spear, 1989).
The viral proteins responsible for the attachment 
of the virions to receptors on cell surfaces have not yet 
been identified, but several envelope viral
glycoproteins have been implicated in the process of virus 
attachment. It is thought that gB, an essential
glycoprotein (Sarmiento et al., 1979; Little et al., 1981; 
Deluca et al. , 1982), may play a role in adsorption since
virosomes, which are lipid vesicles enriched with HSV-1 
glycoproteins, bind to cells more efficiently when gB is 
present than when it is absent (Johnson et al., 1984) . 
However, the finding that gB deficient virions were able to 
bind to cells, has clearly shown that gB is not essential 
for attachment of virus to cells (Cai et al., 1987, 1988a), 
but is required in a later step in virus entry. Polyclonal 
and monoclonal antibodies directed against gC and gD
inhibit adsorption of HSV-1 to cells, while high
concentration of of IgG and Fc fragment can partially
inhibit attachment of the virus to cells, suggesting that 
gC, gD, and possibly gE, which binds the Fc portion of IgG 
(Bauke and Spear,1979), may also play a role in virus 
adsorption (Para et al., 1982; Fuller and Spear, 1985).
Since gC and gE are not essential for virus infectivity in 
tissue culture, those glycoprotens like gB, are not 
absolutely required for virus attachment (Ruychan et al. , 
1979; Holland et al. , 1983; 1984; Longnecker and Roizman,
1986). A recent study revealed that gD deficient mutants 
were able to bind to cells, but unable to initiate
synthesis of viral early polypeptides (Ligas and Johnson,
1988) . These results suggest that gD is also not essential 
for virus adsorption. From the the work mentioned above 
together with the finding that gD, gC, and gB form separate 
spikes on the envelope (Stannard et al. , 1987), it seems
likely that envelope glycoproteins may individually 
interact with cell receptors for HSV. Recent results 
obtained by Campadelli-Fiume et al. (1988) and Johnson and 
Spear (1989), showing that HSV adsorbed to gD expressing 
cell lines but was unable to be internalised by fusion of 
virion envelope with plasma membrane, has led to the 
suggestion that gD may recognise a cell receptor, different 
from cell surface heparan sulphate. Other studies on cell 
surface receptors have suggested that HSV-1 and HSV-2 
recognise different cell surface receptors (Vahlne et al., 
1979; Addison et al.,1984).
1.4.2 Penetration
Penetration of nucleocapsids into cell occurs 
rapidly after the virus particle binds to the receptors on 
the surface of the cell. Electron microscopic studies 
indicate that the entry of the virus into the cell occurs 
either by viropexis (phagocytosis) (Dales and Silverberg, 
1969; Hummeler et al. , 1969), or by fusion of the viral
envelope with cell membrane (Morgan et al. , 1968; Abodeely 
et al., 1970). Evidence presented so far supports the 
fusion model of virus penetration. In particular, the work 
by Para et al. (1980; 1982), showing that gE from the
infecting virions was incorporated into the surface 
membrane of infected cells immediately after vi?ral 
penetration, is indicative of fusion between the virion 
envelope and cell surface membrane.
Several lines of research have implicated gB in
virus penetration. Studies using gB-null mutants or ts
mutants of gB have shown that mutants lacking gB or
containing abberrant gB bound as well as wt virus to the
plasma membrane but were unable to penetrate the cell
surface (Sarm.iento et al. , 1979; Little et al. , 1981; Cai
et al. , 1988). Other work has shown that monoclonal
antibodies, which recognise two major antigenic sites
within the external domain of gB, neutralized virus
adsorbed to cell monolayers (Highlander et al., 1988).
These results suggest that gB is important at a stage after
been
virus attachment. Glycoprotein B has also/shown to affect 
the rate of entry, since mutants with lesions in gB 
penetrated cells more rapidly than wt virus. Furthermore a
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syn lesion has been identified within gB (Deluca et al. , 
1981; 1982; Bond et al., 1982; Bzik et al. , 1984; Cai et
al., 1988). All of these results indicate that gB is 
directly involved in virus penetration.
Although gC is non essential, Deluca et al. (1982) 
reported that recombinants of K0SXtsB5, which made little 
or no g C , entered cells at an accelerated rate at the PT in 
comparison to viruses which contained gC. It has also been 
demonstrated that virus strains which lacked gC were able 
to penetrate restrictive cell line X C , whereas strains 
which had a high gC content failed to do so. This led to 
the suggestion that gC may influence penetration of virus 
by negatively modulating the gB-promoted fusion between 
virion and host cell membranes, or by interacting with 
other glycoproteins such as gD or gH involved in fusion of 
membranes (Epstein/et al.,1984; Machuca et al., 1987).
Recent work by Fuller and Spear (1987) and 
Highlander et al, (1987) suggested that gD has a role in 
virus penetration since gD-specific monoclonal antibodies 
(mAB) neutralised in the absence of complement HSV-1 virus 
bound to cells. The subsequent finding that gD deficient 
virions were able to bind to tissue culture cells as well 
as virion containing gD supports this idea (Ligas and 
Johnson, 1988) .
The gene product of UL25, which does not appear to 
be a glycoprotein, is also important for virus penetration, 
since a mutant of HSV-1, tsl204, which has a lesion in gene 
UL25, binds to cells at the NPT, but fails to penetrate the 
cell membrane (Addison et al., 1984).
1.4.3 Uncoating of the viral DNA
The step which follows penetration of herpesvirions
into the cell is the release of the viral DNA from the
capsids. Studies have indicated that viral DNA is rapidly
transported to the sites of replication in the nucleus
within 15-20 min post infection (Hummeler et al., 1969;
Miyamoto and Morgan, 1971; Wahren et al., 1984). Early
work showed that capsids undergo disintegration (Morgan et
al. , 1968). The transport of viral DNA from the cytoplasm
to the nuclei of infected cells was unaffected by RNA and
protein synthesis inhibitors, suggesting that the viral DNA
is released from the capsid by a pre-existing cellular
enzyme or virion protein (Hochberg and Becker, 1968).
Analysis of the HSV-1 ts mutant, tsBl which failed to
uncoat at the NPT, has provided further clues about the
release of DNA from the capsid (Knipe et al., 1981;
iVie.
Batterson et al. , 1983). The proximity ofAmutant in the
cytoplasm to nuclear pores suggested that the viral DNA 
enters the nucleus by an active cellular mechanism which 
probably involves host cell microfilaments (Lycke et al. ,
1984) .
1.5 EFFECT OF HSV INFECTION ON CELLULAR MACROMOLECULAR
SYNTHESIS
Infection of cells with HSV results in the 
inhibition of host DNA, RNA and protein synthesis. 
Inhibition of protein synthesis is probably a multistep 
process, resulting from the reduction in mRNA levels and 
disaggregation of polyribosomes (Sydiskis and Roizman,
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1967; Wagner and Roizman, 1969; Nishioka and Silverstein, 
1977; 1978; Silverstein and Engelhardt, 1979; Bastow et
al., 1986; Strom and Frenkel, 1987). Inhibition of 
cellular protein synthesis during HSV infection has been 
divided into two stages referred to as "early" and 
"delayed" shut-off.
Early shut-off of protein synthesis is thought to 
be mediated by the virion protein UL41 (Fenwick and Walker, 
1978; Peirera et al. , 1977; Fenwick et al. , 1979; Fenwick
and McMenamin, 1984; Schek and Bachenheimer, 1985; Kwong et 
al. , 1988). The isolation of viable mutants in tissue
culture, defective in virion host shut-off (vhs), has 
provided evidence that this function is not absolutely 
essential for virus replication. It is, nevertheless, 
important for optimal growth since the mutant virus did not 
replicate as well as wt virus (Read and Frenkel, 1983; 
Kwong et al. , 1988). Recently it has been shown that vhs
function decreases the half lives of both host and viral 
mRNA, and therefore may have a dual role in viral 
infection, inhibiting host gene expression and enabling the 
rapid transition of viral gene expression (Strom and 
Frenkel, 1987; Oroskar and Read, 1989). Evidence obtained 
by Kwong and Frenkel (1988) suggests that a single virion 
protein, is responsible for early shut-off of protein 
synthesis since a population of viruses which had the 
virion host shut-off (vhs) mutation in UL41 replaced by wt 
sequences regained levels of shut-off similar to wt virus. 
This finding supports the idea that disaggregation of 
polyribosomes which occures in the absence of viral protein
synthesis and mRNA degradation (Nishioka and Silverstein, 
1977; 1978; Hill et al., 1983), are carried out by the same 
protein. The available evidence favours the idea that UL41 
gene product (vhs) either activates a preexisting host 
nuclease or increases susceptibility of mRNAs to nuclease 
attack (Kwong et al., 1988). The delayed shut-off of host 
protein synthesis requires the expression of an early or 
late viral gene and reduces further the level of host 
protein synthesis (Fenwick and Clarke, 1982; Hill et al., 
1983; Read and Frenkel, 1983; Schek and Bachenheimer,
1985). Although it has been suggested that an additional 
viral function is required for complete host protein 
inhibition it is possible that the vhs protein is involved 
in delayed or complete host shut-off, since the findings of 
Kwong and Frenkel (1987) and Oroskar and Read (1987; 1989) 
indicate that mutations in UL41 protein cause an increase 
in the stability of not only IE mRNA, but also early and 
late RNAs in absence of protein synthesis inhibitors. 
There is, however, in cells infected with vhs mutants some 
inhibition of host proteins although it is delayed and 
incomplete suggesting another protein may be involved in 
delayed host shut-off (Read and Frankel, 1983). Stenberg
and Pizer (1982) have evidence that an IE gene function is 
responsible for the decrease in cellular RNA synthesis 
which follows HSV infection, and this result could account 
for the findings observed by Read and Frenkel (1983).
1.6 HSV TRANSCRIPTION
HSV DNA is transcribed in the infected cell nucleus
(Wagner and Roizman, 1969). The observation that all 
stages of HSV RNA synthesis are sensitive to a-amanitin 
inhibition has led to the suggestion that HSV transcription 
is carried out by RNA polymerase II (Alwine et al. , 1974;
Ben Zeev et al., 1976; Costanzo et al., 1977). This 
conclusion is supported by the finding that naked DNA is 
infectious (Graham et al., 1973). Since, however, only IE 
mRNA is synthesised in the absence of de novo viral protein 
synthesis (Honess and Roizman, 1973; 1974; Clements et al., 
1977; Watson et al., 1979), it is clear that viral proteins 
are important for transcription of HSV mRNA .
Since HSV utilizes much of the cellular 
transcription machinery it is therefore not surprising
that many of the transcriptional signals are identical to 
those of eukaryotic genes and that transcripts are 
processed in the same way as most cellular mRNAs. A 
polyadenylation consensus signal "AATAAA" in the DNA, 
specifying the 3'-termini of transcripts, is essential for 
the correct processing of viral mRNAs (McKnight, 1980; Cole 
and Santangelo, 1983), and a consensus "G-T” rich signal 
"5-YGTGTTYY-3'" is thought to be necessary for efficient 
formation of the mRNA 3'-terminus. This signal is usually 
located approximately 30bp downstream from the 
polyadenylation signal (Taya et al. , 1982; McLauchlan et
al., 1983; Whitton et al. , 1983; McLauchlan et al. , 1985;
Cole and Stacy, 1985). The "TATA-box" homology, which is 
thought to be important for accurate initiation of 
transcription and is located close to the 5'-termini of 
most eukaryotic genes (Gannon et al., 1979), is also
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present close to the 5' end of HSV genes (McGeoch et al. , 
1985; 1986). Like most cellular mRNAs, HSV transcripts are 
capped at their 5' end. This modification is thought to be 
necessary both for efficient translation (Shatkin, 1976), 
and protection of the mRNA from nucleases and phosphatases 
(Moss et al., 1977). Methylation of HSV transcripts at 
internal adenine residues has been reported (Bartkoski and 
Roizman, 1976; Moss et al., 1977).
In comparison to eukaryotic transcripts, spliced 
mRNAs are not a common feature in HSV. Only five of the 72 
open reading frames have spliced mRNAs. IE 68 (Usl) and IE 
12 (Us 12) genes, which share a common 5'-non-coding region 
in IRs but have unique polypeptide coding sequences within 
Us, have an intron within the common 5'-non-coding region 
(Watson et al. , 1981; Murchie and McGeoch, 1982; Rixon and 
Clements, 1982; Watson and Vaude-Woude, 1982). In contrast 
to IE 68, and IE 12 genes, IE 110, which is a diploid gene, 
contains two introns in the coding sequence of the gene 
(Perry et al., 1986). The only other gene in which introns 
have been identified is UL15. This gene is thought to 
encode a late viral protein (Costa et al., 1985; McGeoch et 
al., 1988) .
1.6.1 The regulation of HSV transcription
Viral mRNAs and proteins are temporally regulated 
and expressed as a sequential cascade which is differentia 
ted into three broad classes defined as IE or a, early (E 
or 0), and late (L or X ) (Honess and Roizman, 1974; 1975; 
Swanstrom and Wagner, 197 4; Clements et al., 1977). Recent
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work on IE gene regulation has provided evidence that the
cascade pattern of HSV protein expression is more complex
than originally proposed by Honess and Roizman (1974;
the
1975), who based their work on kinetic studies andieffect 
of metabolic inhibitors on viral protein synthesis.
1.6.2 IE genes, their expression and regulation
IE mRNA species are the first class of transcripts
to be detected during a normal viral infection. These
mRNAs are made even in the presence of a protein synthesis
inhibitor, such as cycloheximide or anisomycin, added at
the time of infection, and therefore do not require de novo
viral protein synthesis for abundant expression (Honess and
Roizman, 1974; Clements et al., 1977; 1979; Anderson et
al., 1980; Harris-Hamilton and Bachenheimer, 1985). Five
major IE polypeptides, Vmw175, 110, 68, 63, 12 are
synthesised when the protein synthesis block is removed
from viral-infected cells (Clements et al. , 1977; Preston,
1979a; 1979b; Watson et al., 1979; 1981; Anderson et al. ,
1 9 8 0 ) . All IE polypeptides except Vmw12 (IE5) are
1We
phosphorylated, and transported into/\ nucleus (Marsden et 
al., 1976; 1978; Pereira et al., 1977), and with the
exception of IE12, all bind to DNA in vitro (Hay and Hay, 
1980) .
Analyses of IE gene promoter and regulatory regions 
have revealed a number of different upstream elements. 
Important transcriptional elements were identified in IE 
genes 1 (VmwII O), 2 (Vmw63), 3 (Vmw175), 4 (Vmw68), 5
(Vmw12) . These included: (I) TATA box homology located
approximately 30 bp upstream from the mRNA start site, (II) 
A proximal promoter region, located between -37 to -108bp, 
which is important for transcription initiation since the 
deletion of this region abolishes transcription of IE genes 
(Mackem and Roizman, 1982a; 1982b; Cordingley et al. ,
1983). Within these sequences is a GC-rich region which 
may be involved in interactions with the cellular 
transcription factor Spl (Jones and Tjian, 1985). (Ill) 
Elements containing regulatory signals resembling enhancer­
like sequence. These elements can function in either 
orientation from the promoter and at a distance up to 1300 
bp (Cordingley et al., 1983; Lang et al., 1984; Preston and 
Tannahill, 1984; Bzik and Preston, 1986). (IV) A 
consensus sequence TAATGARAT (R is a purine), located far 
upstream within all IE gene promoters (Mackem and Roizman, 
1982b; Cordingley et al., 1983; Whitton et al. , 1983;
Whiton and Clements, 1984; Gaffney et al., 1985).
1.6.3 IE transactivation
IE transcription is stimulated by UL48 gene product 
(VMw 65, VP16, also known as trans-inducing factor or 
"TIF"), present as a component of the HSV-1 infecting 
virion (Post et al., 1981; Batterson and Roizman, 1983;
Campbell et al., 1984; Preston et al., 1984; Pellett et
al., 1985). Transactivation of IE transcription by Vmw65 
depends onacis-acting regulatory element which contains the 
consensus TAATGARAT sequence ( Kristie and Roizman, 1984; 
Preston et al., 1984; Gaffney et al., 1985, Bzik and
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Preston, 1986; O'Hare and Hayward, 1987). Although Vmw65 
itself does not bind to DNA (Marsden et al., 1987), it has 
been recently shown that Vmw65 associates with cellular 
proteins, including nuclear factor III octamer-binding 
protein, to form an IE complex which binds to the 
regulatory TAATGARAT sequence (McKnight et al., 1987; 
Kristie and Roizman, 1987; Ace et al. , 1988; Gerster and
Roeder, 1988; O'Hare and Goding, 1988; Preston et al.,
1988). The analysis of deletion and insertion mutants has
revealed the existence of at least two functional separable
domains in Vmw65. A domain, localised within the amino-
terminal 411 amino acids, is sufficient for binding to the
cellular transcription factor (Triezenberg et al. , 1988a;
1988b), and a carboxy terminal region, unusually rich in
as
acidic amino acids, also known/ithe "acid tail" is required 
for stimulation of transcription (Sadow ski et al., 1988). 
This acid tail is probably analogous to the activating 
domains of the yeast gene activator protein GAL4, GCN4 
(Ptashne, 1986; Sadowski et al., 1988; Triezenberg et al., 
1988a). Characterisation of the HSV-1 Vmw65 insertional 
mutant, inl814, defective in transinduction of IE gene 
transcription, revealed that transinduction of IE 
transcription by V m w 6 5  was not essential for virus growth 
at high moi, but was important at low moi (Ace et al. ,
1989) . Although the precise mechanism of IE 
transactivation in HSV is still obscure, it has been 
suggested that the interaction between the yeast activator 
(GAL4) or the mammalian activator protein (ATF) and the 
mammalian TATA factor (TFIID) with the adenovirus E4
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promoter facilitate promoter recognition by the RNA 
polymerase II and other initation factors (Horikoshi et 
al., 1988a; 1988b).
1.6.4 Negative regulation of IE gene expression
It is well known that the synthesis of IE 
polypeptides decreases as the virus infection proceeds. 
Observations obtained from the analysis of ts and deletion 
mutants of HSV-1 in Vmw175 suggest that IE synthesis is 
autoregulated by Vmw175 at the level of transcription 
(Preston, 1979a; 1979b; Dixon and Schaffer, 1980; Deluca et 
al. , 1985) since the mutants overproduced IE transcripts,
and failed to synthesize E and L transcription. This 
conclusion was supported by results of transient-expression 
assays with cloned wt Vmw175 gene. These experiments 
showed that E and L viral genes transcription was 
stimulated by Vmw175 whereas the expression of a gene under 
the control of Vmw.175 promoter was repressed (Everett, 
1984; Gelman and Silverstein, 1985; Deluca and Schaffer, 
1985; O'Hare and Hayward, 1985a; 1985b; 1987; Mavromara-
Nazos et al., 1986a). There is good evidence that binding 
of V m w 175 to the consensus sequence 5' ATCGTCNNNNYCGRC 3' 
at the capsite of Vmw175 is important for autoregulation of 
VMw 175 (Beard et al., 1986; Gelman and Silverstein, 1987a; 
Deluca and Schaffer, 1988; Paterson and Everett, 1988; 
Smith et al., 1989). This consensus sequence is also 
present in Vmw.110 promoter, but further downstream of the 
mRNA start site (Faber and Wilcox, 1986; Kristie and 
Roizman, 1986a; 1986b; Muller, 1987; Michael et al. , 1988)
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and it is not known whether this sequence is required for 
repression of Vm w IIO gene expression. Other IE genes do 
not contain this binding site and thus it is unclear how 
those IE genes are repressed.
1.6.5 Early gene expression and regulation
Early genes are transcribed after IE genes, and are 
not dependent on viral synthesis for maximal expression 
(Honess and Roizman,1974; 1975). Early proteins include
enzymes required for viral DNA synthesis and some 
structural proteins.
Early genes have been divided into two classes pi f
and P2 , on the basis of their synthesis in the presence of
different amino acid analogues and the analysis of 
polypeptides induced by tsK at the NPT (Pereira et al. ,
1977; Preston, 1979). IE proteins are required for the
transcription of early mRNA (Wagner et al., 1972; Swanstrom 
et al., 1975; Clements et al., 1977).
1.6.6 Early gene transactivation
A varity of approaches, including mutant analysis 
and transient expression assays, have been used to identify
the transactivating IE genes. It has been shown that
Vmw175 is essential for the regulation and transcription of 
E and L genes. The first experiments implicating Vmw175 in 
transactivation were based on the characterisation of the 
HSV-1 mutant tsK with a lesion in Vmw175 (Stow et al. ,
1978; Davison et al., 1984). This mutant over produced IE 
transcripts, and failed to synthesize E gene transcripts at
the NPT. The ts phenotype could be reversed by downshift 
of tsK infected-cells from the NPT to the PT. When cells 
were transferred back to the NPT, IE transcripts 
accumulated and the amount of E mRNA declined. These 
experiments suggested that functional Vmw175 was required 
throughout infection for the transition from IE to E 
transcription (Preston, 1979a; 1979b; Watson and Clements, 
1980) . Similar results were obtained with deletion and 
other ts mutants in Vmw175 (Dixon and Schaffer, 1980; 
Deluca et al. , 1985). Experiments using cells transformed 
with either IE or E genes confirmed that Vmw175 is 
important for transactivation of E genes (Kit et al., 1978; 
Sandri-Goldin et al. , 1983; Davidson and Stow, 1985).
Transient expression systems have been useful for 
identifying other IE genes, in particular VmwIIO, that 
affect gene expression (Everett, 1983; 1984a; 1984b; O'Hare 
and Hayward, 1985a; 1985b; Gelman and Silverstein, 1985;
1986; Quinlan and Knipe, 1985; Mavromara-Nazos et al., 
1986b). Using this approach, it was shown that V mw I I O  
transactivates all three classes of viral genes and 
interactssynergistically with Vmw175 (Everett, 1984; 1985;
1986; Gelman and Silverstein, 1985; 1986; 1987b; Shapira et 
al., 1987). Despite the finding that VmwIIO is a strong 
transactivator, virus mutants lacking a functional VmwIIO 
are viable (Stow and Stow, 1986; 1989; Sacks and Schaffer,
1987). Although these mutants have similar phenotypic 
properties to wt virus at high moi, at low moi their growth 
is impaired and they synthesize reduced amounts of some E 
and most L proteins (Stow and Stow, 1986; 1989). It is
25
thought that at low moi where V m w 175 is present in low
amounts, V m w IIO is important for boosting viral gene 
e x p r e s s i o n .
Results from the analysis of ts or deletion mutants 
and transient expression assays have implicated Vmw63 in
regulation of HSV gene expression (Sacks et al. , 1985;
Everett, 1986; Gelman and Silverstein, 1987b). In 
transient expression assays, Vmw63 either enhanced or 
repressed expression of genes activated by VmwIIO and
Vmw175 (Sekulovich et al., 1988). It has also been
reported that Vmw63 can stimulate expression of a gene
containing the gB promoter (Rice and Knipe, 1988).
The two IE polypeptides V m w 6 8  and V m w 1 2  did not 
appear to affect gene expression either alone or in the 
presence of other IE proteins in transient expression 
assays (Everett, 1984; DeLuca and Schaffer, 1985), and both 
genes could be deleted without markedly affecting virus 
growth in most cells (Post and Roizman, 1981; Mavromara- 
Nazos et al., 1986a).
1.6.7 Cis-acting and Promoter regulatory sequences of E
genes
The control elements responsible for constitutive
transcription of early genes have been identified using the
viral thymidine kinase (TK) gene, since basal levels of
hie
promoter activity could be detected in cells where\TK gene 
has been integrated into their chromosomes (Minson et al., 
1978) , and functional TK produced when HSV TK gene is 
microinjected into Xenopus laevis oocytes (Cordingley and
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Preston, 1981). Analysis of the TK gene promoter region
has been investigated by both insertion and deletion of
clustered sets of mutations at random locations of the
promoter (McKnight and Kingsb11^ ^ 1 982). The results
elements
identified three promoter regulatoryArequired for efficient 
transcription of the TK gene: (I) A TATA box or a proximal
signal (II) An upstream distal signal, dsl (III) A second 
upstream distal signal, dsll (McKnight, 1980, 1982). The
two distal signals exhibited sequence homology to one 
another and were required for quantitative transcriptional 
control, each distal signal has a GC-rich region which 
includes the hexanucleotide sequence GGGCGG (McKnight et 
al. , 1984). These GC rich elements bind the Spl cellular 
transcription factor which can stimulate the rate of gene 
transcription by 10 to 50 fold. Dsl has a weaker affinity 
to Spl than dsll, which is explained on the basis of a 
single nucleotide change from G to C in the GC-consensus 
sequence 5'GGGGCGGGGC 3' (Jones et al., 1985; Jones and 
Tjian, 1985). The distal signal dsll also contains an 
inverted CCAAT-box, (Graves et al., 1986). Two 
transcriptional factors, CTF isolated from HeLa cells 
(Jones et al., 1985) and CBP isolated from rat liver nuclei 
(Graves et al. , 1986), have been shown to bind to this
pentanucleotide. These two proteins appear to be different 
gene products with a related ability to bind to specific 
sequences (McKnight and Tjian, 1986). Although several 
workers have been unable to identify any specific promoter 
region essential for transactivation of gD and TK in trans- 
inducing assays, Coen et al. (1986) showed that sequences
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which were sensitive to base substitution upstream of the TK 
gene were important for recognition by cellular 
transcription factors, therefore suggesting that E gene 
trans-activation by IE proteins possibly occurs by an 
interaction with cellular factors which recognise promoter 
elements.
1.6.8 Late gene expression and regulation
Genes whose expression is significantly reduced in 
the presence of viral DNA synthesis inhibitors such as ara- 
C and PAA are defined as late (L) genes (Honess and 
Roizman, 1974; 1975; Clements et al. , 1977). Late
transcripts are divided into two classes leaky late ( Ifi or 
3*0 and true-late ( K2 or ft) . Leaky-late transcripts are 
easily detectable in the absence of virus DNA replication, 
but only reach maximum abundance after DNA synthesis 
commences (Clements et al., 1977). True-late mRNA
synthesis is also dependent on viral DNA replication for 
high level of expression. Unlike leaky-late mRNAs, 
however, true-late transcripts are present in very small 
amounts early in infection (Powell et al., 1975; Holland et 
al., 1980; Johnson and Everett, 1986a; Homa et al. , 1986). 
The promoter region of Us 11, a true-late gene, has been 
investigated in detail using a transient expression system 
to assay the expression of L genes (Johnson and Everett, 
1986a). No detectable elements upstream of the TATA box 
were required for fully regulated expression of Us 11 
promoter. This result suggested that only the TATA-box 
homology and capsite were required for late gene expression
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(Johnson and Everett, 1986a). The finding that gD could be 
converted from an E gene to a L gene by removal of promoter 
sequence upstream the TATA-box confirmed these results 
(Johnson and Everett, 1986b). Similar results were 
obtained for another L gene, UL44 (gC) (Homa et al. 1986; 
Shapria et al., 1987).
It is thought that prior to DNA synthesis, L genes 
are repressed in their expression by the major DNA binding 
protein (MDBP, V m w 1 3 6 ) , since ts mutants with lesions in 
MDBP overproduced late gene products at the NPT (Godowski 
and Knipe, 1985).
Both Vmw175 and VmwIIO have been shown to 
transactivate L genes in transient expression assays 
(Deluca and Schaffer, 1985; Mavromara-Nazos et al., 1986a). 
The recent findings obtained from the analysis of Vmw63 
deletion mutants, which failed to synthesize Vmw63 
transcripts (McCarthy et al. , 1989), suggest that Vmw63
down-regulates transcription of certain E genes, and 
stimulates transcription of some L genes, since Vmw63 
mutants overexpressed E proteins, and did not make true 
late proteins.
1.7 Herpesvirus DNA Replication
1.7.1 Viral DNA synthesis
Semi-conservative HSV DNA synthesis takes place in 
the nuclei of infected cells (Roizman, 1969). Replication 
can be detected in BHK cells by 3 hpi and reaches a maximum 
between 9-11 hpi (Wilkie, 1973; Rixon, 1977). The amount 
of input HSV DNA entering the replicative pool is low,
estimates vary from 5-10% (Jacob and Roizman, 1977). By
contrast, more than 60% of input PRV DNA participates in
DNA synthesis (Ben-Porat et al., 1976). Electron
microscopic analysis of viral DNA present in the nuclei of
infected cells revealed that the linear genome circularises 
early in infection (Jacob and Roizman, 1977; Ben-Porat and 
Veach, 1980) . Restriction endonuclease analysis of non­
inverting mutants, lacking most of the internal inverted 
repeat sequences including the a sequence (Poffenberger et 
al. , 1983; Poffenberger and Roizman, 1985), revealed that
circularisation is rapid, and does not require de novo 
protein synthesis. These results suggest that fusion of 
the termini is mediated by a host or virion protein 
(Poffenberger and Roizman, 1985). Sequence analysis of the 
joint and terminal region indicates that circularisation of 
linear HSV genome probably occurs by direct ligation of the 
termini (Davison and Wilkie, 1983).
DNA has been extracted from cells replicating virus 
at early and late times in infection and examined under the 
electron microscope. Early in infection circular molecules 
with linear tails larger than unit length viral genome, Y- 
shaped molecules, and a variety of linear DNA molecules 
differing from mature viral DNA in structural features such 
as lariats, loops (eye and D loops) have been observed 
(Ben-Porat et al., 1976; Shlomai et al. , 1976; Ben-Porat
and Tokazewiski, 1977; Friedmann et al., 1977; Jacob and 
Roizman, 1977; Jean et al. , 1977, Becker et al., 1978).
Evidence, particularly from PRV, favours the idea that the 
genome may replicate early in infection as a theta
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molecule. Late in infection, large tangles of DNA, many of 
which are greater than unit length viral DNA molecules are 
present. Sedimentation properties of HSV replicating DNA 
at late times of infection are consistent with electron 
microscopic observations that the viral DNA is of high 
molecular weight. Data obtained from restriction 
endonuclease analysis revealed that the proportion of 
terminal fragments relative to the joint spanning fragments 
was low in replicating virus DNA (Ben-Porat and Rixon, 
1979; Jacob et al. , 1979), suggesting that replicating HSV 
DNA is endless. On the basis of electron-microscopic 
observations of replicative intermediates, sedimentation 
properties of newly synthesised viral DNA late in 
infection, and results obtained from restriction 
endonuclease analysis of replicating viral DNA, Jacob et 
al. (1979) proposed that HSV replicates via a rolling 
circle mechanism, whereby head-to-tail concate""'mers of DNA 
are formed by the continuous synthesis of one strand and 
discontinuous synthesis of the other strand. During 
replication virus DNA contains nicks and gaps which are 
repaired at later stages (Wilkie, 1973; Wadsworth et al.,
1976) . Short stretches of ribonucleotides along the viral 
genome have also been reported (Biswal et al., 1974). The 
role of these ribonucleotides is not clear. It is possible 
that these stretches may act as a primer for discontinuous 
DNA synthesis.
1.7.2 Cis-acting elements involved in DNA replication
The first evidence for multiple origins of
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replication was obtained from electron microscopic
observations on replicating HSV-1 DNA (Shlomai et al. ,
1976; Friedman et al., 1977). Similar observations were
obtained for PRV (Jean et al. , 1977; Ben-Porat and Veach,
1980). Studies on HSV defective viruses, which are
generated by serially passaging virus stocks at high moi,
identified two classes of defective viruses, both of which
consist of tandem reiterations of portions of the virus
genome. Class T contain tandem reiterations of Us linked 
repeat
to the entire S/tregion, while class II has DNA sequences 
from Ul fused to a small part of the S repeat (Frenkel et 
al., 1976; Graham et al. , 1978; Kaerner et al. , 1979;
Locker and Frankel, 1979), Subsequent studies provided 
direct evidence that the repeat units of class I and II of 
HSV defective genomes contains origins of replication 
(Vlazny and Frenkel, 1981; Spaete and Frenkel, 1982; 1985). 
The experiments showed that monomeric units of both 
defective classes were amplified to generate tandemly 
reiterated DNA when cotransfected into cells with wt HSV 
DNA which provided essential helper functions in trans. 
Using a plasmid replication assay the oris sequence in the 
short repeat was located within a 90bp region in the 
intervening sequences between the 5' transcribed region of 
V m w 175 genes and Vmw68 or V m w 1 2  genes (Mocarski and 
Roizman, 1982; Stow, 1982; Stow and McMonagle, 1983). The 
oriL sequence, which lies within the noncoding sequences at 
5' ends of DNA polymerase and the MDBP genes, was difficult 
to determine because deletions occurred at high frequency 
in orii when plasmids carrying the sequence were propagated
in bacterial vectors. Cloning of oriL was, however, 
successfully achieved using a yeast vector which allowed 
the precise localisation of orii in HSV-1 DNA (Weller et 
al., 1985). The sequence of oriL was also determined by 
directly sequencing oriL in HSV-1 strain 17 virion DNA 
(Quinn and McGeoch, 1985) and in defective DNA of HSV-1 
strain angelotti (Gray and Kaerner, 1984). Sequence 
analysis revealed that both HSV-1 strain 11syn* oris and 
orii contain a palindromic sequence with an A-T rich 
central region (Murchie and McGeoch, 1982; Quinn and 
McGeoch, 1985).
A question which has been raised is whether orii. 
and both copies of oris are essential for viral DNA 
synthesis ? Clearly both oris are not essential for DNA 
synthesis, since a mutant of HSV-1 lacking one copy of oris 
has been isolated in tissue culture (Longnecker and 
Roizman, 1986). Furthermore, the isolation of the HSV-1 
mutant dl61, which is able to replicate despite the 
deletion in orii , suggests that a functional oriL is not 
essential for virus replication in tissue culture (Polvino- 
Bodnar et al., 1987). On the basis of these results it was 
thought that one origin of replication was sufficient for 
virus replication. Recent findings of Smith et al. (1989), 
however, suggest that the presence of at least one copy of 
oris is essential for virus replication since viable 
deletion mutants lacking all copies of oris could not be 
generated in HSV-2. The reason for three origins of 
replication in the virus genome is still unclear.
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1-7.3 Identification of proteins involved in DNA 
metabolism
A variety of approaches have been employed to
identify viral gene products which are important for DNA 
replication. In early studies, virus-infected cell 
extracts were screened for the presence of enzymes with 
altered properties from uninfected cell enzymes. Using 
this approach the TK (Dubbs and Kit, 1964), a DNA 
exonuclease (Morrison and Keir, 1968), a DNA polymerase
(Hay et al., 1971), ribonucleotide reductase (Cohn, 1972), 
dUTPase (Wohrab and Francke, 1980; Preston and Fisher,
1984), and the DNA repair enzyme uracil-DNA glycosylase 
(Caradonna and Cheng, 1981; Caradonna et al., 1987) were
detected. DNA binding properties of certain proteins have 
been used to identify gene products which might be 
important for DNA replication such as the MDBP (Bayliss, et 
al., 1975; Purifory and Powell, 1976), origin specific DNA 
binding protein (Elias et al., 1986), and more recently the 
non-specific ds DNA binding protein (Marsden et al., 1987; 
Parris et al. , 1988). The characterisation of mutants has
been another approach used to identify genes involved in
DNA replication. Analysis of ts and host range {hr) 
mutants which fail to synthesize DNA under restrictive 
conditions identified seven genes as candidates involved in 
DNA replication (Conley et al. , 1981; Coen et al. , 1984;
Weller et al., 1983; Carmichael et al., 1988; Goldstein and 
Weller, 1988; Marchetti et al., 1988; Carmichael and 
Weller, 1989).
A new approach has been used by Challberg (1986) ,
to identify genes required for HSV replication. Cloned 
restriction fragments of HSV—1 DNA were screened for the 
ability to supply the functions required for the 
replication of plasmids containing oris or orii when 
transfected into tissue culture cells. Using this 
complementation assay, Wu et al. (1988), identified seven 
HSV genes that were necessary for transient expression of 
plasmids containing oris or oriL . These were UL30 which 
encodes DNA polymerase (Gibbs et al. , 1985; Quinn and
McGeoch, 1985), UL29 which encodes the MDBP (Conley et al., 
1981; Quinn and McGeoch, 1985), a 65,000 M m w  non-specific 
ds DNA-binding protein encoded by UL42 (Marsden et al., 
1987; Parris et al. , 1988), and four less well
characterised genes UL5, UL8, UL9, and UL52. Results 
obtained by Olivo et al. (1988), suggested that the product 
of gene UL9 binds to a viral origin of replication. 
Similar results were obtained by Weir et al. (1989) , using 
a gel retardation assay. An HSV-1 specific DNA helicase 
activity has been identified in virus-infected Vero cells 
(Crute et al., 1988), and shown to consist of three
subunits. Immunochemical analysis suggested that these 
three subunits are the products of HSV-1 UL5, UL8, UL52.
In addition, it was reported that a DNA primase activity 
was tightly associated with the three subunits (Crute et 
al., 1989). It is thought that the helicase-primase 
complex primes 1agging-strand synthesis as the complex 
unwinds DNA at the replication fork.
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1.7.4 Viral DNA maturation and cis-acting signals
Cleavage of high mw concatemeric DNA to unit-length 
linear genomes is closely associated with encapsidation of 
viral DNA. The characterisation of ts mutants of PRV and 
HSV has revealed clear evidence that these two processes 
are linked together (Ladin et al. , 1980; 1982; Preston et
al. , 1983; Addison, 1986; Sherman and Bachenheimer, 1987;
1988). To date, most studies have been directed towards 
determinating the cis-acting sequences required for 
cleavage and packaging. All defective virus genomes 
contain sequences from the terminus of the S region of HSV 
genome, suggesting that these sequences encode the 
signal(s) for cleavage and packaging of DNA (Kaerner et 
al., 1981; Vlazny and Frenkel, 1981; Spaete and Frenkel, 
1982). Studies on defective viral genomes generated by 
serial passage of HSV-1 virus stocks at high moi have also 
shown that only full-length defective genomes were present 
in cytoplasmic virions, suggesting that only capsids 
containing unit length DNA were enveloped (Vlazny et al. , 
1982). Subsequent work by Stow et al. (1983), demonstrated 
that all the signals required for HSV-1 DNA encapsidation 
were located within the a sequence, since only plasmids 
contain ing HSV-1 oris and the a sequence were packaged 
into capsids when transfected into cells with helper virus 
DNA. The a sequence, which is present as a direct repeat 
at both the termini, aijd in an inverted orientation at the 
L-S junction, is composed of unique elements (Ub , Uc ) , 
separated by direct repeated (DR) elements. It has been 
shown that DR1 elements lie at each end of a single a
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sequence, and multiple copies of a sequence are separated
by a single DR1 element (Figure 4) . Heterogeneity in the
size of a sequences ot different HSV strains is due to the
variation in the copy number of DR elements (Locker and
Frenkel, 1979; Davison and Wilkie, 1981; Mocarski and
Roizman, 1981; Mocarski et al., 1985). Sequence analysis
of HSV DNA has revealed that the a sequence ends at both
termini in a partial copy of DR1 (Davison and Wilkie, 1981;
Mocarski and Roizman, 1982), such that the ligation of TRs
and TRl regenerated the complete DR1 between two a
sequences. It was concluded from this information that the
cleavage site is present within the DR1 element (Mocarski
and Roizman, 1982). The findings obtained from the
of
analysis^HSV-1 strain Justin defective genomes revealed the 
presence of a complete copy of DR1 at the end of the a 
sequence adjoining the short repeat sequence but only 4bp 
of DR1 at the novel Us-a junction. This finding led to the 
conclusion that the DR1 sequence does not contain the 
cleavage-packaging signal (Mocarski et al., 1985). Studies 
by Varmuza and Smiley (1985) supported this prediction. 
Various sub-fragments from the a sequence were inserted 
into the viral TK gene and assayed for the ability to 
direct cleavage/packaging when introduced into a plasmid 
containing an HSV-1 origin of replication. The mutant TK- 
fragments were also inserted into HSV DNA and the 
recombinants screened for the ability to produce novel 
termini. A 250 bp subfragment, which lacked DR1 and part 
of Ub at one end and contained an incomplete copy of DR1 at 
the other end, retained cis-acting cleavage-packaging
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Figure 4
The "a" sequence of HSV-1 strain F, which is present as a 
direct repeat at both termini and in an inverted 
orientation at the L-S junction. The region shown is
composed of unique elements (Ub and Uc ) , separated by 
direct repeated elements (DR). At the each end of a single 
"a" lies a DR1 element. (taken from Chou and Roizman,
1985).
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signals. Furthermore, sequence analysis revealed that the 
novel termini generated by the TK- recombinant viruses were 
produced by two distinct cleavage events, one specifying 
the location of the new S terminus, the other the new L 
terminus. Both cleavage sites occured in flanking TK DNA 
sequences at a defined distance from the cleavage signals. 
On the basis of these results Varmuza and Smiley (1985) 
proposed that in the standard HSV genome the two cleavage 
events occurred normally within DR1, but that the cleavage 
signals mapped elsewhere within the a sequence, probably 
within Ub and Uc . Eventually, it was shown that two 
separate signals, one located within Ub and the other in Uc 
element of the a sequence, were essential for cleavage and 
encapsidation of defective virus (Deiss and Frenkel, 1986; 
Deiss et al. , 1986). Comparison of concatemeric junctions
of six different herpesviruses revealed two blocks of 
conserved sequences (referred to as p a d  and pac2) which 
were homologous to Ub and Uc . It was suggested on the 
basis of these findings that there was a uniform mechanism 
for cleavage and packaging of herpesvirus DNA (Deiss et 
al. , 1986). Using a transient cleavage assay it was
demonstrated that a 179bp cloned fragment from the junction 
of two tandem a sequences, containing the cis-acting 
signals for cleavage and encapsidation, was cleaved at the 
appropriate site even though the fragment was unable to 
replicate in HSV-infected cells (Nasseri and Mocarski
1988). This result suggested that cleavage is independent 
of replication or concatemerisation. The same fragment, 
when linked to an HSV origin of replication, was able to be
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replicated and packaged into progeny virus as a defective 
genome in the presence of helper virus.
1.7.5 Viral DNA packaging models
Several models have been proposed to explain the 
processing of concatameric DNA into packaged unit length 
DNA. The simplest of all models is based on a single 
cleavage event within DR1 to produce L and S termini. 
However, this model (Fig. 5A) requires junctions bearing 
two or more tandem a sequence for processing (Mocarski and 
Roizman, 1982). Since 50% of L-S junctions contain only 
one a . sequences, there must be a mechanism which 
discriminates between a single and multiple a sequences or, 
alternatively, a system for regenerating a lost a sequence. 
It is also clear from work on defective genomes that: one a 
sequence is sufficient in the monomer unit for cleavage and 
packaging. These observations led Varmuza and Smiley
(1985) to propose two models for cleavage and packaging. 
In the first model, known as the staggered nick-repair 
model, the termini are generated by staggered single­
stranded nicks followed by repair synthesis rather than ds 
cleavages proposed by Mocarski and Roizman (1982). S and L 
recognition complexes bind to signals in Ub and Uc 
respectively and each complex makes a single-stranded nick 
in the adjacent DR1 sequence at the end of the a sequence 
(Fig. 5B) . Repair synthesis occurs across the staggered 
cleavages to produce two termini, each containing an a 
sequence. Junctions bearing two or more tandemly 
reiterated a sequences can also be processed by cooperation
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Figure 5
DNA cleavage model of Mocariski and Roizman (1982) , A 
single cleavage event within the DR1 element generates 
the L and S termini. (I) The single a sequence 
present at the L-S junction is flanked by DR1. (II) 
Tandemly repeated a sequences share a single copy of 
DR1. (Ill) A single cleavage event within a copy of 
DR1 separating two adjacent a sequence may give rise 
to the termini.
The staggered nick-repair model. The L and S termini 
arise either by staggered single-strand nicks followed 
by repair synthesis or, alternatively, the junctions 
bearing two or more reiterated a copies are processed 
by cooperation between L and S recognition complexes 
in adjacent a sequence and produce a double strand 
break. The circles represent the L and S recognition 
complexes bound to signals in Ub and Uc respectively. 
Taken from Varmuza and Smiley (1982).
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between L and S recognition complexes in adjacent a 
sequences. It was suggested that the ds break created by 
this process generates ends which have a protruding 3' 
nucleotide (Mocarski and Roizman, 1982). Varmuza and 
Smiley (1985) also proposed a simple mechanism, the theft 
model, in which two separate ds cleavages events occur 
(Fig. 6), one creating an L terminus, the other an S 
terminus. Thus, at any L-S junction containing a single a 
sequence, only one cleavage is made creating (for example) 
an L terminus with an a sequence and an S terminus lacking 
it. This step is followed by packaging of the genome 
containing the a sequence at the terminus until the next L- 
S junction in the same orientation is encountered. A 
second cleavage event (in an opposite fashion) takes place 
to generate (for example) an S terminus with an a sequence 
and an L terminus lacking one. The theft model was 
subsequently modified by Deiss et al. (1986) to include 
polarity in cleavage-packaging process. In their model, 
referred to as the directional cleavage model, the 
packaging complex binds to the concatameric viral DNA at 
random and proceeds in a random walk until a junction 
containing the a Uc signal is found (Fig. 7). Cleavage 
occurs at the first DR1 element producing a terminus with a 
3' protruding nucleotide. Packaging begins at the 
generated L terminus, which contains one or more a 
sequences, and the DNA is scanned for the next direct 
repeat junction. A second cleavage occur within the DR1 
element proximal to the first Ub signal within this 
junction to give a terminus with 3' single-base overhang
D o u b l e  s t r a n d  c u t  a t  L  t e r m i n u s  
s t a r t s  p a c k a g i n g
d i s c a r d e d
d o u b l e  s t r a n d  c u t  a t  S  t e r m i n u s
c o m p l e t e s  p a c k a g i n g
d i s c a r d e d
Figure 6
The Theft model proposed by Varmuza and Smily (1982) for 
cleavage and packaging of DNA. A ds cleavage at one of two 
cleavage sites creates an L terminus carrying an a sequence 
and an S terminus lacking an a sequence. Packaging of the 
genome carrying the a sequences after the L terminus is 
initiated and continues until the proper orientated L-S 
junction is encountered. At this point a cleavage at the S 
terminal is made generating an S terminus with an a 
sequence and an L terminis lacking the a sequence. The L 
and S ends lacking a sequence are thought to be rapidly 
degraded. Triangles represent packaging signals while 
circles represent packaging complexes.
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Figure 7
Directional cleavage model proposed by Diess et al., (1986)
In this model packaging complex binds to concatemeric 
standard viral DNA and moves randomly until a junction 
containing a Uc signal is found. Cleavage occurs at the 
first DR1 element, producing a terminus with 3' single base 
overhang. The generated L terminus, which contains one or 
more a sequences, is packaged towards the L-S junction. 
DNA is scanned for the next direct repeat junction and a 
second cleavage event occurs proximal to the first Ub 
signal encountered to give rise to a 3' single base 
overhang. Termini lacking an a sequence are suggested to 
be rapidly degraded. The open circle represent the 
packaging complex.
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(Deiss et al. , 1986). In this model and the preceding one 
unpackaged termini, lacking an a sequence, are generated. 
Since termini lacking a sequences have not been detected it 
has been suggested that they are rapidly degraded (Varmuza 
and Smiley, 1985; Deiss et al., 1986). To account for 
absence of termini devoid of a sequences Deiss et al.
(1986) postulate another model based on the double-strand 
break and gap repair mechanism for gene conversion 
proposed by Szostak et al. (1983) to explain recombination 
events resulting in gene conversion. In this model a 
complex binds to and moves randomly along the DNA. 
Packaging begins without cleavage at the first Uc sequence 
encountered and proceeds in an L-S direction until a 
directly repeated junction is encountered. The first and 
second junctions interact by the ds break-gap repair 
mechanism resulting in the reciprocal copying of an a 
sequence from one junction to the other. The generated 
double a junctions are cleaved within the DR1 elements 
flanked by the Uc and Ub and packaged. During this process 
no termini lacking a sequences are generated, and the a 
sequence is amplified. Unlike the other models this model 
accounts for the structure of defective genomes generated 
from plasmids, containing an a sequence with a deletion in 
Ub and an origin of replication, cotransfected into cells 
with helper virus DNA. The possibility that the defective 
genome progeny acquired the a sequence by high frequency 
recombination with helper virus, however, cannot be ruled 
out.
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1.8 HSV ENCODED PROTEINS
Early studies using one dimensional SDS PAGE, 
identified about 50 HSV-induced polypeptides in virus- 
infected cells (Honess and Roizman, 1973; Powell and 
Courtney, 1975; Marsden et al. , 1976). Recently, however, 
analysis of the complete DNA sequence of HSV-1 17syit 
genome has indicated the presence of at least 72 genes 
specifying 70 distinct proteins (McGeoch et al. , 1985;
1986; 1988).
1.8.1 Structural proteins
Over 30 virus polypeptides have been identified in 
purified virions, suggesting that nearly half of the HSV- 
induced proteins are structural (Spear and Roizman, 1972; 
Heine et. al. , 1974; Cassai et al. , 1975; Marsden et al.,
1976). It should be noted, however, that although several 
minor proteins are present as virion components in some 
preparations, it is not clear whether they represent 
contaminating non-structural proteins, or whether they are 
in fact true components of the virion.
1.8.1.a Capsid proteins
The protein composition of capsids has been largely 
determined by purification of capsids from the nuclei of 
infected cells. In HSV-1 two types of intranuclear 
capsids, designated as A and B capsids, were identified 
using sucrose gradients (Gibson and Roizman, 1972), In 
comparison to A capsids, B capsids had a faster 
sedimentation rate, contained DNA and had an internal core
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structure. A capsids lacked DNA and contained mainly
coreless capsids. Recently it has been suggested that the 
heavy band containing B capsids was in fact a
mixture of DNA containing capsids and capsids lacking DNA 
but containing some internal structure (partially-cored 
capsids) (Rixon et al., 1988). These capsids could also be 
seen in thin section preparations of virus-infected cells 
under the electron microscope.
Seven polypeptides with apparent MW ranging from 
12,000-155,000, have been recognised in HSV-1 full capsids
(Heilman et a l . , 1979; Zweig et al. , 1979; Cohen et al.,
1980) (See table 1).
The major capsid protein (also referred to as 
Vmw155, ICP5, VP5, NCI) is encoded by gene UL19 (Costa el 
al., 1984; Davison and Scot, 1986; McGeoch et al. , 1988), 
and has been identified as the capsomere protein which is 
arranged in a six-fold symmetry within the icosahedron T=16 
(Wildy et al., 1960; Palmer et al. , 1975; Furlong, 1978;
Vernon et al., 1981; Stevens et al., 1986; Weller et al., 
1987; Schrag et al., 1989). Recent evidence obtained from 
cryo-electron microscopy of HSV-1 suggests that pentameric 
capsomeres may also be composed of Vmw155 (Schrag et al.,
1989) .
Early electron microscopic studies of disrupted 
capsids indicated that the capsomeres were linked by 
intercapsoujeric fibrils (Vernon et al., 1974; Palmer et 
al., 1975), and that NC3 or NC4 or both may represent the 
intercapsomeric fibrils (Vernon et al., 1981). However,
the results obtained by Braun et al. (1984a) on surface
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iodination labelling of capsids revealed that V m w 33 (see 
table 1) and not NC3 or NC4, was located on the outer 
capsid surface. On the basis of this finding, it was 
suggested that this protein may function as intercapsomeric 
connections. The cryo-electron microscopy study by Schrag 
et al. (1989) confirmed that there are capsomeric 
connections and calculated that the mass of this protein 
could be accommodated within the outer surface of the 
capsid. On the assumption that the protein density at each 
local three-fold position is a trimer, then the capsid 
should contain 960 copies of V m w 33 which is similar to 
estimates of the copy number of this protein within the 
capsid (Heine et al., 1974; Schrag et al., 1989).
The capsid protein V m w 50 (table 1), is a DNA 
binding protein (Braun et al. , 1984a). The exact location
of this protein within the capsid is uncertain. However, 
surface iodination studies suggest that this protein is 
present in an internal position in the capsid (Braun et 
al. , 1984b). Schrag et al. (1989) speculated that this
protein was located within the outer capsid (at a radius 
between 500 A0 and 425 A0 ) , which is consistent with the 
observations of Zweig et al. (1979) that there are 
disulfide-linkages between V m w 50 and V m w 155. Recent data 
obtained from the sequencing of the amino-terminus of 
capsid proteins (F.J. Rixon, personal communication), 
suggest that UL38 encodes the capsid protein V m w 50. The 
HSV-1 ts mutant, HSV-lA44ts2, which fails to assemble 
capsids at the NPT, has a ts defect within UL38 (Pertuiset 
et al., 1989). This finding suggests V m w 50 is required for
TABLE 1
predicted 
molecular 
weight 
(if known)
Apparent
MW
X 103
Proposed nomenclatures 
(A) (B) (C)
149,075 155 NCI pl55 VP5 (ICP5)
50,260 50 NC2 p50 VP19C (ICP32)
62,466 40 NC3/4 p40 VP22/22a(ICP35)
NA 33 NC4 p32 VP23
1? 26 NC5 p25 VP24
II 12 NC6 pl2 ND
TABLE 1
Capsid polypeptide nomenclature proposed by different 
workers and the their approximate mw compared with the 
predicted mw determined from the nucleotide sequence 
of HSV (McGeoch et al., 1988). NA-not available since 
no capsid protein have been assigned to a gene.
(A) The nomenclature used by Cohen et al.(1980) where NC 
represents nucleocapsid proteins.
(B) The nomenclature proposed by Heilman et al. (1979).
(C) The nomenclature used by Gibson and Roizman (1972) for
virion proteins. The virus-infected cell polypeptide
nomenclature is given in Brackets (Heine et al. ,
1974). (ND) not detected.
In this thesis capsid proteins have also been referred 
to by their approximate mw e.g. Vm w 155.
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the formation of capsids.
A family of related polypeptides, designated as 
VP22a, VP22, the assembly protein (Gibson and Roizman, 
1972; 1974), p40 (Heilman et al. , 1979; Zweig et al., 1979; 
1980), or ICP35 (Braun et al., 1984b), is encoded by gene 
UL26 (Preston et al. , 1983; McGeoch et al. , 1988). This
assembly protein was thought to be a major component of
full DNA-containing capsids, but not empty capsids lacking 
any internal structure (Gibson and Roizman, 1972; Braun et 
al., 1984b). Recent work by Rixon et al. (1988), however, 
based on immunoelectron microscopy has provided clear 
evidence that p40 is present in partially-cored capsids 
which do not contain DNA and is not a major component of
full capsids or mature virions. Since the p40 is only
transiently associated with capsids it cannot be an 
integral capsid protein. Further investigations are needed 
to determine whether the p40 is required for the formation 
of partially-cored capsids. VP21, which was thought to be 
an unprocessed form of the ICP35 family, is only present in 
type B and C capsids (C capsids are prepared by treating 
virions with detergents which remove the envelope) (Gibson 
and Roizman, 1972; Braun et al., 1984a). Schrag et al.
(1989) proposed that VP21 may be present within the 
intermediate shell T=4, although the estimated amount of 
VP21 present in the capsid (Heine et al., 1972) is not 
sufficient to explain the excess in density found in the 
cryo-electron microscopic constructions. It is likely that 
the nucleocapsid contains an additional as yet unidentified 
component (Schrag et al., 1989).
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The location and role of the other two capsid 
proteins p25, and pl2 are not known. It has been suggested 
that pl2, a highly basic protein, may be an internal 
component of the capsid (Vernon et al., 1981), and involved 
in the events leading to the packaging of HSV DNA (Cohen et 
al., 1980). Cryo-electron microscopic studies by Schrag et 
al. (1989) suggested that the mass inside the inner capsid 
is large enough to accommodate some protein in addition to 
the genomic DNA and the polyamine spermine detected in 
earlier studies by Gibson and Roizman (1971), and Roizman 
and Furlong (1974) . It is thought that the function of 
spermine in the nucleocapsid is to neutralise the phosphate 
charge on DNA, to allow the DNA to be densely packed into 
the capsids.
1.8.1.b HSV tegument proteins
The tegument is thought to contain at least 15 or 
more non-glycosylated proteins. The assignment of 
structural proteins to the tegument is generally based on 
their presence in de-enveloped virions, and their absence 
from capsids purified from infected cell nuclei (Gibson and 
Roizman, 1972; Lemaster and Roizman, 1980). This 
criterion, however, excludes non-glycosylated proteins 
close to the envelope, for example Vmw65, which are 
solubilised by detergents (Spear, 1980; Johnson et al.,
1984). In practice, therefore, detergent-soluble non- 
glycosylated structural polypeptides are normally placed in 
the tegument.
The tegument polypeptide V m w 65, which is the
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product of gene UL48, is responsible for trans-activating 
IE gene transcription (Batterson and Roizman, 1983; 
Campbell et al., 1984). The precise structural role of
V m w 65 is not known, although work on the HSV-2 ts mutant 
ts2205 (Halliburton and Timbury, 1976) has shown that it is 
important in stabilizing the capsid (Ramsay, 1987) .
A 10,000 MW phosphoprotein encoded by gene US9 has 
also been identified as a tegument protein. Oligopeptide 
antiserum, raised against a portion of US9 amino acid 
sequence, precipitated a family of polypeptides with MW of 
around 10,000 from NP40 soluble extracts of HSV-1 virions 
(Frame et al.,1986). The 10,000 MW protein is located on 
the surface of capsids in the nucleus, and it is thought 
that this protein becomes associated with the nucleocapsids 
shortly after their formation.
The gene UL36 encodes a huge tegument protein known 
as V m w 273 (Batterson et al., 1983; McGeoch et al. , 1988). 
The lesion in the HSV-1 strain HFEM ts mutant tshl was 
localised within this protein. Capsids from input virions 
of tsBl accumulated at the nuclear pores at the NPT and 
failed to release the viral DNA into the nucleus (Batterson 
et al., 1983), suggesting that this protein is important 
for uncoating.
A protein kinase activity has been located in the 
tegument by Lemaster and Roizman, (1980). It was suggested 
that the protein kinase is possibly a host casein kinase 
II, since there are similarities between the tegument 
protein kinase and the host enzyme (Stevely et al., 1985).
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1 .8. lc Envelope glycoproteins
At least seven major glycoproteins have been 
recognised on the virion surface (table 2) . These 
glycoproteins have been intensively studied since they 
mediate entry of the virus into the infected cell, the 
spread of virus between cells, and they form targets for 
antibody-mediated neutralization of virion infectivity and 
therefore may be potential targets for anti-HSV vaccines 
(Spear, 1985; Marsden 1987). The genes encoding the 
glycoproteins aredistributedthroughou t the genome within 
both Us , which contains a high concentration of 
glycoproteins, and U l (Fig 8). The virion glycoproteins 
gH, gB, g C , gD, g l , gE all possess N-terminal hydrophobic 
signal sequences and C-proximal hydrophobic sequences. It 
should be noted that a minor glycoprotein, which has not 
been identified as a component of the envelope, is thought 
to be encoded by gene US5,(McGeoch, 1985; McGeoch et al. , 
1985; McGeoch et al., 1987; McGeoch et al., 1988a).
Finally, sequence analysis of U l have identified eight 
other potential membrane-associated genes, UL1, UL3, UL10, 
UL20, UL34, UL43, UL45 and UL53 (McGeoch et al., 1988).
1.9 VIRION ASSEMBLY
1.9.1 Capsid assembly
The chain of events leading to nucleocapsid 
assembly in herpesviruses is still unclear. There is, 
however, general agreement that structural proteins migrate 
from the cytoplasm to the nucleus where capsids are 
assembled (Morgan et al., 1954; 1959; Olshevsky et al.,
TABLE 2
The function of HSV glycoproteins
Function gB gC
glycoproteins 
gD gE gG gH gi
Essential genes 
in tissue culture yes no yes no no yes no
Adsorption + ? + ? + ? + ?
Penetration + + + +
Cell fusion (syn) + +
Virus egression - - - + ?
Neutralisation + + + + + +
C3b receptor gC-1
gc-2
Fc receptor +
(+) indicates a positive role
(-) indicates a negative role
(?) either unclear or unknown
For references refer to the text
0  5 0  1 0 0  1 5 2  K b p
 1 I I I I I l i  » i i I i i l l
|---- 1---- 1---- 1---- 1 T  1---- 1---- 1---- 1---- 1
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 ™.u.
m a p  l o c a t i o n  o f  g H  g B  g C  g G  g D  g l  g E
( A )  g l y c o p r o t e i n s I I  I N \ I /t
\ ’\
( B )  U L 6  UL25 UL26 UL28 l o c a t i o n  o f  g e n e s  i n v o l v e d
1 \ i / j n  D |yjA  p a c k a g i n g\/Z
Figure 8
The diagram represents the map location of HSV-1 (A) 
glycoproteins and (B) the genes which are thought to be 
involved in DNA encapsidation (refer to the text for 
details).
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1967; Spear and Roizman, 1968; Ben-Porat et al., 1969).
Analysis of ts mutants of PRV, which failed to assemble 
capsids but synthesised DNA at the NPT, suggested that 
capsid assembly is required for the continual movement and 
accumulation of capsid proteins in the nuclei of infected 
cells (Ladin et al., 1980; 1982). The nuclear matrix, i.e. 
the residual nuclear skeletal framework obtained by 
sequential extraction of purified nuclei with low salt, 
DNase, and high salt treatment (Berezney and Coffey, 1977), 
is thought to be the site within the nucleus where 
herpesviruses capsids are assembled, and viral DNA 
replication takes place (McCready et al. , 1980; Pardoll et 
al., 1980; Bibor-Hardy et al., 1982a; 1982b; Tsutsui et
al. , 1983; Ben-Porat et al., 1984; Bibor-Hardy et al. ,
1985). As mentioned earlier, Vmw155 is the major component 
of T=16. Like Vmw155 mutants, the UL38 ts mutant HSV-1 
A44ts2 fails to produce capsids at the NPT (Pertuiset et 
al. , 1989). This finding suggests that UL38 gene product
is also an essential component of capsids. Analysis of DNA 
+ve ts mutants of PRV and HSV, together with pulse-chase 
experiments have shown that empty, coreless capsids are 
breakdown products of full, DNA-containing capsids (Ladin 
et al. , 1980; 1982). This information suggests that an
internal shell must be present for the formation of the 
outer T= 16 capsid shell. It is interesting to note that 
electron translucent core-like structures have been 
observed in the nuclei of cells infected at the NPT with 
Vmw155 ts mutants. The correct processing of UL26 gene 
product ICP35 is probably important for capsid assembly,
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since the mutant isl201, which has a defect in p40 (ICP35),
produces capsids at the NPT which have a larger internal
core structure than capsids produced by packaging mutants
containing defects in other genes (Preston et al. , 1983;
Addison, 1986) . In a recent study on capsids of EHV-1 the
only difference in the protein composition between core-
less empty capsids and partially-cored capsids was the
presence of p40 in partially cored capsids (Newcomb et al.,
1989). This work supports the results obtained by Rixon et 
which
al. (1988)^~demonstrated the presence of p40 in partially- 
cored capsids. Either p40, which is present outside the 
capsids, is required for the maintainance of the internal 
core structure or a minor unidentified protein is 
important. To date no scaffolding proteins have been 
identified, however, it is likely that viral proteins in 
addition to V m w 155 and V m w 50 will be required for the 
formation of capsids.
1.9.2 Encapsidation of herpesvirus DNA
The available experimental evidence favours a model 
in which the virus DNA is packaged into a preformed capsid. 
A model based on this mechanism was first suggested by 
Perdue et al. (1976) . It was proposed that DNA enters 
intermediate capsids (partially-cored capsids) which 
contain an internal structure and DNA is spooled around a 
large cylinder core structure. During this process the 
cylinder is condensed to form a densely staining toroid of 
the type observed by Furlong et al. (1972) in thin sections 
of HSV-1 infected cells under the electron microscope. The
insertional model was based on work on EHV-1 (Perdue et 
al., 1975; 1976). Three distinct species of EHV-1 capsids 
were identified on renografin-76 density gradients. 
Analysis of the capsid species revealed significant 
differences in their protein composition and DNA content. 
Capsids were classified into light or empty, medium or 
partially-cored and heavy or DNA-containing capsids. 
Perdue et al. (1976) showed that partially-cored capsids 
were precursors to DNA-containing capsids, since, in 
"pulse-chase" experiments, during the "chase" the amount of 
radioactive label in partially-cored capsids decreased and 
this was accompanied by an increase in label in DNA- 
containing capsids. Observations of capsids by Schrag et 
al. (1989), using cryo-electron microscopy revealed that 
there are channels located at the six coordinated positions 
of the T= 4 lattice, which are aligned with the channels
that penetrate through T= 16 shell. Schrag et al. (1989) 
suggested that the genome might be inserted through these 
channels. Perdue et al. (1976) proposed that the 
intermediate capsids contained four cylinders which fused 
to form a large cylinder around which the DNA is spooled. 
In view of the recent finding that HSV has an inner as well 
as an outer capsid, this scheme should be viewed with some 
doubt. Further evidence favouring the entry of DNA into 
partially-cored capsids has been obtained from the studies 
of DNA positive ts mutants of PRV and HSV-1 which fail to 
encapsidate DNA at the NPT (Schaffer et al. , 1973; 1974;
Cabral and Schaffer, 1976; Atkinson et al., 1978; Ben-Porat 
et al., 1982; Sherman and Bachenheimer, 1987; 1988). Cells
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infected with these mutants at the NPT generally contained 
large amounts of partially-cored capsids in the nuclei. In 
cases where the effect of the mutation could be reversed 
upon shiftdown to the PT in the presence of cycloheximide, 
the number of partially-cored capsids decreased and this 
accompanied by the appearance of full capsids in the 
nucleus and virus particles in the cytoplasm (Ladin et al. , 
1980; Preston et al., 1983). Various photographs have been 
published from electron microscopic studies on HSV and CMV 
which claim to show dense filaments, presumed to be viral 
DNA, extending from the nucleoplasm through the capsids to 
the cores (Friedmann et al., 1975; Haguenau and Michelson- 
Fiske, 1975).
An alternative method for the formation of DNA 
containing capsids was suggested by Pignatti and Cassai 
(1980). They proposed that newly synthesised DNA is packed 
and condensed into nucleoprotein complexes (NPC) containing 
HSV-encoded proteins VP5, VP12, VP15.5, VP19, and VP24.
The mature nucleocapsid is formed by the addition of other 
structural proteins to the NPC. The possibility, however, 
that NPC detected in virus-infected cells represents 
degraded nucleocapsids has not been excluded. It should be 
noted that this model of DNA encapsidation has little 
support, since the weight of evidence favours insertion of 
DNA into a preformed capsid.
Results obtained from work on herpesvirus DNA 
maturation (See section ) suggest that replicated viral DNA 
concatemers are cleaved at specific sites while DNA is 
packaged into capsids (Vlazny et al., 1982; Varmuza and
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Smiley, 1985; Deiss and Frenkel, 1986; Deiss et al., 1986). 
Ts mutants of PRV and HSV which fail to encapsidate viral 
DNA at the NPT also fail to cleave endless DNA into unit 
length DNA. This finding suggests that the concatemeric 
DNA is cleaved while the DNA is being packaged (Ladin et 
al. , 1980; Preston et al., 1983; Addison, 1986).
Subsequent work on defective virus genome supports this 
relationship between cleavage of viral DNA concatemers and 
encapsidation, since most of the termini of defective 
genomes were present in DNase-protected structures in the 
nuclei of virus-infected cells (Deiss and Frenkel, 1986).
1.9.3 Genes involved in DNA encapsidation
Characterisation of HSV ts mutants with defects in 
DNA packaging at the NPT has led to the identification of 
several genes involved in DNA encapsidation (see fig 8) ; 
these include genes UL6, UL25, UL26, UL28 (Preston et al. , 
1983; Addison et al., 1984; Addison, 1986; Sherman and 
Bachenheimer, 1987; 1988). Analysis of the HSV-1 ts mutant 
tsl201 with a defect in UL26 revealed that the mutant 
failed to package virus DNA and to process p40 to its lower 
MW forms at the restrictive temperature. The effect of the 
mutation could be reversed upon down-shift of the mutant- 
infected cells from the NPT to the PT. When virus-infected 
cells were transferred to 31° in the presence of 
cycloheximide correct processing of p40 was achieved and 
concatemeric DNA was cleaved and packaged. The partially- 
cored capsids, which accumulated in the nucleus at the NPT, 
decreased after mutant-infected cells were shifted to 31°
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and this was accompanied by the appearance in the nucleus 
of capsids containing DNA. The results suggested that the 
processing of p40 is important for DNA packaging (Preston 
et al., 1983). The ts mutant of HSV-1 with a defect in 
gene UL25 made low numbers of partially-cored capsids in 
the nucleus at the NPT, and no full capsids were detected. 
The precise role of gene UL25 in capsid assembly and DNA 
packaging is u nclear. It may be important for capsid 
stability since only low numbers of capsids were present in 
the nuclei at t he NPT (Addison et al., 1984; Addison,
1986). The analysis of HSV-1 ts mutant tsl203 with a
lesion in gene UL28 has revealed that partially-cored 
capsids accumulated in the nucleus at the NPT, and
concatemeric DNA was not cleaved and packaged (Matz et al., 
1983; Addison, 1986; Rixon et al., 1988).
Other polypeptides have also been implicated in DNA 
encapsidation. The product of gene UL38, VP19C, has been 
speculated to play a role in DNA encapsidation, since this 
protein is present as an internal component of full and 
empty capsids, and binds to DNA. It was suggested that
this protein may function in packaging or anchoring the DNA 
in the capsid (Braun et al., 1984b). However, no evidence 
has been presented to support this suggestion. The 
identification of the gene products of Us 11 (McGeoch et 
al., 1985; Johnson et al., 1986), V m w 21 and 22, which
interacted specifically with the a sequence of HSV-1 DNA, 
led Dalziel and Marsden (1984) to propose that this 
polypeptide is involved in packaging and/or genome 
inversion. This gene, however, is unlikely to be important
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in virus DNA packaging because it is not essential for 
growth of virus in tissue culture and because the products 
of Us 11 localise very strongly within the nucleoli of the 
infected cell (Longnecker and Roizman, 1986; Brown and 
Harland, 1987; Maclean et al., 1987).
1.10 Envelopment and Egression of HSV
The nucleocapsids are thought to acquire their 
envelope by budding through the inner nuclear membrane 
(Darlington and Moss, 1968; Nii et al., 1968; Watson, 1973; 
Roizman and Furlong, 1974; O'Callaghan and Randall, 1976). 
The sites of envelopment in the nuclear membrane appear to 
lack normal complement of cellular proteins, but are 
enriched with viral glycoproteins (Asher et al. , 1969;
Spear and Roizman, 1970). Other sites of envelopment have 
also been reported, such as golgi membranes and cytoplasmic 
vacuoles (Haguenau and Michelson, 1975). On the basis of 
electron microscopic studies on HSV a novel process of 
envelopment, whereby nucleocapsids acquire envelopes by de 
novo synthesis around DNA containing capsids, was suggested 
(Atkinson et al., 1978; Dargan and Subak-Sharpe, 1983).
The precise mechanism of envelopment and the viral 
polypeptides involved in envelopment are not known. It was 
proposed by Gibson (1981) that exposed hydrophobic regions 
of tegument proteins present on the nucleocapsid surface 
promoted capsids envelopment by the interacting with 
hydrophobic elements, possibly viral glycoproteins located 
on the nuclear membrane. However, no tegument proteins or 
glycoproteins have yet been shown to be involved in such an
interaction. It has been suggested that ICP35 may play a 
role in envelopment, since it was thought that ICP35 coated 
the surface of full capsids and was absent from empty 
capsids (Gibson and Roizman, 1972; Braun et al., 1984b). 
It was proposed that the presence of ICP35 on the capsid 
surface permitted full capsids to interact with other 
proteins and to eventually become enveloped. Work, 
however, by Rixon et al. (1988) has shown that ICP35 is in 
fact present in partially-cored and not full capsids. It is 
therefore unlikely that ICP35 is directly involved in 
envelopment. Subsequent cryo-electron microscopic studies 
of Schrag et al. (1989) revealed that both empty and full 
capsids but no partially-cored capsids were present in 
their purified virion preparations suggesting that the
process of envelopment does not distinguish between full or 
empty capsids. Schrag et al. (1989) proposed that the
absence rather than the presence of ICP35 could act as the 
capsid surface marker for envelopment.
Virions spread to other cells either by fusion of
virus-infected cell membranes with adjacent cellular
membranes, or by release of virus into the extracellular 
space. The transport of the virion from the nucleus to the 
cell surface is thought to be relatively fast and takes 
about l-2h after virus maturation. Virus particles are 
thought to move to the cell surface with streaming of the 
cytoplasm, since in cells treated with cytochalasin B, an 
inhibitor of cell movement by microfilaments, HSV particles 
were retained within the nucleus (Marciano-Cabral et al. , 
1977). Two mechanisms have been proposed for the transport
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of virus from the nucleus to the plasma membrane. The 
first is reverse phagocytosis (Morgan et al. , 1959; Nii et 
al. , 1968; Katsumoto et al., 1981) whereby the virus
particle enters a cytoplasmic vacuole, and is transported 
within the vacuole to the plasma membrane. Fusion of the 
vacuole with the cytoplasmic membrane releases the 
enveloped virus into the extracellular space. In the 
second mechanism the virus particle buds through the inner 
nuclear membrane into vesicles and moves along the
reticulo-endothelial system to the golgi complex, and from 
there to the cytoplasmic membrane. The results obtained by 
Johnson and Spear (1982), favour the latter mechanism.
They found that enveloped virions accumulated in membrane 
vesicles when HSV-infected cells were treated with the
ionophore monensin, which is thought to inhibit the 
transfer of vesic les from the golgi apparatus to the
cellular membrane.
Very little is known about proteins involved in 
envelopment. Results obtained from the analysis of mutants 
deficient in particular glycoproteins, such as gD (Ligas 
and Johnson, 1988) or gE (Longnecker and Roizman, 1986; 
1987; Neidhardt et al., 1987) have revealed that none of 
these well characterised viral glycoproteins are essential 
for virus envelopment. Tt is possible that gH may have a 
role in envelopment as it has been shown that a monoclonal 
antibody directed against gH inhibited plaque formation 
when added in an overlay after virus adsorption (Buckmaster 
et al. , 1.984), and efficiently inhibited cell fusion by
syncytial virus strains (Gompels and Minson, 1986) . A
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mutant, tsQ26, which has a point mutation in gH, has been 
isolated. This mutant fails to form plaques at the NPT 
(Weller et al. , 1983 Desai et al., 1988). Intracellular
virus retaining gH is infectious while extracellular virus 
lacking gH is non-infectious (Desai et al. , 1988).
However, the possibility that the block in infectivity is 
at a stage of entry not exit cannot be ruled out and that 
gH may act in a similar manner to gD.
1.11 LATENCY
A common feature of herpesviruses is their ability 
to establish latent infections (Goodpasture, 1929; Stevens 
and Cook, 1971). HSV reactivation often leads to recurrent 
epithelial lesions which can be triggered by UV- 
irradiation, fever, hormonal changes, stress or other 
stimuli. Studies have shown that the latent virus genome 
resides in neuronal cells (Cook et al. , 1974; McLennan and 
Darby, 1980) . Latent HSV has also been found in sensory 
and sympathetic ganglia of man (Bastian et al. , 1972) .
HSV-1, HSV-2 wt viruses and ts mutants have been 
successfully isolated from different regions of latently 
infected mice by cocultivating the explanted tissue, such 
as ear skin, foot pad, the dorsal root ganglia as well as 
the corneas of infected rabbits (Al-Saadi et al. , 1983;
Cook and Brown, 1987; Cook et al., 1987). Recently it was 
reported that HSV-2 could also establish latency in 
infected mouse foot pad, and that treatment with 
acycloguanosine in vivo or in vitro did not prevent virus 
n recovery (Al-Saadi et al., 1988; Clements and Subak-Sharpe,
1988)  .
Although most of HSV-1 virion DNA is linear, it is 
thought that latent virus DNA exists either as a circle or 
as a large, unintegrated concatemer since genomic termini 
could not be detected (Rock and Fraser, 1983; 1985;
Efstathiou et al. , 1986; Mellerick and Fraser, 1987). The
latent HSV-1 virus DNA has a nucleosomal structure similar 
to that of cellular chromatin, and it has been suggested 
that this structure is important in the control of HSV-1 
gene expression during latency (Deshmane and Fraser, 1989).
Little is known about the mechanism involved in the 
establishment, maintenance and reactivation of HSV-latency. 
It has been demonstrated recently that viral DNA 
replication was not required for the establishment of 
latency in experimental animals (Coen et al. , 1989a), and
that viral DNA inhibitors did not prevent the establishment 
of latency in vitro (Wilcox and Johnson, 1988). The role 
of TK in latency is controversial. The problem with early 
experiments using TK- viruses was that mutations in TK 
affected not only TK but also adjacent genes. Recently a 
mutant of HSV-1 strainF containing a deletion in TK has 
been shown to establish latency in rabbits but not in mice, 
favouring the possibility that the rabbits were able to 
complement a function important for latency, which was 
deleted from the virus (Meignier et al. , 1988). This is
supported by work on TK deletion mutants by other workers 
(Sears et al. , 1985). More recent data, however, have
provided strong evidence that TK is not essential for the 
establishment of latent infection but may be required in
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the reactivation process (Coen et al. , 1989a; 1989b;
Efstathiou et al., 1989; Tenser et al. , 1989). In
addition, VmwIIO of HSV-1 has been proposed to play a role 
in the establishment and reactivation of latency (Leib et 
al. , 1989) , along with the host cellular factors such as
nerve growth factor (Wilcox and Johnson, 1988).
During acute viral infection most of the genome is 
actively transcribed (Clements et al., 1977; Wagner, 1985). 
In latent infections of the peripherial and central nervous
systems of humans and experimental animals, however.
Dealty
transcription is limited to a small region of the genome (A 
et al. , 1987; Rock et al. , 1987; Spivack and Fraser, 1987; 
Stevens et al. , 1987; Steiner et al. , 1989). HSV
transcripts present in latently infected cells have been 
termed latency-associated transcripts (LATs). The two 
major transcripts, which are not polyadenylated, appeared 
to share their 5' and 3' ends and to be produced by 
alternative splicing (Wechsler et al., 1988a; 1989). These 
mRNAs are complementary to Vm w IIO mRNA and partially 
overlap the 3' end of Vm w IIO gene (Rock et al. , 1987;
Spivack and Fraser, 1987; Stevens et al., 1987). LATs have 
been shown to be localised in the nucleus of the neuron 
(Rock et al. , 1987; Stevens et al., 1987; Javier et al.,
1988; Wechsler et al., 1988b). It is not clear whether 
these transcripts are translated. Results, however, 
obtained from SI nuclease and primer extension mapping 
suggest that an open reading frame may be a protein- 
encoding region (Wagner et al. , 1988) , and that a small
amount of the abundant transcript may be translated.
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Although the functions of these transcripts have not yet 
been elucidated, evidence from the analysis of deletion 
mutants, which do not make detectable amounts of LAT 
transcripts, clearly demonstrates that LAT transcripts are 
not required for establishment and maintenance of latency 
in mouse neurons (Javier et al. , 1988). Work on the HSV-1 
variant 1704, however, showed that reactivation was 
significantly delayed in comparison to wt virus, suggesting 
that these transcripts had a role in reactivation (Steiner 
et al., 1989). It is also thought that the LAT transcripts 
may keep VmwIIO region of the DNA in an open conformation 
such that during reactivation the VmwIIO gene can be 
rapidly transcribed.
1.13 CELL TRANSFORMATION AND ONCOGENESIS BY HSV
The involvment of HSV-2 in the development of
cervical carcinoma has long been speculated upon. The
higher prevalence of HSV-2 antibodies in woman with
cervical neoplasia than in matched controls (Nahmias et
al., 1980), and the detection of HSV sequences in certain
carcinoma biopsies led to the suggestion that HSV might be
a causal agent (McDougall et al., 1980; Eglin et al., 1981;
Macnab et al. , 1985). However, in a prospective study
Vonka et al. (1986) failed to find an association between
HSV-2 and cervical neoplasia.
Morphological transformation studies have been used
to investigate the oncogenic potential of HSV (Macnab,
1987) . Duff and Rapp (1973) were the first to demonstrate
\
that UV-.inactiva ted HSV-2 induces morphological
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transformation of mouse 3T3 cells. Subsequent studies 
identified a region from the HSV-1 genome, referred to as 
MTRI (Morphological transformation region), which maps in 
Xbal f fragment between 0.29 to 0.45mu (Camacho and Spear, 
1978; Reyes et al. , 1979). Two MTRs have been identified
in HSV-2 DNA. MTRII maps in the Bglll n fragment between 
0.58-0.62mu (Reyes et al., 1979; Galloway and McDougall, 
1981; Cameron et al.,1985; Jones et al. , 1986), and MTRIII 
maps in Bglll c between 0.54 to 0.58mu (Peden et al., 1982; 
Jariwalla et al., 1983).
A "hit and run" mechanism of cell transformation 
has been proposed for HSV (Skinner, 1976; Minson et al., 
1976), since the viral DNA was not retained within the 
transformed cells (Minson et al., 1976; Galloway and
McDougall, 1983; Galloway et al., 1984; Cameron et al., 
1985) , and there did not appear to be any HSV-encoded 
transforming proteins or oncogenes (Cameron et al. , 1985;
Macnab et al., 1985). Studies have suggested that HSV DNA 
can stimulate expression of cellular genes and induce 
specific mutations (Schlehofer and Zur Hausen, 1982), and 
cause gene amplification in a similar manner to chemical 
carcinogens (Lavi, 1981) while the viral DNA polymerase may 
be involved in cellular gene amplification (Matz et al. , 
1984), and induce chromosomal rearrangments.
1.14 GENETICS STUDIES OF HSV
Perhaps one of the most important approaches which 
has enabled individual genes to be identified and their 
functions elucidated is the isolation and analysis of HSV
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mutants. The information obtained on the genomic location 
of the mutations and virus-encoded polypeptides has helped 
to expand our knowledge of the functional organisation and 
regulation of HSV genes.
1.14.1 Temperature sensitive mutants
In HSV the majority of conditional lethal mutants
isolated are ts. Generally, the temperature sensitivity is
produced by a missense substitution of an amino acid in the
protein which results in a polypeptide with a temperature-
impaired function. As a consequence, ts mutants of HSV are
able to replicate at the PT (31°-34°) but not at the NPT
(38°-39.5°). At the high temperature the affected protein
is either unstable or is unable to form a functional
conformation. Ts mutants can arise spontaneously in wt
virus stocks, however, most ts mutants have been induced by
treatment of virions with UV light, nitrous acid, or
nitrosoguanidine, by treatment of viral DNA with nitrous
acid, hydroxylamine or UV light, or by exposing virus-
infected cells to 5-Bromodeoxyuridine (BUdR) or 2-
aminopurine (Schaffer et al.,1970; Timbury, 1971; Brown et
al. , 1973; Schaffer et al. , 1973; Esparza et al. , 1974;
Manservigi, 1974, Chu et al., 1979; Machtiger et al., 1980;
Jofre et al. , 1981). The total number of essential genes
■fte
encoded by/HSV genome is still unclear. More than 30
cistrons in HSV-1 (Schaffer et al., 1978) and 20 cistrons 
in HSV-2 (Timbury et al., 1976; Schaffer et al., 1978),
have been identified by complementation studies, suggesting 
that there are at least 30 essential genes. Although ts
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mutants have been extreme ly useful in elucidating the 
functions of essential genes, there are large regions of 
the genome in which it has not been possible to induce ts 
lesions affecting virus viability. For this reason 
alternative approaches have been employed to extend the 
range of genetic material.
1.14.2 Insertion and deletion mutants
Deletion and insertion mutagensis have been used to 
determine functional domains of both essential and non- 
essential proteins and to identify non-essential genes. A 
variety of insertional mutagensis strategies have been 
adopted, including insertion of TK (Post and Roizman, 
1981), mini-Mu-phage-system (Jenkins et al. , 1985),
transposon Tn5 carrying a kanamycin resistant marker (Weber 
et al., 1987). Analysis of insertion and deletion mutants 
showed that, with the exception of gD, all Us genes are 
dispensable for growth in tissue culture (Longnecker and 
Roizman, 1986, 1987; Brown and Harland, 1987; Weber et al.,
1987).
1.14.3 Drug resistant HSV mutants
Many drugs against HSV are nucleoside analogues
which interfere with viral DNA replication, and select
mutations which depend in most cases on the HSV-encoded TK
for their antiviral effect. The virus-encoded enzyme will
oP
phsosphorylate a variety/nucleoside analogues, converting 
them from harmless compounds to an active drug which 
inhibits viral DNA polymerase activity by binding
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irreversibly to the active site, or by causing chain 
termination when incorporated into DNA. Most mutants 
resistant to analogues are deficient in TK activity (Kit 
and Dubbs, 1963; Dubbs and Kit, 1964; Ellion et al. , 1977; 
Stow et al., 1978; Field et al. , 1980), and compensate for 
their deficiency in exponentially growing cells by using 
cellular dTMP. Although most acycloguanosines-resistant 
mutants have altered TK, TK+ acyclovir resistant mutants 
have been isolated with lesions in DNA polymerase. The 
altered polymerase fails to interact with the 
phosphorylated acyclovir, thus preventing the incorporation 
of the lethal nucleotide analogue into virus DNA 
(Crumpacker et al., 1980; Larder and Darby, 1985; Larder et 
al., 1987). Some drugs act directly on DNA polymerase, for 
example phosphonoacetic acid (PAA). This drug interacts 
with the pyrophosphate binding site on the viral DNA 
polymerase (Hay and Subak-Sharpe, 1976; Leinbach et al.,
1976; Purifoy and Powell, 1977). PAA-resistant mutants 
have been isolated with an altered DNA polymerase.
1.14.4 Immune cytolysis-resistant mutants (icr)
Mutants which are resistant to immune cytolysis 
have either altered conformation of glycoproteins, or 
aberrant glycosylation or fail to insert viral 
glycoproteins into the plasma membrane. Hence, mutant- 
infected cells becomes resistant to antibody and complement 
mediated immune cytolysis (Machtiger et al., 1980; Glorioso 
et al., 1980; Pancake et al., 1983). An icr locus has been 
identified within UL32 (Coen et al., 1984).
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1.14.5 Host range mutants (hr)
Transformed cell lines which provide essential gene 
products in trans to complement defects in viral genes have 
been developed. HSV mutants, with inactive essential 
genes, are incapable of growth on normal cells, but can be 
propagated on cell lines which express the required wt 
gene. The isolation of hr mutants has been particularly 
useful in cases where it has not been possible to isolate 
ts mutations and for detailed functional analysis of 
essential genes such as Vmwl75 (Davison and Stow, 1985; 
Deluca et al. , 1985), gB (Cai et al. , 1987), MDBP (Oberg
and Schaffer, 1987), and the UL8 gene product (Carmichael 
and Weller, 1989) .
1.14.6 Syncytial Mutants
Mutants with defects in certain genes of HSV cause 
extensive fusion of virus-infected cells instead of 
individual cell rounding. Virus mutants which give rise to 
syncytial plaque morphology are known as syn mutants. At 
least five loci are thought to influence syncytial 
morphology (See table 3), of which only UL1 and UL53 appear 
to specify membrane-associated proteins (McGeoch et al.,
1988) .
1.14.7 Genetic interactions
1.14.7.a Complementation
Generally complementation refers to enhancement of 
yield or plaque formation at the NPT in cells mixedly
TABLE 3
Genes associated with syn loci
(*)
Gene
Map coordinates of 
isolated mutants(m.u.) Locus no.
Ref. 
No.
UL1 0.04-0.064 Syn 4 1
UL24 around 0.3 Syn 5 2
UL27 0.345-0.355 Syn 3 3
UL53 0.724-0.74 Syn 1/2 4
References
1- Little and Schaffer, 1981.
2- Sanders et al., 1982.
3- Ruyechan et al., 1979; Deluca et al., 1982.
4- Little and Schaffer, 1981; Bond and Person, 1984; 
Pogue-Geile et al., 1984
*- McGeoch et al., 1988
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infected with two different mutants. Complementation 
occurs as a result of the interaction between the gene 
products of two ts mutants, one of which is defective in 
one gene product while the other is defective in another. 
Normally, each mutant can compensate for the defective gene 
product in the other virus by supplying the active gene 
product. However, it is possible sometimes that only one 
mutant can supply a functional gene product for the other 
mutant and therefore, only the yield of one of the mutants 
is enhanced in the mixed infection. Two quantitative 
assays, the progeny yield test and the infectious centre 
test have been widely used. However, the progeny test is 
considered to be more reliable since fewer recombinant 
viruses are generated. A complementation index greater 
than at least 2.0 is regarded as positive complementation. 
(Timbury, 1971; Brown et al., 1973).
1.14.7.b Recombination
Results of recombination frequencies obtained from 
crosses of ts mutants led to the construction of linear 
linkage maps (Brown et al., 1973; Schaffer et al., 1974; 
Timbury and Calder, 1976). Subsequent work using ts 
mutations and a variety of selected and unselected markers 
led Honess et al. (1980) to conclude that the genetic 
linkage map was circular and that recombination normally 
occured between concatemeric or circular DNA. A circular 
genetic map was also obtained with PRV ts mutants. In 
addition evidence was obtained suggesting that
recombination occured mainly between parental DNA rather
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than progeny genomes prior to DNA replication (Ben-Porat et 
al. ,1982). The finding that recombinants were in an 
arrangement that minimized the number of crossover events 
supports the idea that parental DNA participates in the 
generation of recombinants (Umene, 1985). In contrast to 
these observations it was shown that recombination 
frequency increased with time, indicating that both 
parental and progeny DNA took part in recombination 
(Ritchie et al., 1977; A. MaClean, 1988), and that multiple 
rounds of recombination occured.
Recombination can occur between HSV-1 and HSV-2 
(Timbury and Subak-Sharpe, 1973; Esparza et al., 1976).
Restriction endonuclease analysis has been used to map the 
crossover points in recombinants (Morse et al., 1977;
Preston et al., 1978; Wilkie et al., 1979). Intertypic
recombinants have been useful for mapping mutations and 
polypeptides on to the virus genome (Halliburton et al. , 
1977; Marsden et al., 1978, Morse et al., 1978; Preston et 
al., 1978), although more precise localisation of markers
has been achieved by intratypic marker rescue technique 
using cloned restriction endonuclease viral fragments (Stow 
et al. , 1978; Stow and Wilkie, 1978; Chartrand et al. ,
1979; 1981; Preston, 1981).
Studies on intramolecular recombination have 
suggested that site-specific recombination between inverted 
copies of the a sequence in a single genome is responsible 
for inversion of unique sequences (Mocarski and Roizman, 
1981; Smiley et al., 1981; Chou and Roizman, 1985). The b 
sequence in the long repeat is thought to be less actively
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involved than the a sequence in inversion of U l (Longnecker 
and Roizman, 1986). However, results obtained recently by 
Weber et al. (1988), has provided evidence that the a
sequence in HSV-1 is not a target sequence for site 
specific recombination. Instead sequence inversion in 
HSV-1 appears to be mediated by the same complex of 
proteins that replicate the viral DNA, and not by an 
independent recombinase function acting at a specific site. 
It is clear, however, that viral DNA replication is not 
absolutely required for recombination, since recombinants 
can be formed between two DNA negative mutants with lesions 
in V m w 175 (V. Preston, personal communication).
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MATERIALS
VIRUSES
The HSV-1 wt virus used in this study was strain 
17syn* which has a non-syncytial plaque morphology (Brown 
et al. , 1973). Two HSV-1 ts mutants were characterised.
The first mutant, tsl201 (Preston et al., 1983), was
derived from the multiple mutant 17tsJC116 (Coates, 1982). 
EcoRI f from a syn* derivative of 17 tsJC116 was cloned into 
the plasmid pACYC184 and recombined into 11syn* . Tsl2Ql 
was isolated from this transfection experiment. The 
revertants for growth at the NPT, tsl201 rev2, and fcsl201 
rev3, were independent isolates from low passage mutant 
stocks (Preston et al., 1983). The second HSV-1 mutant,
tsl233, was isolated from a UV mutagenised wt virus stock 
by Miss I. McDougall. Two independent revertants for 
growth at the NPT, tsl233 revl and tsl233 rev2, were 
isolated from low passage stocks of the mutant during this 
study. Additional viruses used were HSV-17tsKsyn* 
(Crombie, 1975; Preston, 1981), HSV-1 KOStsN20 (Schaffer 
et al., 1974), HSV-l/HSV-2 recombinant BX1(31-1) (Marsden
et al. , 1976), and the wt HSV-2 strain HG52 (Timbury,
1971). Seed stocks of viruses were kindly provided by Mrs 
M.Murphy with the exception of tsK and tsl233 which were 
supplied by Dr. V.G. Preston.
TISSUE CULTURE CELLS
BHK21 clone 13 cells, a fibroblastic line established
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by Macpherson and Stoker (1962), and low passage HFL cells 
(Flow 2002) were used throughout this study. Cell lines 
were obtained from Dr. V.G. Preston.
TISSUE CULTURE MEDIA
BHK cells were grown in IX Glasgow modified Eagle's 
medium (Busby et al. , 1964) (supplied as a 10X concentrate 
by Gibco Ltd.), supplemented with 100 units/ml penicillin, 
100 ug/ml streptomycin, 10% new born calf serum, and 10%
tryptose phosphate. HFL cells were cultured in the same
medium except that 10% foetal calf serum and 1% non 
essential amino acids were used instead of calf serum and 
tryptose phosphate. The following modified media were also 
used in this study:-
Eagle's medium containing n% calf serum______________ ECn .
" " " n% foetal calf serum________EFCn .
" " " n% human serum_____________ EHun .
Agar overlay. This consisted of Eagle's medium lacking 
phenol red, 10% calf serum, and 0.6% Noble's agar.
BACTERIA
Escherichia coli strain DH1 (F- ,recAl, gyrA96, end
Al, supE44)(Hanahan, 1983), was used for propagating
plasmids.
Escherichia coli strain JM101 was the host bacterium 
for M13mpl8, M13mpl9, and recombinant bacteriophage used in 
DNA sequencing analysis (Messing et al., 1981).
Escherichia coli strain RB791 (=W3110 lacT* , L b ,
Brent and Patashue, 1981) was used for the expression of
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UL33 gene.
BACTERIAL CULTURE MEDIA
Bacteria were either grown in L-broth or 2YT medium.
PLASMIDS
The following plasmids were supplied by Dr. V. G. 
Preston:
PLASMID INSERT VECTOR
PGX22
pGX24
pGX56
pGX7 4
PGX142
PGX198
PGX208
BamHI k of ts* 17syn+
BamHI a
BamHI u
EcoRI o
Kpnl t
BamHI u of tsl201 
BamHI u of tsl201 rev2
PAT153.
ft
ff
PACYC184
PAT153.
ft
VI
Three other plasmids used in this study were kindly 
provided by Dr. C. Preston.
pKK233-2 : A vector used for high level expression of an
intact cloned gene (Amann and Brosius, 1985). This vector 
contains a unique Ncol site at the 3' end of the trc 
promoter for cloning either blunt end or Ncol fragments, 
pCI15 : An expression vector containing a deletion of 15
amino acids from the N-terminal portion of the 
bacteriophage cl repressor (Amann and Brosius, 1985). 
p23 : was derived from the plasmid pGX166 and contains IE 
Vmwl75 promoter sequences inserted into HSV-1 TK gene 
(Details of this plasmid are in chapter 3).
CHEMICALS
Chemicals were obtained from the following suppliers:
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BDH chemicals, Poole, England; Bio-Rad Laboratories, 
California, USA; Koch-Light Laboratories, Suffolk, 
England; Pharmacia Fine Chemicals, Uppsala, Sweden; and 
Sigma(London) Ltd. Reagents for electron microscopy were 
obtained from two companies, Agar Aids, Stanstead, Essex, 
and Taab Laboratories, Emmer Green, Reading. Analytical 
grade reagents were used wherever possible.
ENZYMES
Restriction endonucleases were supplied by 
Gibco/Bethesda Research Laboratories (U.K.) Ltd., Paisley, 
Scotland, Northumbrian Biological Ltd., Cramlington, 
England, and Boehringer Corporation Ltd., Lewes, England. 
Other enzymes were obtained from the following suppliers:
ENZYME SUPPLIER
Calf intestinal phosphatase.
Proteinase K
Lysozyme
DNase
RNase
DNA polymerase holoenzyme 
Klenow fragment DNA polymerase
Boehringer Corp. Ltd
l
Sigma Chemical Ltd.
l
it
New England Biolabs. 
Gibco, Bethesda Lab.
OLIGONUCLEOTIDES
Phosphorylated Xhol oligonucleotide linkers were 
purchased from New England Biolabs, CP laboratories.
RADIOCHEMICALS
All radiochemicals were obtained from Amersham 
International pic.
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ANTIBODIES
Monoclonal antibody 5010B, specific for HSV-1 P40 
(UL26 gene product), was prepared by Dr. A. Cross.
OLIGOPEPTIDES
Oligopeptides specific to part of UL33 gene product
were purchased from Peptide and Protein Research, Windson
Berks, England. Oligopeptides specific to a portion of 
UL26 gene product were made in the Institute of Virology by 
Miss Anna Owsianka, using LKB BioLynx 4170 Automated
Peptide Synthesiser.
IMMUNOLOGICAL REAGENTS
Protein A-Sepharose was obtained from Sigma (London) 
Ltd. BSA coupled to CNB activated Sepharose 4B was
prepared by Dr. G. Hope. t1 2 3 I]-Protein A was made and 
generously supplied by Mrs. M. Murphy at the Institute of 
Virology. Bis-diazotized benzidine (DAB) was prepared and 
supplied by D r . H. Marsden. A 10% suspension of formalin 
fixed Staphylococcus aureus was provided by Dr. V. G. 
Preston.
ANIMALS
New Zealand white rabbits were purchased from Hylyne 
Rabbits Ltd., England. Polyclonal antibodies were raised 
in these animals.
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MISCELLANEOUS
Nitrocellulose membranes were supplied by Schleicher 
and Schuell, Dassel, West Germany. Noble's agar was 
obtained from Difco Ltd. Photographic film was supplied by 
Kodak Ltd., London, England. Plastic petri dishes, and 
plastic microtiter plates (24-wells and 96-wells) were 
purchased from Nunclon Ltd. Plastic 850 cm2 roller bottles 
for cell culture were supplied by Becton Dickinson Ltd.
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STANDARD SOLUTIONS
Tissue Culture Reagents and Buffers
Giemsa stain 1.5% (w/v) Giemsa in glycerol, heated
at 56° for 120 min and diluted with an 
equal volume of methanol.
Phosphate buffered 170 mM NaCl, 3.4mM KC1. lOmM Na2 HPO4
saline (PBS) and 2mM KH2 PO 4 pH 7.2 (Dulbecco and
Vogt, 1954).
140mM NaCl, 30mM KC1, 28mM NazHP04 , 
lmg/ml glucose, 0.0015%(w/v) phenol 
red, 100 units/ml penicillin, 100 pg/ml 
streptomycin, 25mM Tris-HCl pH 7.4. 
0.25% (w/v ) trypsin (Difco) in tris- 
saline.
0.6mM EDTA dissolved in PBS containing 
0.002% (w/v) phenol red.
Tris-saline
Trypsin
Versene
DNA Gel Electrophoresis Buffers
Dye Ficoll
Electro-elution
buffer (10X) 
Elution buffer
TBE buffer (10X)
15% (w/v) ficoll, 0.2% (w/v) 
bromophenol blue, lOOmM EDTA.
50mM sodium acetate, lOmM EDTA,
400mM Tris-HCl pH 7.8.
500mM ammonium acetate, ImM EDTA and 
0.1% SDS.
89mM tris-HCl pH 8.3, 89mM boric 
acid, 2mM EDTA.
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Southern Blot Buffers
Denhardt's
buffer (5X) 
Gel Soak I 
Gel Soak II 
Hybridization 
buffer
Nick translation 
buffer 
SSC buffer (10X)
0.1% (w/v) Ficoll, 0.1 (w/v) 
polyvinylpyrollidone, 0.1% (w/v) BSA. 
200mM NaOH, 600mM NaCl. 
lOOOmM Tris-HCl pH 8.0, 600mM NaCl.
5X Denhardt's buffer, 0.1%(w/v) SDS 
6X SSC, 30pg/ml denatured calf thymus 
DNA.
50mM Tris-HCl pH 7.5, 5mM MgCl2 , 
50ug/ml BSA, ImM DTT.
3000mM NaCl, 300mM tri-sodium citrate, 
pH with 300mM citric acid to pH 7.5.
DNA Sequencing Reagents and Buffers
Gel bottom mix (6%) 150ml 40% acrylamide:N ,N ' methylene bis
(2.5X TBE)
Chase mix
Formyl dye
Labelled mix
acrylamide (20:1), 540g urea, 50g 
sucrose, 20ml 1% bromophenol blue 
(BPB), dissolved in H2 O, de-ionised, 
filtered and made up to 1000ml with 
62.5ml of 40X TBE. For every 14ml of 
bottom mix 30yl of 25% ammonium 
persulphate (APS) and 30pl TEMED were 
added.
dATP, dTTP, dCTP, dGTP, each at a 
concentration of 0.5mM in H2 O.
0.1% (w/v) BPB, 0.1% (w/v) XC, 20mM 
Na2EDTA in deionised formamide.
6pl of [32P] dATP (lmCi/100pl), and 
18yl of 11.8yM dATP.
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Sequencing buffer
(10X) . lOOmM Tris-HCl pH 8.5, lOOmM MgClz .
TE buffer lOmM Tris-HCl pH 7.4, O.lmM EDTA.
Gel top mix 150ml 40% acrylamide:N ,N ’ methylene bis
acrylamide (20:1), 540g urea dissolved 
in H2 O and made up to 1000ml with 50ml 
10X TBE. For 100ml of top mix add 
160ul 25% APS and 160pl TEMED were 
added.
Sequencing solutions:
\Ml dA-0 dT-0 dC-0 dG-0
5mM 7-deaza dGTP 20 20 20 1
5mM dCTP 20 20 1 20
5mM dTTP 20 1 20 20
TE (10X) 50 50 50 50
HzO 540 370 370 370
Sequencing mixes:
\pl dN-0 ddNTP HzO
T seq 500 500 (600pM ddTTP) 0
C seq IV 105 (140yM ddCTP) 395
G seq I I 155 (200pM ddGTP) 345
A seq II 125 (140pM ddATP) 375
Protein Gel Electrophoresis Buffers
Destain 
Gel fixative
Resolving gel
buffer (4X) 
Stacking gel
buffer (4X) 
Tank buffer
5% Methanol, 7% acetic acid.
50% Methanol, 7% acetic
acid, 0.2% Commassie brilliant blue.
1500mM Tris-HCl pH 8.9, 0.4% (w/v) SDS.
490mM Tris-HCl pH 6.7,0.4% (w/v) SDS. 
53mM Tris, 53mM glycine, 0.1%(w/v) SDS
78
Western Blot Buffers
Antibody solution IX NT, 0.005% Tween 20, 1% BSA.
5X TBS, 3% gelatin, mixture left at 37° 
for lh to allow gelatin to dissolve. 
160mM borate, 140mM NaCl pH 9.
25mM Tris, 192mM glycine, 20% (v/v) 
methanol (pH 8.3).
0.23g benzidine hydrochloride, 180mM 
HC1, 50mM sodium nitrate.
IX NT, 0.05% Tween 20, 1M KI.
0.09% NaCl, ImM Tris (pH 7.4).
Blocking buffer
Borate buffer 
Blotting buffer
Bis-diazotized 
benzidine (DAB) 
KI solution
NT buffer 
Protein A solution IX NT, 3% BSA.
Tris buffered 
saline (TBS) (5X) 20mM Tris, 500mM NaCl (pH 7.5) 
Wash buffer IX NT, 0.05% Tween 20.
Immunopreciptation Buffers
Disruption buffer 2% (w/v) SDS, 10% (v/v) glycerol,5%
(v/v) p-mercaptoethanol, 50mM Tris- 
HCl pH 6.7, 0.004% (w/v) bromophenol 
blue.
Glycine elution 
buffer 
RIPA buffer
Washing buffer
200mM Glycine pH 2.5.
0.1% (w/v) SDS, 1% (w/v) sodium 
deoxycholate, 1% (v/v) NP40, ImM 
EDTA, 150mM NaCl, lOmM Tris-HCl pH 
pH 7.4.
600mM LiCl, lOOmM Tris-HCl pH 7.4, 1% 
(v/v) p-mercaptoethanol.
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Zweig's buffer 0.1M Tris-HCl pH 8, 10% glycerol,0.5% 
NP40, 0.5% sodium deoxycholate, 0.2mM 
phenylmethylsulphonyl fluoride (PMSF).
Bacterial Growth Medium and Cloning Solutions
L-broth
Ligation
buffer (10X) 
STET buffer
2YT
170mM NaCl, 5 g/1 yeast extract 10 g/1 
Difco Bactotryptone, supplemented with 
25-50pg/ml of appropriate antibiotic. 
200mM Tris-HCl pH 7.5, lOOmM MgCl, 
lOOmM dithiotheritol (DTT) and 5mM ATP. 
8% (w/v) sucrose, 5% (v/v) NP40, 50mM 
EDTA, 50mM Tris-HCl pH 8.
292mM NaCl, 16 g/1 bactotryptone,10 g/1 
yeast extract.
E.M. fixative 
HEPES buffered
Miscellaneous
Cell lysis buffer 0.6% SDS, lOmM EDTA, 500ng/ml pronase,
lOmM Tris-HCl pH 7.4.
2.5% gluteraldehyde in PBS.
130mM NaCl, 4.9mM KC1, 1.6mM Na2HP04 , 
saline (HEBS) 5.5 mM D-glucose, 21mM HEPES (N-2-
hydroxyethylpiperazine-N'-2- 
ethanesulphonic acid) pH 7.05. 
lOmM Tris-HCl pH 7.5, lOOmM NaCl, ImM 
EDTA.
lOmM Tris-HCl pH 7.5, lOmM KC1, 1.5mM 
MgClz.
NTE buffer
RSB
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METHODS
2.1 CELL CULTURE
BHK cells were grown in rotating 850cm2 culture 
bottles containing 100ml tissue culture medium in an 
atmosphere of 95% air, 5% CO2 at 37° . One bottle gave a 
confluent monolayer of approximately 3X108 cells which was 
used to seed five further 850cm2 bottles. Cells were 
harvested by washing the monolayers first with 20ml of 
versene, then with 40ml trypsin:versene (1:1). Cells were 
shaken off the bottles and resuspended in culture medium. 
HFL cells were routinely grown in flat flasks. A confluent 
monolayer from a 175 cm2 flask was sufficient to seed two 
flasks of the same size. To obtain a subconfluent 
monolayer of BHK or HFL cells after an overnight incubation 
at 31° , cells were seeded at a density of 2X106 per 50mm 
petri dish and 1X106 per 30mm dish.
2 . 2 VIRUS CULTURE
2.2.1 Production of virus stocks
Virus stocks were prepared from confluent BHK cells
grown in 850cm2 glass roller bottles. Growth medium was
removed and the cells were infected with a moi of 0.003 
pfu per cell in 60ml ECs . Virus-infected cells were
incubated at 31° for 3-4 days until extensive CPE had 
developed. Cells were shaken off the roller bottles into
the medium and pelleted at 1500 rpm at 4° for 15 min The 
virus-infected cell pellet was resuspended in a small
volume of supernatant medium, and sonicated to release 
cell-associated virus. Cell debris was removed by 
centrifugation at 3000 rpm for 15 min at 4° . The 
sonication step was repeated if necessary and the cell- 
associated virus stocks were pooled and stored at -70° . 
Cell-released virus from the clarified virus-infected cell 
medium was concentrated by centrifugation at 12,000 rpm at 
4° for 2h. The pellet was resuspended in virus-infected 
medium by sonication, and virus stored at -70° .
2.2.2 Sterility checks
Medium from virus-infected cells was streaked onto 
blood agar plates and plates incubated at 31° for 3-5 days.
Any virus stocks containing bacteria which grew on blood
agar were discarded.
2.2.3 Titration of virus stock
Serial ten-fold dilutions of virus stocks were made 
in PBS containing 5% calf serum. Growth medium was removed 
from 80% confluent BHK cell monolayers in 50mm plates and 
lOOul of diluted virus added to each dish. After virus 
absorption for lh at either 37° (for plates to be incubated 
at the PT) or 38.5° (for plates to be incubated at the 
NPT), cells were overlaid with EHus to prevent formation of 
secondary plaques. Plates were incubated either for 2 days 
at a NPT of 38.5° or 39° , depending on the mutant, or for 3
days at the PT of 31° , after which the medium was replaced
with Giemsa stain for 15 min at RT. The plates were washed 
with water to remove excess stain, and virus plaques
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counted under a dissecting microscope.
2.2.4 Ts mutant infections
Virus infections were carried out at a NPT of 38.5° 
or 39° depending on the mutant, and a PT of 31° . Cell 
monolayers were absorbed at the required temperature for a 
maximium of lh. The medium for washing and overlaying 
virus-infected cells grown at the NPT was prewarmed to 42° . 
All manipulations at NPT were carried out as rapidly as 
possible to prevent any drop in the NPT.
2.2.5 Isolation of spontaneous ts* revertants of tsl233 
Single plaques were isolated from a low passage
stock of tsl233 titrated on BHK cells at 31° . BHK cell 
monolayers from five 50mm petri dishes were infected with 
the progeny from a single plaque and a small seed stock 
prepared. The seed stocks were titrated at the NPT and 
cell monolayers showing CPE after incubation for 2 days 
were harvested. Progeny virus which formed plaques at the 
NPT were plaque purified once at the NPT and twice at the 
PT. All plaques were isolated from cells overlaid with 
agar. 50mm plates of BHK cells were infected with ts* 
virus from two independent seed stocks of tsl233, and virus 
from each plate harvest was used to grow up a high titre 
virus stock.
2.3 PREPARATION OF VIRION DNA
2.3.1 Large scale preparation of DNA
BHK cells were grown in 5-10 850cm2 roller bottles.
These were infected with virus as described for the 
production of stocks. When extensive CPE had developed, 
the virus-infected cells were shaken into the medium and 
pelleted by low speed centrifugation for 15 min at 4° . The 
infected cell pellet was resuspended in 20ml RSB containing 
0.5% NP40. After incubation on ice for 10 min, the sample 
was centrifuged at 2,500 rpm for 10 min at 4°. The pellet 
of nuclei and cell debris was resuspended in 20ml RSB-NP40 
buffer, and the sample left on ice for 10 min prior to 
centrifugation. The two cytoplasmic supernatant fractions 
were pooled with the clarified virus-infected cell medium 
and the virus concentrated by centrifugation at 12,000 rpm 
for 2-3h at 4° . The virus pellet was resuspended in 5ml 
NTE buffer and lysed by the addition of SDS at a final 
concentration of 2% (w/v). The virus DNA was extracted
three times with phenol saturated with TE, followed by a 
chloroform extraction. The DNA was precipitated by the 
addition of two volumes of ethanol, concentrated by low 
speed centrifugation and resuspended in 10ml lOmM Tris-HCl. 
RNA was removed by incubating the sample with 10jig/ml 
RNasel overnight at RT. The DNA solution was deproteinised 
with proteinase K at 31° for 2-3h, then extracted once with 
phenol-chloroform (1:1), once with chloroform, made 200mM 
with NaCl, and precipitated with two volumes ethanol. The 
DNA was pelleted by low speed centrifugation, lyophilised 
and resuspended in lOmM Tris-HCl pH 7.6.
2.3.2 Small scale preparation of virus-infected cell DNA 
HFL cells (4X106 ) were infected with a moi of 5 pfu
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virus per cell and incubated at the appropriate temperature 
for 18h before extraction of DNA. Total virus-infected 
cell DNA or DNase-resistant (encapsidated) DNA was prepared 
from the virus-infected cells as described by Stow et al. 
(1983).
2.3.2.a Total virus-infected cell DNA
Cell-released virus in the growth medium was 
pelleted by centrifugation at 18,000 rpm for lh at 4° in an 
SS21 rotor. The virus pellet was resuspended in a small 
volume of lysis buffer containing 500yg/ml pronase and 
combined with virus-infected cells harvested in 2ml of the 
same buffer. After incubation for 4h at 37° , NaCl was 
added to a final concentration of 200mM, and the DNA 
solution was extracted twice with phenol:chloroform (1:1), 
once with chloroform and precipitated with ethanol. DNA 
was pelleted, lyophilised and resuspended in 400pl H2 0 
containing 10pg/ml RNase I.
2.3.2.b Encapsidated DNA (DNase-resistant DNA) 
Virus-infected cells were harvested into 0.5ml RSB,
containing 0.5% (v/v) NP40 and 100pg/ml DNase I, combined
with cell-released virus, and incubated for 2h at 37°.
SDS, EDTA, and pronase, at the same concentration present
in lysis buffer, were added and incubation continued for a 
further 2h at 37° . The DNA was extracted twice with
phenol:chloroform (1:1), once with chloroform and 
precipitated in ethanol. DNA was pelleted, lyophilised and 
resuspended in 200pl H2 0 containing lOpg/ml RNase I.
2.4 ANALYSIS OF DNA
2.4.1 Restriction endonuclease digestion of DNA
DNA was digested with restriction endonucleases 
according to the conditions recommended by the suppliers 
for each enzyme.
2.4.2 Agarose gel electrophoresis
DNA fragments were separated on horizontal agarose 
gels containing agarose at a concentration of 0.8-1% (w/v), 
(depending on the size of DNA fragments to be resolved) in 
IX TBE buffer containing 0.5pg/ml ethidium bromide. DNA 
samples in 10% (v/v) dye ficoll were loaded into wells
formed with plastic combs, and the gel was electrophoresed 
at 2-10 v/cm2 in IX TBE buffer at RT for 8-18h. The 
separated fragments were visualised under UV light.
2.4.3 Purification of DNA fragments from agarose gels 
Separated DNA fragments were eluted from gel slices
by electrophoresis at lOOv for 3h using electroelution 
buffer. DNA fragments were further purified by extraction 
twice with phenol: chloroform (1:1) and once with 
chloroform. Sodium acetate (pH 5.5) was added to a final 
concentration of 0. 3M and DNA fragments precipitated with 
an equal volume of isopropanol at RT. DNA fragments were 
pelleted, lyophilised and resuspended in lOmM Tris-HCl 
(pH 7.5).
2.4.4 Polyacrylamide gel electrophoresis (PAGE)
PAGE was used for separating small DNA fragments
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ranging from 30-900 bp in size. Vertical slab gels 
consisted of 10% polyacrylamide (prepared from a stock 
solution of acrylamide/N-N'-methylene bisacrylamide in a 
ratio of 29:1 w/v) in 0.55X TBE. A final concentration of 
0.006% (w/v) APS, and 0.004% (v/v) TEMED were added to the 
polyacrylamide solution to polymerise the gels. Teflon 
combs were used to form wells. Electrophoresis was carried 
out at 3v/cm2 for 12-16h in 0.55X TBE. Gels were stained 
in 0.55X TBE containing 0.5yg/ml EtBr for 30 min, and the 
DNA bands were visualized under UV light.
2.4.5 Purification of DNA fragments from polyacrylamide
gels
The polyacrylamide gel slice containing separated 
DNA fragment was placed in a small eppendorf tube pierced 
with holes at the bottom and centrifuged in a large 
eppendorf tube. The crushed gel slice was incubated in 
400ul of DNA elution buffer overnight at 42°. DNA samples 
were filtered through a GF/C glass fiber disc fitted in a 
syringe, and precipitated with two volumes of ethanol. The 
DNA pellet was dissolved in 0.3M sodium acetate and 
reprecipitated with ethanol. DNA fragments were 
concentrated by centrifugation, lyophilised and resuspended 
in H2 O.
2.5 MARKER RESCUE TECHNIQUE
Marker rescue experiments were carried out as 
described by Stow et al. (1978) with the modification of 
Preston (1981) . Calcium chloride was added to a final
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concentration of 130mM to a solution containing 0.8pg of 
intact mutant virion DNA, 10yg/ml calf thymus carrier DNA, 
HSV-1 DNA fragment (usually between 5-10 fold molar excess 
relative to virion DNA) in IX HEBS. The samples were left 
for 5 min at RT to allow a fine suspension to develop. The 
suspension was added to 50mm dishes containing BHK cell 
monolayers from which growth medium had been removed. The 
cells were incubated at 37° for 45 min, then overlaid with 
ECg . At 4h pi, the cells were washed once with ECg , and 
treated with 25% (w/v) DMSO in IX HEBS for 4 min at RT.
DMSO was removed from the monolayers by washing the cells 
twice with E C g, and cells were incubated in 4ml of ECi o at 
31° for 3-4 days until extensive CPE had developed. Cells 
were scraped into the growth medium, disrupted by 
sonication, and the virus yield was determined at the PT 
and NPT.
2.6 COMPLEMENTATION YIELD TEST
Cells were infected at a moi of 10 pfu per cell (5 
pfu per cell of each of the ts mutants in the mixed 
infections). After lh absorption at the NPT, cells were 
washed three times with warm ECg to remove unadsorbed 
virus, and incubated in 2ml of ECg for 24h at the NPT. 
After this time cells were scraped into growth medium, 
sonicated and virus titrated at the PT and NPT to determine 
the virus yield. Complementation indices (Cl) were 
calculated as described by Brown et al. , (1973) using the
following formula:
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(X + Y)pt- (X + Y)NPT
Cl = _________________________________________________________________________________________
1 / 2 { (Xp T + Yp t )-(Xnpt+ Ynpt)}
where (X+Y)PT and (X+Y)NpTrepresent the titre of progeny 
virus from the mixed infection of tsX and tsY at PT and 
NPT respectively. Usually Cl greater than five were 
considered positive.
2.7 SOUTHERN BLOT ANALYSIS
2.7.1 Transfer of DNA fragments to nitrocellulose
The method used was essentially the same as that 
described by Southern (1975). The agarose gel, containing 
separated restriction endonuclease fragments, was shaken 
gently in 200mM HC1 for 30 min at RT to depurinate the DNA. 
The gel was then washed in distilled water, treated with 
gel soak I for lh to denature the DNA, and neutralized with 
gel soak II for lh. The gel was then placed on two sheets 
of Whatman 3mm filter paper, the ends of which were in 
contact with a reservoir of 10X SSC buffer. A 
nitrocellulose sheet, moistened with distilled water, was 
placed on top of the gel, and any air bubbles were removed. 
Four sheets of 3mm filter paper, cut slightly smaller than 
the gel size, were placed over the nitrocellulose sheet, 
and a weighted stack of paper towels was laid on the 
Whatman filter paper. The nitrocellulose sheet was removed 
the next day, rinsed in 2X SSC buffer, air dried and baked 
in a vacuum oven at 80° for 2h. The blotted gel was soaked 
with IX TBE containing 0.5pg/ml EtBr for 30 min and
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visualised under shortwave UV light to ensure that 
efficient transfer of DNA fragments from the gel had 
occured.
2.7.2 In vitro [32P]-labelling of DNA by nick translation
DNA fragments were labelled with [32P] in vitro as
described by Rigby et al. (1977). Plasmid DNA (0.5jig) in 
50pl reaction mixture containing, 40pM dATP, 40jiM dTTP, IX 
nick translation buffer, and 1X10-6 mg/ml DNase I, was 
incubated in a 37° water bath for 2-3 min. The mixture was 
then placed on ice, and 30pCi each of a-[3 2 P]-dGTP, a- 
[32P]-dCTP together with 1 unit of E.coli DNA polymerase I 
were added. Incubation was carried out at 15° for 2h. The 
isotope incorporation into DNA was determined by spotting 
2pl of the reaction mix on to a filter disc, precipitating 
the DNA with 5% TCA (w/v) , and measuring the amount of 
radioactivity by Cherenkov counting. The reaction was 
terminated by the addition of lOOmM EDTA, and the samples 
extracted once with phenol:chloroform (1:1). A Sephadex 
G50 column (10ml) equilibrated with TE buffer was used to 
separate unincorporated deoxyribonucleoside triphosphates 
from [32P]-labelled DNA. The first peak of radioactivity, 
which contained the nick-translated DNA, was eluted, 
denatured in 0.2N NaOH for 10 min at RT, and then 
neutralised with 0. 2N HC1. A specific activity of 1X107- 
1X108 cpm per ug plasmid DNA was usually obtained.
2.7.3 DNA blot hybridisation
High stringency conditions of DNA hybridisation in
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aqueous solution were based on those described by Southern, 
(1975) and Denhardt, (1966). Vacuum-dried nitrocellulose 
sheets were prehybridised in 20ml solution, containing 6X 
SSC, 5X Denhardt's buffer, 0.1% (w/v) SDS and 20yg/ml
denatured calf thymus carrier DNA, at 72° in a sealed 
plastic bag submerged in a shaking water bath. After 2-3h 
the prehybridisation solution was replaced by hybridisation 
solution which contained, in addition to the above 
reagents, 1X107 cpm of denatured [32P]-labelled DNA probe 
per ml of hybridisation mix. Incubation was continued 
overnight at 72° . After incubation the nitrocellulose 
sheets were washed four times in 2X SSC, once in IX SSC, 
and once in 0.5X SSC. All washes contained 0.36% SDS and 
lOmM sodium pyrophosphate. Blots were air-dried and placed 
in contact with Kodak X-Omat XS-1 film and a Dupont 
phosphotungstate intensifying screen at -70° for 24h or lo 
nger.
2.8 RECOMBINANT DNA TECHNIQUES
2.8.1 Construction of chimeric plasmids
Vector DNA was linearised with the appropriate 
enzyme, treated with calf intestinal phosphatase at a 
concentration of 5 units per yg of plasmid DNA in the 
presence of 20mM Tris-HCl (pH 8) and 40mM NaCl. The sample 
was incubated at 37° for lh, after which the DNA was 
extracted twice with phenol:chloroform (1:1,v/v), once with 
chloroform, and precipitated with ethanol. A 4-10X molar 
excess of the purified HSV-1 DNA fragment relative to 
phosphatase-treated vector (40ng) was incubated overnight
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at 15° in a 20pl ligation reaction containing 1 unit of T4 
DNA ligase in ligation buffer.
2.8.2 Preparation of competent bacteria and plasmid DNA 
transfection
The procedure used for DNA transfection was based 
on the method described by Cohen et al., (1972). E.coli 
K12 strain DH1 was grown in 50ml of L-broth to an ODs 9 o n n 
of approximately 0.25. Bacteria were pelleted at 3000rpm 
for 15 min at 4° , resuspended in 25ml of ice-cold sterile 
lOOmM CaCl2 and incubated on ice for lh. The cells were 
pelleted and resuspended in 0.5ml lOOmM CaCl2 . At this 
stage the competence of the bacteria for transfection was 
tested using uncleaved plasmid. A sample containing 0.1ml 
of CaCl2 -treated cells and 20-40ng of plasmid DNA was 
incubated on ice for lh. The cells were heat shocked at 
42° for 2 min, and 1.5ml of L-broth was added to the 
bacteria. After lh incubation at 37° in a shaker, the 
bacteria were plated onto L-broth agar containing either 
50pg per ml ampicillin or tetracycline depending on the 
plasmids used. Plates were incubated overnight at 37°. 
Routinely >1X106 colonies per pg plasmid vector DNA were 
obtained. Competent bacteria were left at 4° for 16-18h 
prior to transfection since treatment for this period of 
time had been shown to increase the competence by 5 fold.
2.8.3 Small scale preparation of plasmid DNA (STET preps) 
Small amounts of plasmid DNA were prepared using a
modified method of Holmes and Quigley (1981) described by
Maniatis et al.,(1982). Single colonies from a bacterial 
plate were grown in 1.5ml L-broth containing 35-50yg/ml 
ampicillin or tetracycline (depending on the vector used) 
in an orbital shaker at 37° for 16-18h. The bacteria were 
pelleted at 10,000 rpm for 40 sec, and resuspended in 75pl 
STET buffer. After the addition of 6pl of lOmg/ml 
lysozyme, the sample was boiled for 1-2 min and centrifuged 
at 10,000 rpm for 10 min. The supernatant was extracted 
once with phenol:chloroform (1:1), once with chloroform, 
and the plasmid DNA precipitated with an equal volume of 
isopropanol at RT in the presence of 300mM sodium acetate. 
The DNA was pelleted at 10,000 rpm for 10 min, lyophilised 
and resuspended in 40pl Tris-HCl (pH 7.4).
2.8.4 Large scale preparation of plasmid DNA
The method used was based on the procedure
described by Godson and Vapnek (1973). A flask, containing
500ml L-broth supplemented with 25-50pg/ml ampicillin or 
tetracycline, was inoculated with 2ml of an overnight
bacterial culture. After incubation at 37° in an orbital 
shaker for 6-7h, a final concentration of 25yg/ml
chloramphenicol was added and incubation continued for a 
further 16h. Bacteria were pelleted by centrifugation at
4,000 rpm for 15 min at 4°. The pellet was resuspended in 
5ml of 25% (w/v) sucrose in 50mM Tris-HCl pH 8. After the 
addition of 2.5ml of 5mg/ml lysozyme in 50mM Tris-HCl pH 8, 
the mixture was incubated for 30 min on ice. EDTA (pH 7.9) 
was added to a final concentration of 50mM, and 5 min 
later, NaCl and SDS were added to a final concentration of
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750mM and 2.5% (w/v) respectively. The sample was left at 
4° for 2-3h, then centrifuged at 18,000 for lh at 0° to 
remove debris and high molecular weight bacterial DNA. The 
resulting supernatant was extracted twice with 
phenol:chloroform (1:1), and once with chloroform. Ethanol 
(2.5 volumes) was added and samples left at -20° for 2h. 
DNA was pelleted by centrifugation at 2,500 rpm for 15 min. 
The pellet was resuspended in 2-4ml of lOmM Tris-HCl, 0.ImM 
EDTA containing 100pg/ml RNase and incubated at 37° for
2-3h. Proteinase k, at a final concentration of 200yg/ml, 
was added and the sample incubated for 2h at 31°. The DNA 
was extracted twice with phenol:chloroform (1:1) and once 
with chloroform and precipitated at RT with 0.5 vol 
isopropanol in the presence of 300mM sodium acetate. The 
plasmid DNA was pelleted at 2,500 rpm for 30 min at RT, 
washed with 70% ethanol, lyophilised, and resuspended in 
lml lOmM Tris-HCl (pH 7.4).
2.8.5 Bacterial stocks
For long term storage, bacteria were concentrated 
by centrifugation at 4,000 rpm for 10 min and stored in 40% 
(v/v) glycerol, 1% (w/v) bactopeptone at -70°.
2.8.6 Construction of recombinant bacteriophage DNA
Two bacteriophage vectors M13mpl8, and M13mpl9 
(Norrander et al., 1983) were used. The double stranded RF 
DNA was linearised with the appropriate restriction 
endonuclease. A 4-10X molar excess of the purified HSV-1 
DNA fragment relative to the linearised vector (50ng) was
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incubated at 15° for 12-24h in 20pl ligation mix containing 
1 unit of T4 DNA ligase in ligation buffer.
2.8.7 Transfection of bacteriophage DNA into E.Coli JM101
The procedure for preparing competent E.coli strain 
JM101 (Messing, 1979) was essentially the same as the one 
used to make competent DH1 except that the bacteria were 
grown in 2YT medium instead of L-broth. Cells (200pl) were 
incubated with lOpl of ligation mix on ice for lh in glass 
tubes. Cells were heat treated at 42° for 5 min, then 
200pl of fresh bacterial stock was added together with 25pl 
2.5% isopropyl-D-thiogalactoside (IPTG) , 25]il 2% 5-chloro- 
4-bromo-3-indolyl-p-D-galactoside (BCIG or X-gal) in 
dimethylformamide and 3ml of top agar warmed to 42° . The 
sample was plated on to L-broth agar plates and incubated 
overnight at 37° .
2.9 Preparation of single stranded DNA for sequencing
Bacteriophage which contained inserts gave white 
plaques, while uninterrupted vectors gave blue plaques. 
Bacteriophage from a white plaque were transferred to 1.5ml 
of 2YT containing 1/100 dilution of an overnight culture of 
JM101, and the sample incubated in an orbital shaker at 37° 
for 5-6h. Bacteria were pelleted by centrifugation and the 
supernatant transferred to a tube containing 200pl of 20% 
polyethelene glycol in 2500mM NaCl. After at least 30 min 
at RT, the sample was centrifuged at 13,000 rpm for 5 min, 
and the bacteriophage suspended in lOOpl of TE. The 
bacteriophage DNA was extracted with 50pl of phenol
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saturated with TE. The DNA was precipitated in three 
volumes of ethanol in the presence of lOOmM sodium acetate, 
concentrated by centrifugation, washed with 70% ethanol and 
lyophilised. Finally the single stranded (ss) DNA was
resuspended in 50pl of 0.2% TE.
2.9.1 Sequencing single stranded DNA
The dideoxy chain termination/M13 vector method of 
DNA sequencing (Sanger et al. , 1977; 1980; Messing and
Vieira, 1982) was used during this study, the steps are;
A) Annealing primer to template DNA;
2pl of bacteriophage ssDNA was mixed with 2.5ng of
M13 17 base oligonucleotide primer in lOpl reaction mix
containing IX sequencing buffer. The sample was incubated 
at 37° for 30 min.
B) Sequencing reaction;
Two units of Klenow polymerase were added to lOpl 
of annealed DNA, and 2\il of the mix were dispensed in each 
of 4 wells which contained 2pl of either dT, d C , dG, and dA 
squencing mix in a 96-well microtitre plate. 2yl of 
labelled mix was then added to each well. The plate was 
covered, centrifuged at 1000 rpm briefly and incubated at 
31° . After 15 min 2\il of chase mix was added to each well 
and incubation continued for a further 30 min. Prior to 
loading on a gel, 2pl of formyl dye was added to each 
sample, and the microtitre plates boiled for 2 min in a 
water bath.
C) Sequence fractionation;
The boiled sequencing reaction (2-4yl) was loaded
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into a well of gradient sequencing gel and the gel 
electrophoresed at 70 watts for 4h. The notched glass 
plate was removed and the bonded gel washed with 10% acetic 
acid for 30 min, rinsed with tap water, and dried for 2-3h 
at 75°-80°. The gels were placed in contact with X-Omat 
XS-1 film, and the film exposed overnight before being 
developed.
2.9.2 Preparation of gradient sequencing gels
The unnotched glass plate was treated with 10ml 
solution of ethanol containing 300jil of 10% acetic acid and
50pl of waker silane GF38, and left to dry for 3 min. The
plate was washed three times with ethanol and polished 
well. The notched glass plate was treated with 2ml of 
repelcote and subsequently washed with ethanol. The glass 
plates were taped together, and 7ml of bottom gel mix taken 
up in a syringe with 7ml top mix, after adding APS and
TEMED, were poured into the glass plate sandwich. Followed 
by the remaining top gel mix. Gels were left to polymerize 
for lh before being used. Wells were formed with a
plastikard comb.
2.10 LABELLING OF VIRUS DNA WITH [32P] ORTHOPHOSPHATE
The method used was based on the procedure 
described by Lonsdale (1979). BHK cells in phosphate-free 
Eagle's medium containing 1% calf serum (P.I.C. medium) 
were seeded at a density of 5X103 cells per linbro well. 
The following day, cells were infected with a moi of 5-10 
pfu per cell, and virus absorbed at 37° . One hour later,
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cells were washed twice with P.I.e. medium, overlaid with 
450yl of the same medium and incubated at 31° . At 3hpi, 
50yiCi of [3 2 P]-orthophosphate (carrier free) in 50pl was 
added to each well. After incubation for 48h at 37° , the 
cells were lysed by the addition of 0.5ml of 5% SDS (w/v), 
and the samples left for 10 min at 37° . DNA was extracted 
once with phenol saturated in TE buffer and precipitated 
with 2 volumes of ethanol. The DNA was subsequently 
concentrated by centrifugation at 2,000 rpm for 10 min at 
4°, lyophilised and resuspended in 150pl H2 O. Samples were 
digested with restriction endonuclease, and the fragments 
separated on an 0.8% agarose gel. After electrophoresis, 
the gel was dried onto the glass plate at 80° , and placed 
in contact with X-Omat XS-1 film. The film was exposed for 
a minmium of 18h.
2.11 ANALYSIS OF VIRUS INDUCED PROTEINS
2.11.1 Preparation of radiolabelled cell extracts
Sub-confluent HFL cells or BHK cells were infected 
at a moi of 20 pfu per cell. After lh absorption at the PT 
or NPT, cells were washed once with growth medium, overlaid 
with the appropriate medium, and incubated at either PT or 
NPT. Immediately prior to addition of [38S]-methionine, 
cells were washed twice with prewarmed PBS, and incubated 
in prewarmed PBS containing 100yCi/ml [33S]-methionine for 
15-30 min. The monolayers were washed twice with ice cold 
water and harvested. Alternatively, samples were washed 
with prewarmed medium and incubation continued for a 
further 5h before the samples were harvested. Virus-
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infected cell extracts were harvested in 300ul disruption 
buffer, and were boiled for 5 min before SDS PAGE. All 
radiolabelled infected-cell polypeptide samples were stored 
at -20° prior to analysis.
2.11.2 Immunoprecipitation using monoclonal antibodies
Radiolabelled virus-infected cells were lysed by
the addition of RIPA buffer, transferred to glass vials and 
sonicated. Cell debris was removed from the samples by 
centrifugation at 10,000 rpm for 15 min. The procedure 
used for immunoprecipitation was based on the method 
described by Kessler (1975). 1X106 cpm [39S]-labelled
virus-infected cell extracts were incubated with 20ul of 
diluted ascitic fluid overnight at 4° . Sheep anti-mouse 
immunoglobulin (10pl) was added and incubation continued at 
4°. After 4h, lOOpl of 10% (w/v) suspension of formalin-
fixed Stapholococcus aureus was added, and incubation 
continued for lh at 4° . The bacteria were washed three 
times by centrifugation at 10,000 rpm for 20 sec followed 
each time by resuspension in 600pl of lithium chloride 
washing buffer. Samples were finally resuspended in 100pl 
of 200mM glycine (pH2.5 at 4°) to elute the antigen from 
the bacteria. After incubation on ice for 30min, the 
bacteria were pelleted by centrifugation at 10,000rpm for 5 
min and the supernatant transfered to a vial containing 
50pl 3X disruption buffer.
2.11.3 SDS PAGE
Proteins were separated on two types of slab
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polyacrylamide gels either Single concentration gel, 
containing 10% polyacrylamide gels in which the acrylamide 
was cross linked with 1 part in 40 (w/w) N , N ' -methylene
bisacrylamide in resolving gel buffer, or gradient gels, 
composed of a 6-12.5% or 6-15% linear gradient of 
polyacrylamide in which the acrylamide was cross linked 
with 1 part in 20 (w/w) N,N' -methylenebisacrylamide in
resolving gel buffer. Gradient gels were formed using a 
proportioning pump (Technicon Ltd.). APS and TEMED at a 
final concentration of 0.006% (w/v) and 0.004% (v/v)
respectively were added to gel solution just before pouring 
to polymerise the gel. The gel was overlaid carefully with 
butan-2-ol to ensure a smooth interface on polymerisation. 
The butan-2-ol was removed once the gel had polymerised and 
the interface washed twice with % strength resolving gel 
buffer. The stacking gel, which contained 5% 
polyacrylamide (in which the acrylamide was cross linked 
with 1 part in 40 (w/w) N , N '-methylenebisacrylamide in
stacking gel buffer) was poured on top of the resolving 
gel. Wells were formed with teflon combs. Protein samples 
were separated by electrophoresis at either 0.45 mA/cm2 for
3-4h or 0.09 mA/cm2 for 18h in tank buffer.
2.11.4 Autoradiography
Gels were removed from glass plates after 
electrophoresis and treated with gel fixative and 
subsequently soaked in destain solution. Gels were either 
dried down under vacuum and exposed to X-Omat XS-1 film, or 
were soaked in En2hance (Dupont, Boston, USA) for 30 min at
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RT, rehydrated in several changes of water for 30 min and 
then dried under vacuum. Dried gels treated with En2hance 
were placed in contact with flashed Kodak X-Omat XS-1 at 
-70° and exposed for at least 18h.
2.12 ANTIPEPTIDE ANTIBODIES
2.12.1 Production of polyclonal antibodies to synthetic
oligopeptides
Since low mw peptides are poor immunogens, their 
immunogenicity was enhanced by coupling to a carrier 
protein. The coupling reaction was performed essentially 
as described by Bassiri et al. (1979) with a few
modifications. Briefly, 40mg of BSA or 3-galactosidase we 
re added to the peptide (5-10mg) in 2-4ml of IX borate
buffer pH9. While the sample was being stirred on ice 1ml 
of DAB was added dropwise until the solution turned dark 
brown. After the pH was adjusted to pH 8.7-9.0 with 0.5N 
NaOH, the sample was left on ice for 2h prior to dialysis. 
If, however, a precipitate began to form, dialysis was
started earlier. The sample was dialysed for 2 days at 4° 
with five changes of PBS. The dialysed sample was diluted 
with PBS and 1ml aliquots, containing approximately 150ug 
of coupled peptide, were stored at -20° . 1ml of either co 
mplete or incomplete Freund's adjuvant was mixed with 1ml 
of coupled peptide and the sample emulsified. Six month
old New Zealand white female rabbits (two rabbits for each 
peptide) were immunised intradermally at 5 sites in the
scruff of the neck. Pre-immune sera were obtained from all
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rabbits before immunisation was started. The first 
injection contained antigen in complete Freund's adjuvent, 
followed by a total of four booster injections of antigen 
in incomplete Freund's adjuvent, each at 10-20 day 
intervals. Prior to each injection, a 20ml blood sample 
was taken from each rabbit. After 50-60 days the rabbits 
were killed and the whole blood collected. The clotted 
blood was centrifuged at 2,000 rpm for 10 min, and the 
serum removed and stored in aliquots at -20° .
2.12.2 Removal of BSA antibodies from oligopeptides
antiserum using K50 column
Serum, prepared from rabbits injected with an 
oligopeptide coupled to BSA, was passed through a K50 
column (Pharmacia Fine Chemicals) containing BSA linked to 
CNBr activated Sepharose 4B to remove antibodies to BSA. 
Prior to the addition of serum, the K50 column was washed 
overnight with 1-2L of PBS. The serum was first pumped 
through a small column containing 10ml of BSA linked to 
CNBr activated Sepharose 4B to remove any large particles, 
and then into a large column. Once the serum had reached 
the middle section of the second column the pump was 
switched off, the column clamped off, and the serum left 
for at least lh at RT. After that time the pump was 
switched on, the clamps removed, column washed with PBS 
while the serum was collected, and stored at -20° .
2.12.3 Fast protein liquid chromatography (FPLC)
This technique was used to purify IgG from rabbit
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serum. A column was packed with DEAE-Trisacryl* M beads 
(LKB instruments, Ltd.), equilibrated with a low salt 
solution (0.025M Tris-HCl, 0.035 NaCl pH 8.8), and inserted 
into an automated FPLC machine (Pharmacia). 10ml serum was 
dialysed in 2L of the low salt overnight prior to addition 
to the column. After the l-2h of incubation, the column 
was first washed with the low salt solution, which removed 
the IgG bound to the beads in the column, and then with a 
high salt solution (lOOmM Tris-HCl, lOOOmM NaCl pH 8.8), 
which removed other serum proteins bound to the beads. 
Fractions were collected and stored at -20° .
2.12.4 Radioimmunoassay (RIA)
The method used to detect the presence of 
antibodies to oligopeptides or BSA was based on a modified 
method of Green et al. (1982). Each well of a microtitre 
plate (96-well) was coated with lpg/well of peptide 
dissolved in 25pl of PBS, or 25pl/well of 10% (w/v) BSA in 
PBS. The antigens were adsorbed on to the round bottom 
plates overnight at 37° . The solutions were shaken off the 
wells and peptides were fixed to the wells with 200pl 
methanol per well. After 5 min incubation at RT the 
methanol was removed. Non-specific protein binding sites 
were blocked with 200yl 0.5% polyoxyethylene sorbitan
monolaurate (Tween 20)in PBS for lh. Wells were then 
washed with PBS, and dried. BSA solution was shaken off 
the BSA treated wells, wells were washed once with PBS, and 
dried. 25pl of diluted serum in 0.05% Tween 20 in PBS was 
added to each well. Plates were sealed and incubated at
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37° for lh. This step was followed by three washes of
200yl of 0.05% Tween 20 in PBS. Protein A conjugated to 
[123I] was diluted in PBS containing 0.05% Tween 20, and 
25pl (20,000 cpm) added to each well. After the plates had 
been incubated for 30 min at 37° , the wells were washed 
three times with PBS by flooding the plates. Finally, 
200yl of 5M NaOH was added to each well to elute bound 
protein A, and the plates left for 25 min at RT. Samples 
were transferred to plastic tubes and the amount of [123I] 
monitered by a Gamma counter (NE 1600, Nuclear Enterprises 
Ltd., Edinburgh, Scotland).
2.12.5 Western blotting technique
The method used was based on the procedure
described by Towbin et al.(1979) . Proteins from infected­
cell extracts, labelled with [33S]-methionine were 
separated by SDS PAGE. After electrophoresis, proteins 
were transferred onto nitrocellulose paper using a Bio Rad 
Transblot apparatus. A sandwich was prepared in which the 
gel, equilibrated in blotting buffer, was placed on a sheet 
of 3mm Whatman's filter paper, soaked in the same buffer. 
Underneath the filter paper was a fiber pad. Strips of 
nitrocellulose, also presoaked in buffer, were carefully 
placed on the gel and covered with a sheet of moistened 3mm 
Whatman's filter paper. After air bubbles were removed, a 
fiber pad was placed on top of the filter paper and the 
sandwich held together in a plastic holder. The holder was 
placed in a tank filled with blotting buffer. The strips
faced the anode while the gel faced the cathode. Proteins
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were removed onto the nitrocellulose strips by 
electrophoresis at 250mA. After 3h, strips were carefully 
removed to plastic dishes, containing 200ml of preheated 
blocking buffer, which were placed in a shaking water bath 
for lh at 37°. After one change of blocking buffer, the 
strips were removed, air dried, and stored at -70° .
2.12.6 Detection of Antibodies bound to protein on 
nitrocellulose strips using [125I] protein A 
Strips were placed protein side up in shallow slots 
of a perspex block, and covered with different dilutions of 
serum in IX NT buffer containing 0.05% Tween 20 and 1% BSA. 
The blocks were shaken at 37° for 2-4h or overnight at RT. 
Strips were then transferred to plastic dishes, washed 
twice with wash buffer at RT for 10 min, and incubated in 
protein A solution containing [123I] protein A at 37°. 
After 2h, strips were washed twice with KI solution for lh, 
and rinsed several times with wash buffer. Finally, strips 
were air dried, aligned on a piece of cardboard and placed 
in contact with three X-Omat XS-1 films. A screen of black 
paper was inserted between the first and the second sheets 
of film sheet,and an image intensifying screen placed after 
the third sheet. This procedure, described by Haarr ejt 
a_l. (1985) , was used to determine which of the [33S]-
methionine labelled proteins the antibody reacted with 
as [123I] protein A bound to that antibody. The
first film was used to detect [33S]-methionine labelled
proteins. The [33S]-methionine does not penetrate the
second film, whereas the high energy emission from the
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[123I] passes through the three films to interact with the 
intensifying screen and produce photons which affect mainly 
the third film, and to an extend the second film but are 
prevented from reacting to the first film by the black 
paper. The films were exposed for at least 18h before 
developing.
2.12.7 Immunoprecipitation with polyclonal antibodies
Antibody (50pl) was incubated with 20pl (1X106 cpm) 
of [33S]-methionine labelled virus-infected cell extracts 
overnight at 4° . Protein A sepharose (60pl), which had 
been swollen and washed with RIPA buffer three times, was 
added to the antigen-antibody mixture and samples shaken 
gently for lh at 4° . This step was followed by four washes 
with 600]il washing buffer. Disruption buffer (50yl) was 
added to the samples, and tubes boiled for 5 min. Samples 
were then centrifuged, and 40pl of each supernatant was 
loaded into a well of a protein gel.
2.13 ISOLATION AND PURIFICATION OF HSV VIRIONS AND
NUCLEOCAPSIDS
The method of Gibson and Roizman (1972) was used 
for the isolation and purification of nucleocapsids. BHK 
cells grown in 850cm2 culture bottles were infected with 
0.03 pfu of virus per cell. After 7-8hpi incubation at 31° 
luCi of [33S]-methionine was added to each bottle. When 
extensive CPE had developed cells were shaken off into 
medium, and pelleted at 2,000 rpm for 10 min at 4° . 
Virions were purified from the supernatant, and capsids
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were isolated from the cell pellet.
The supernatant was centrifuged at 12,000 rpm for 
2h at 4°. The pellet was resuspended in 2ml Eagle's medium 
without phenol red (E w/o PR)and loaded onto 2X12ml, 5-15% 
Ficoll gradients in E w/o PR. After 2%h centrifugation at
t
13.000 in 4°, the tubes were placed under a strong light 
source and the virion band was removed using a syringe 
needle pierced through the side wall of the tube. The band 
was suspended in E w/o PR and pelleted in a TST41 rotor at
21.000 for 2h at 4°. The pellet was resuspended carefully 
in 500pl PBS.
The cell pellet obtained from one burrler of virus- 
infected cells was resuspended in 50ml PBS containing 0.5% 
NP40, incubated for 10 min at 4° , and the nuclei 
concentrated by centrifugation at 2,000 rpm for 10 min at
4°. The nuclei were resuspended in 3.8ml PBS, and lysed
with a final concentration of 1% (w/v) sodium deoxycholate. 
50yl of DNase 1 (lOmg/ml) was added, and the sample 
incubated for 30 min at RT to reduce the viscosity of the 
solution. Urea, at a final concentration of 500mM was
added, and incubation continued for a further 15-20 min. 
The sample was loaded onto a 10-40% (w/v) sucrose gradient 
in PBS, and the tubes centrifuged at 40,000 rpm for 20 min 
at 4° . The tubes were placed under a strong light source 
and the nucleocapsid bands removed by puncturing the side 
with a syringe. The nucleocapsids were suspended in PBS, 
and centrifuged at 40,000 for 30 min at 4° . The
supernatant was discarded, and the pellet resuspended in 
250yl of PBS.
107
2.14 Bacterial expression assay
A (60yl) sample of bacteria carrying the expression 
vector was removed from an overnight culture, diluted in 
3ml of L-broth containing ampicillin and shaken for 30 min 
at 37°. The culture was then divided between two vials and 
lOOmM IPTG added to one of the samples to enhance the 
expression of the foreign gene. Incubation was continued 
until the bacteria reached an OD-jgonm of 0.2. The bacteria 
were then pelleted by centrifugation, resuspended in IX 
disruption buffer and boiled for 15min. A sample of the 
boiled solution was loaded on a 6-15% SDS polyacylamide 
gradient gel. After electrophoresis the gels were stained 
in gel fixative solution containing coomassie blue stain 
and then destained.
2.15 ELECTRON MICROSCOPY
2.15.1 Preparation of samples in Epon-resin
The growth medium was removed from mock- and virus- 
infected HFL cells in 30mm dishes (at 14 hpi for PT 
samples, 12 hpi for NPT samples and 16 hpi for samples 
shifted at 12 hpi from the NPT to the PT in the presence of 
cycloheximide) and the monolayers washed three times with 
PBS. Cells were scraped into 0.5ml PBS, transferred to 
beem capsules and the samples centrifuged at 5000 rpm for 
10 min. The supernatant was removed, 500iil of 2.5% (v/v) 
gluteraldehyde in PBS added to each sample, and the 
capsules left at 4° . The next day, the pellets were washed
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three times with PBS and post fixed with 1% (w/v) OsC>4 . 
After lh the OsOi was removed by three washes with PBS. 
The pellets were subsequently dehydrated through a series 
of increasing ethanol concentrations (30%, 50%, 70%, 90%,
100% (v/v) in PBS) . The pellets were infiltrated with 50% 
(v/v) epon resin in ethanol, followed by two changes of 
epon resin alone. Epon resin, added to the samples at the 
final stage, was polymerised by incubation at 65° for three 
days.
2.15.2 Thin sectioning
Pelleted cells embedded in polymerised epon resin 
were cut either with a glass knife or with a diamond knife 
on a ultra-micotome (Ultracut E, Reichert-Jung), and thin 
sections were collected on parlodium-coated copper grids. 
Sections were stained with saturated uranyl acetate in 50% 
(v/v) ethanol for lh, rinsed with deionised water and 
counter-stained with lead citrate for lh. The stained thin 
sections were examined at 80KV in a Jeol 100S electron 
microscope.
2.16 COMPUTING AND ANALYSIS OF SEQUENCE DATA
Sequence handling was carried out in a DEC PDP11/44 
computer under RSX11M operating system or a DEC VAX 
computer. The programmes used in the PDP11/44 computer 
were either designed or implemented by Dr. P. Taylor. In 
the DEC VAX computer the Genetic Computer Group (GCG) 
sequence analysis software package version 5.0 and 6.0 was 
used (Devereux et al., 1984; Devereux, 1989).
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3.1 CHARACTERISATION OF THE HSV-1 MUTANT, TS1233 WITH A
DEFECT IN ENCAPSIDATION OF VIRAL DNA AT THE NPT
3.1.1 Introduction
The sequence of events leading to the assembly of 
HSV capsids is still unclear. At least seven polypeptides 
have been identified in capsids purified from the nuclei of 
virus-infected cells and two of these, V m w 155 and V m w 50, 
are required for the assembly of capsids (section 1.9.1). 
Several structural proteins have been directly or 
indirectly implicated in DNA encapsidation. The mechanism 
by which HSV packages the genome into a preformed capsid is 
not known. It is clear from the analysis of defective 
virus genomes and ts mutants that DNA encapsidation is a 
complex process which requires a variety of functions 
including both cis-acting sequences and trans-acting 
elements (see sections 1.7.4 and 1.7.5). Work on ts 
mutants of HSV-1 and PRV has established that cleavage of 
high mw concatemeric DNA to unit length genome is linked to 
DNA encapsidation (Ladin et al., 1980; 1982; Preston et
al., 1983; Addison, 1986; Sherman and Bachenheimer, 1987;
1988) , and that several gene products are involved in the 
process of viral DNA packaging. The following chapter 
deals with the characterisation of a DNA positive ts mutant 
of HSV-1, tsl233, which fails to package DNA at the NPT, 
and the identification of the gene in which the lesion 
lies.
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3.1.2 Electron microscopic analysis of tsl233-infected 
cells reveals that the mutant has a defect in DNA 
encapsidation
Thin section preparations of tsl233 and 11 syn* 
HFL-infected cells were examined under the electron 
microscope. At the NPT the nuclei of tsl233-infected cells 
contained large numbers of intermediate capsids which had 
electron-translucent cores. These capsids were present as 
aggregates or as single capsids (figure 9A) . No dense- 
cored capsids or empty capsids lacking an internal core 
were observed in the mutant-infected cells. By contrast 
all three capsid forms were present in the nuclei of wt 
virus-infected cells at both the PT and NPT and in the 
nuclei of tsl233-infected cells at the PT. Mature virions 
were also detected in these virus-infected cells (figures 9 
b, c,d). These results suggest that tsl233 has a block in 
assembly of full nucleocapsids. When the mutant virus- 
infected cells were shifted from the NPT to the PT at 12 
h.p.i. in the presence of cycloheximide (a protein 
synthesis inhibitor) and incubated for a further 4h before 
being harvested, no full nucleocapsids were detected in the 
nuclei and no enveloped virions were present in the 
cytoplasm or on the surface of infected cells, indicating 
that the effect of the mutation could not be reversed by 
transferring the sample to the PT (figures 9 F, G ) .
3.1.3 Quantitation of different capsid types in virus- 
infected cells
The number of empty, partially-cored, and full

Figure 9
Electron microscopic analysis of 
tsl233- and 17syn*- infected cells
Electron micrograph of thin section preparations of HFL 
cells infected with a moi of 5pfu of tsl233 or wt HSV-1 
17 syn* .
A) Nucleus of a cell infected with tsl233. Cells were
harvested after 12h incubation at the NPT (39°).
B) Nucleus of a cell infected with wt 17syn* . Cells were
harvested after 14h incubation at the PT (31°).
C) Nucleus of a cell infected with wt 11syn* . Cells were
harvested after 12h incubation at the NPT (39°).
D) Nucleus of a cell infected with tsl233. Cells were
harvested after 14h incubation at the PT (31°).
E) Nucleus of a mock infected HFL cell- Cells were
harvested after 12h incubation at the NPT (39°)
F) Nucleus of a cell infected with tsl233 at the NPT.
Cells were shifted to the PT at 12hpi in the presence 
of cycloheximide and harvested after a further 4h 
incubation at the PT.
G) Nucleus of a cell infected with wt virus at the NPT.
Cells were shifted to the PT at 12hpi in the presence 
of cycloheximide and harvested after a further 4h 
incubation at the PT.
Full capsids are indicated by The solid arrows.
Partially-cored capsids are indicated by closed
arrows.Empty capsids are indicated by an open arrow.
The bar represents 0.5pm.
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capsids present in the nuclei of virus-infected cells was
determined by counting capsids seen in thin section
preparations under the electron microscope. 50 nuclei from
both 11syn* -, and tsl233-infected cells were chosen at
random. Results represented in table 4 revealed that mean
total number of capsids varied from 33.42 to 100.56 per
thin section of nucleus. The predominant capsid type was
the partially-cored capsid. This is consistent with the
idea that partially-cored capsids are precursors of full
capsids. No empty capsids were detected in tsl233-infected
cells at at the NPT and this finding supports the proposal
that empty capsids are breakdown products of full capsids
and are not precursors of DNA containing capsids. At the
NPT the total number of capsids/nucleus of tsl233-infected
cells was greater than that of wt virus-infected cells (55
cf 62) . This could be due to capsids remaining in the
nucleus in tsl233-infected cells, whereas in wt virus full
capsids are rapidly enveloped. In wt virus-infected cells
treated with cycloheximide at 31° or 39° a slight decrease
in the proportion of partially-cored capsids was observed,
at 31*
and this was accompanied/by a slight increase in proportion 
of empty capsids and full capsids. The major reason for 
the decrease in partially-cored capsids was a decrease in 
the absolute number of total capsids/nucleus of thin 
section. This result suggested that in wt virus-infected 
cells an unstable gene product might be important for the 
production of partially-cored capsids. In tsl233-infected 
cells treated with cycloheximide at 39° , on the other hand, 
an increase in the absolute number of capsids/nucleus was
TABLE 4
Quantitation of different capsid types 
in virus-infected cells
Temp. Virus E P F Total no.
31°
17 syn* 
(%)
3. 52 
(5.71)
53.64
(87.10)
4.42
(7.17)
61.58
(100.00)
tf)
tsl233
(%)
5. 80 
(8.99)
49.38
(76.55)
9.32
(14.44)
64.50
(100.00)
39°
11 syit 
(%)
4.10 
(7.72)
42.68
(80.40)
6.30
(11.86)
53.08
(100.00)
(2)
tsl233
(%)
0
0
76.58
(100.0)
0
0
76.58
(100.00)
31°
\CH
31°
(3)
17 syn* 
(%)
6.32
(11.40)
4 2. 34 
(76.42)
6.74
(12.16)
55.40
(100.00)
tsl233
(%)
8.76
(17.46)
33.70
(67.18)
7 .70 
(15.35)
50.16
(100.00)
39°
\CH
31°
(3)
17 syn* 
(%)
1. 80 
(5.38)
28 . 40 
(84.97)
3.22
(9.63)
33.42
(100.00)
tsl233
(%)
0
0
100.56 
(100.00)
0
0
100.56
(100.00)
39o
\CH
39°
LS)
17 syn* 
(%)
3.78
(9.26)
30.76
(75.39)
6.26
(15.34)
40.80
(100.00)
tsl233
(%)
0
0
81.44
(100.00)
0
0
81.44
(100.00)
Table 4
The table represent the proportion of dense-cored (F), 
partially-cored (P) and empty>(capsids in the nuclei of 
infected cells determined from the examination of thin 
section preparation of cells under the electron 
microscope (50 cells were screened for each type of 
capsids at:
1) Cells infected with wt virus or tsl233 at the PT 
(31°) and harvested after 14hpi.
2) Cells infected with wt virus or tsl233 at the NPT 
(39°) and harvested after 12hpi.
3) Cells infected with wt virus or tsl233 at the NPT 
(39°) followed by a shift to the PT (31°) at 12hpi in 
the presence of cycloheximide, and harvested after 
further 4h.
Top figure represent the average number of each type 
of capsids per nucleus, brackets represent percentage 
of capsid type per nucleus.
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observed which could possibly be due to the stability of a 
gene product (this is discussed in more details in section 
3.4) .
3.1.4 Analysis of viral DNA processing
Electron microscopic observation of thin section 
preparations of fcsl233-infected cells suggested that tsl233 
did not encapsidate DNA at the NPT. To confirm that the 
mutant DNA was not packaged into capsids at the NPTf and to 
determine whether the DNA was cleaved, processing of tsl233 
DNA was investigated using the technique of Southern 
blotting (refer to Section 2.7).
Total and encapsidated viral DNA from tsl233, 
tsl201, and wt virus-infected HFL cells were prepared as 
described in sections 2.3.2.a; 2.3.2.b. Tsl201 was 
included as a control in this study since this mutant fails 
to cleave and package DNA at the NPT. The viral DNAs were 
digested with BamHI which cleaves not only the unique 
regions but also the L and S repeats. The terminal 
fragments q and s, and the joint spanning fragment k were 
identified by hybridisation to I32PJ-labelled plasmid 
pGX22, which contains BamHI k. [32P]-labelled pGX24, 
containing the HSV-1 U l fragment BamHI a, was included in 
the hybridisation mix to determine the relative amount of 
total and encapsidated viral DNA.
The rationale for using BamHI k as a probe is that 
the presence of terminal fragments q and s gives an 
indication that cleavage of concatemeric DNA is occurring. 
Virion DNA, digested with BamHI, contains fragments k, q
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and s in equimolar amounts since the genome is present in 
virus particles as a linear DNA molecule. Late in 
infection, however, in wt virus-infected cells most of the 
unpackaged DNA is present as high mw concatemers and, as a 
consequence, the proportion of BamHI k increases relative 
to terminal fragments q and s. In Southern blot analysis 
using the probe BamHI k, the intensity of BamHI k should be 
equal to the intensity of q+s bands in virion DNA.
Figure 10a shows an autoradiograph of a Southern 
blot of BamHI digested total virus DNA and encapsidated 
DNA. The terminal s and q fragments were present in 
11syn* , tsl233, and tsl201 total virus-infected cell DNA
prepared from cells grown at 31° , indicating that endless 
DNA was cleaved. Analysis of encapsidated DNA samples 
showed that cleaved DNA was packaged at 31° (figure 10a) . 
Examination of total virus-infected cell samples prepared 
from cells grown at 39° revealed that the terminal 
fragments BamHI s and q were detectable in wt virus- 
infected cells only, suggesting that tsl233 and tsl201 DNA 
were endless (figure 10b), and were not cleaved to unit 
length DNAs. The failure to detect packaged DNA in mutant 
encapsidated DNA samples at 39° confirmed that tsl233 and 
tsl201 had an encapsidation defect at 39°. When virus- 
infected cells were transferred from 39° to 31° in the
presence of cycloheximide at 12 hpi and incubated for a
further 4h before being harvested, the terminal fragments 
were detected in both wt virus- and tsl201 total virus-
infected cell DNA samples. The effect of tsl201 lesion
was, however, only partially reversible upon downshift of
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Figure 10
Autoradiograph of the processing of total and encapsidated 
(DNase-resistant) virus-infected cell DNA
Unlabelled DNA was prepared from HFL cells infected at a 
moi of 5 pfu/cell with wt virus, tsl233 or tsl201 as 
described in section 2.3.2.
Virus-infected cells were incubated at 31° (A), and 39° (B)
and harvested at 18hpi. 1/10 of the samples from 50mm petri 
dish was cleaved with BamHI and the resulting fragments 
were separated by electrophoresis through 0.8% agarose gel. 
The fragments were transferred to nitocellulose sheets and 
hybridised to in vitro labelled [32P]-pGX22 (containing 
BamHI k) and pGX24 (containing BamHI a).
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Figure IOC
Autoradiograph of the processing of total and encapsidated 
(DNase-resistant) virus-infected cell DNA
Unlabelled DNA was prepared from HFL cells infected at a 
moi of 5 pfu/cell with wt virus, fcsl233 or tsl201 as 
described in section 2.3.2.
Virus-infected cells were transferred from the NPT to the 
PT at 12hpi in the presence of cycloheximide and incubated 
for a further 4h prior to harvesting.
1/10 of the sample from 50mm petri dish was cleaved with 
BamHI and the resulting fragments were separated by 
electrophoresis through 0.8% agarose gel. The fragments 
were transfered to nitrocellulose sheets and hybridised to 
in vitro labled [32P]-pGX22 (containing BamHI k) and pGX24 
(containing BamHI a).
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tsl201-infected cells from the NPT to PT (figure 10c) and 
only a low proportion of q+s fragments were detected in 
comparison with the wt virus q+s fragments. In tsl233 
total infected cell DNA sample treated in the same manner 
no terminal fragments were detected suggesting that the DNA 
was not cleaved. This result was confirmed by the 
observation that no packaged tsl233 DNA could be detected 
in mutant-infected cells transferred from 39° to 31° 
(figure 10c) and supported the electron microscopic 
observation that the effect of tsl233 lesion could not be 
reversed by transfer of the sample from the NPT to PT. 
Hence, tsl233 has a block in the assembly of functional 
capsids.
3.1.5 Densitometrie analysis of Southern blots of total
virus-infected cell DNA and encapsidated DNA
The relative amount of viral DNA packaged was
determined by analysis of autoradiographs of Southern blots
of total virus DNA and encapsidated DNA. The amount of the
U l  fragment BamHI a hybridised to total virus infected cell
DNA was compared to the amount hybridised to encapsidated
DNA. The intensity of BamHI k , q and s was not determined
because quantitation of these bands probably gives a less
reliable estimate of packaging. Plasmids which do not
contain the a sequence but have oris are able to form
concatemers in the presence of helper virus. This result
raises the possibility that the ends of the uncleaved viral
mutant
DNA concatemers in/virus-infected cells are different from 
cleaved unit length DNA in wt virus-infected cells.
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Results of the densitometric analysis revealed that 
at 31° wt virus packaged DNA very efficiently. More than 
50% of the viral DNA synthesized had been encapsidated by 
12 hpi. At this temperature tsl233 and tsl201 also
packaged DNA efficiently (see table 5a) . At the NPT of 
39° f about 8% of wt virus DNA was encapsidated (table 5b) . 
It is clear from this result that at 39° packaging of wt 
virus DNA is much less efficient than at 31° , indicating 
that there is a thermolabile step in this process. This
conclusion is supported by the finding that the amount of 
wt virus DNA packaged increased when the sample was 
transferred from 39° to 31° in the presence of 
cycloheximide. Less than 1% of tsl233 and tsl201 was 
encapsidated at the NPT. This result suggests that these 
mutants have a packaging defect at this temperature.
Results of the analysis of shiftdown experiment showed that 
the effect of tsl201 mutation was not fully reversible upon 
downshift from 39° to 31° in the presence of cycloheximide. 
Only about 4% of tsl201 DNA was encapsidated (table 5c) . 
This figure is lower than the value determined elsewhere
(Addison, 1986) possibly because a high NPT of 39° was used 
in this experiment whereas 38.5° had been used in the 
previous work on this mutant. Less than 1% of tsl233 DNA 
was packaged after transfer of mutant-infected cells from 
39° to 31° .
3.1.6 Tsl233 defines a new complementation group
To determine whether tsl233 belonged to an existing 
complementation group or not, complementation analysis was
TABLE 5
Densitometrie analysis of total and encapsidated virus-
infected cell DNA
A
PT 31° 17 syn* tsl233 tsl201
Total DNA 100.00 121.69 189.08
synthesised (%) 100.00 182.00 166.00
Encapsidated 57.50 61.00 32.80
DNA (%) 50.14 22.60 43.96
B
NPT 39° 17 syn* tsl233 tsl201
Total DNA 100.00 65.35 50.00
synthesised (%) 100.00 50.90 75.66
Encapsidated 7.65 <1.00 <1.00
DNA (%) 8 . 59 <1.00 <1.00
C
NPT-PT 390 -31° * 17 syn* tsl233 tsl201
Total DNA (%) 100.00 61.69 80.05
Encapsidated (%) 17.95 <1.00 4.12
(*) cycloheximide treated
Table 5
Densitometric analysis of Southern blot of total and 
encapsidated virus DNA. The amount of DNA synthesised 
or encapsidated by each virus represented by the 
amount of [32P] labelled probe hybridising to the 
BamHI a fragment.
Total virus DNA is represented as a percentage of the 
DNA synthesised by wt 11 syn* virus at the PT (A) , or 
NPT (B) f or following a shift from the NPT to the PT 
in the presence of cycloheximide (*). In each case 
synthesis of 11syn* is taken as 100%.
Encapsidated DNA is presented as a percentage of the 
total virus-infected cell DNA synthesised at the PT 
(A) , NPT (B) or following a shift from the NPT to the 
PT in the presence of cycloheximide (*). The figures 
in A and B represent two sets of experiments.
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carried out. Since ts mutants belonging to complementation
the.
group 1-13 had defects which mapped close to / tsl233
mutation, a member, tsrN20, from this group was used in the
The
complementation yield test. / TsN20 lesion maps within a 
500bp Sall-EcoRI fragment at the right hand end of EcoRI m 
(Coen et al., 1984). Another mutant in this cistron tsW44 
has a mutation within EcoRI o (Pancake et al., 1983). 
Originally these mutants were placed in two different
complementation groups (Pancake et al., 1983), but recently 
they have been assigned to a single cistron c(l-13)
(Schaffer et al. , 1987). TsN20 made large numbers of
aberrant, partially-cored and empty capsids as well as some 
dense-cored capsids and enveloped virus particles at 39° 
(Schaffer et al., 1974). From this electron microscopic
analysis, its phenotype appeared to be very similar to that 
of glycoprotein B mutant tsJ12. TsN20 was chosen for
complementation analysis with tsl233 because this mutant 
was readily available at the Institute. Tsl201, which has 
a mutation in UL26 and like tsl233 failed to package DNA at 
the NPT (Preston et al., 1983), was used as a control. The 
results of two independent experiments (Table 6) revealed 
that tsl233 complemented both tsN20 and tsl201, suggesting 
that tsl233 belongs to a different complementation group 
from that of tsN20 and tsl201.
3.1.7 Analysis of tsl233-infected cell polypeptide
Polypeptides synthesized by tsl233 were analysed by 
SDS PAGE to determine whether the mutant polypeptide 
profile contained any polypeptide bands which had an
TABLE 6
Complementation test between tsl233 and two 
mutants with packaging defects at the NPT
Mutant tsN20 tsl201 tsl233
1 12.06 12.95
tsN20
1 35.90 43.20
1 71.85
tsl201
1 211.00
1
tsl233
1
Complementation yield test was performed between tsl233, 
tsl201, tsN20. The values in the table represent
complementation indices of two separate experiments
calculated from the formula used by Brown et al. (1973). 
Values greater than four were considered positive.
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altered mobility, or intensity in comparison with wt virus 
polypeptide bands. Virus and mock-infected cells were 
grown at the NPT or PT, labelled with [38S]-methionine for 
30 min at 5 hpi and the proteins separated by SDS-PAGE.
Autoradiographs of polypeptides revealed that tsl233 had a 
similar polypeptide pattern to that of wt virus both at the 
PT and the NPT when the polypeptides were separated on
single concentration (data not shown) or gradient 
polyacrylamide SDS gels (figure 11).
3.1.8 Processing of p40 in tsl233 infected cells
The inability of tsl201 to package DNA into capsids 
at the NPT correlates with the failure of the mutant to 
process p40 (gene product of UL26) to its lower mw forms.
Since it is not known if other proteins are required for
modification of p40, processing of p40 in infected cells 
was examined to determine whether the lesion in tsl233 
affected any of the processing steps of p40. Wt virus-, 
tsl233- and tsl201~infected cells, together with mock- 
infected cells were pulse-labelled with [38SJ-methionine 
for 20 min at 5 hpi and samples either harvested 
immediately or incubated for a further 5h in the absence of 
[38S]-methionine prior to harvesting. P40 in virus- 
infected cell extracts was immunoprecipitated with a p40 
specific monoclonal antibody, 5010B, and the 
immunoprecipitates analysed by SDS-PAGE. At the PT at 
least four virus-infected polypeptide bands were detected 
in wt virus-, tsl201- and tsl233-infected cell samples 
pulse labelled with [33S]-methionine. After a 5h chase,
3 1C 39C
HSV-1 
Apparent 
MW X 1000
co *
00 ^  C\|
r -  w
W T^—
w  + CO c
CM >  
T -  W
(0 ^
-
37 /37 .8
6-15%  gradient protein gel
Figure 11
Autoradiograph of polypeptides induced at 31° and 39° in 
HFL cells infected with wt HSV-1 or tsl233 or in mock 
infected cells. Virus-infected cells were labelled with 
[38S]-methionine for 30min at 6hpi and harvested. Protein 
samples were analysed on a 6-15% gradient SDS PAGE. 
Numbers represent apparant mw.
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two lower mw p40 specific bands appeared, indicating that 
p40 was processed normally at the PT in all three virus- 
infected cell samples (figure 12) . At the NPT only tsl201 
failed to process p40 to the lower mw forms after 5h chase. 
Both wt and tsl233 processed p40 normally. The results 
show that the mutation in tsl233 did not affect the 
processing of p40 at the NPT (figure 13).
3.1.9 Isolation of the ts*revertants for growth of tsl233
Two independent revertants for growth of tsl233,
tsl233 revl and rev2, were isolated and high titre virus 
stocks were prepared. The revertants were titrated both at 
the PT and the NPT, together with the wt virus and a ts* 
virus isolated by marker rescue of tsl233 with cloned wt 
EcoRI o (table 7). The eop NPT/PT of revl, rev2, the ts* 
marker rescued virus were similar to that of wt 11syn* 
virus. This information strongly suggests that tsl233 has 
a single ts mutation.
3.1.10 Map location of the tsl233 lesion
Preliminary marker rescue studies localised the 
tsl233 mutation to the region shared by EcoRI o and 
BamHI b' (I.McDougall, unpublished results). Separated 
Xbal restriction endonuclease fragments from cloned wt HSV- 
1 11syn* EcoRI o fragment derived from the plasmid pGX74 
were used in marker rescue experiments to map the tsl233 
lesion to a smaller region of the genome (table 8) . The 
results showed that the lesion mapped within a 941 bp 
fragment at the end of Xbal f. To further refine the map
pulse chase
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1
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Figure 12
Autoradigraph of immuneprecipitates of p40 separated by SDS
PAGE. HFL cells were either mock-infected or infected with
wt virus, tsl201 or fcsl233 at 31° . At 6 hpi, cells were
pulsed-labelled with [35S]-methionine for 30 min and
harvested either immeadiately (pulse) or after incubation
for a further 5h at 31° in EFCi o (chase).
Immunoprecipitation was performed as described in section
2.11.2 using a ma5010B, which is soecific for p40. As a
extract
control, wt virus-infected cell/ was incubated with non- 
immune rabbit serum instead of ma5010B (track 3 and 9) . 
Tracks 1 and 7 represent moc infected cell extracts, tracks 
2 and 8 represent wt virus-infected cell extracts, tracks 
3, 6, 9, 12, represent immune precipitates from wt virus-
infected cells, tracks 4 and 10, immune precipitates from 
tsl201-infected cells, tracks 5 and 11, immune precipitates 
from tsl233 infected cells. The immune precipitated 
polypeptides were analysed on an 8% SDS polyacrylamide gel. 
Solid arrows represent high mw forms of p40.
Dotted arrows " low " " " " .
pulse chase
*
Figure 13
Autoradigraph of immuneprecipitates of p40 separated by SDS
PAGE. HFL cells were either mock-infected or infected with
wt virus, tsl201 or tsl233 at 39° . At 6 hpi, cells were
pulsed-labelled with [3sS]-methionine for 30 min and
harvested either immeadiately (pulse) or after incubation
for a further 5h at 39° in EFCi o (chase).
Immunoprecipitation was performed as described in section
2.11.2 using a ma5010B, which is snecific for p40. As a
extract
control, wt virus-infected cellA was incubated with non- 
immune rabbit serum instead of ma5010B (track 3 and 9). 
Tracks 1 and 7 represent mock-infected cell extracts, tracks 
2 and 8 represent wt virus-infected cell extracts, tracks 
3, 6, 9, 12, represent immune precipitates from wt virus-
infected cells, tracks 4 and 10, immune precipitates from 
tsl201-infected cells, tracks 5 and 11, immune precipitates 
from tsl233 infected cells. The immune precipitated 
polypeptides were analysed on an 8% SDS polyacrylamide gel. 
Solid arrows represent high mw forms of p40.
Dotted arrows " low " " " " .
Eop< « P T /P T )
Table 7
of t£?1233 revl and rev2
Virus EOP< N P T / P T >
17 syn* 0.98
Tsl233 revl 1.00
Tsl233 rev2 0.84
Ts* virus isolated 1.00
by marker rescue
NPT is 39° 
PT is 31°
TABLE 8
Summary of marker rescue of ts!233
Fragments obtained from 
pGX74 (HSV-1 EcoRI o)
Efficiency of 
plating NPT/PT X103 Rescue
pGX74 digested with EcoRI 2.66 +
pGX74 digested with Xbal
Unseparated Xbal frags. 1.73 +
Separated Xbal frags.*/ 
contains part of Xbal f 1.64 +
" Xbal c <0.02 -
pGX74 digested with PvuII
Unseparated PvuII frags. 0.22 +
Separated PvuII frags.*/ 
contains part of PvuII k' 0.16 +
" PvuII o <0.02 -
" PvuII o ’ <0.02 -
None <0.01 -
(*) Xbal digest gives two fragments each containing part 
of the vector sequences. Similarly with a PvuII digest.
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location of the mutation, separated PvuII fragments were 
used in marker rescue experiments. A low level of ts*
virus progeny was obtained with a 602 bp PvuII fragment 
(containing part of the PvuII k ' fragment). The lesion of 
tsl233, therefore, lies within a 152 bp region common to 
Xbal f and PvuII k' (figure 14) between map coordinate 
0.45-0.46 mu.
3.1.11 Cloning EcoRI o of tsl233, tsl233 revl and rev2
Marker rescue experiments showed that the tsl233 
mutation mapped within a 152bp region common to PvuII k 1 
and Xbal jf. The 5' ends of two genes, UL32 and UL33, 
oriented in opposite directions, lie in this part of the
genome (McGeoch et al., 1988). To determine which gene the 
tsl233 lesion mapped in, the sequence alteration 
responsible for the tsl233 mutation was determined. The 
first step in this analysis was to clone the fragment 
containing the ts mutation and the corresponding fragments 
from tsl233 revl and rev2. EcoRI o fragments from an EcoRI 
digest of tsl233, tsl233 revl and rev2 DNA were cloned 
into the EcoRI site in pUC8 (figure 15) . Two independent 
chimeric plasmids, pGX200 and pGX201, containing EcoRI o 
fragment of tsl233, and two chimeric plasmids pGX203 and 
pGX204 containing EcoRI o of tsl233 revl and rev2 
respectively, were constructed. All the plasmid inserts 
appeared to have identical EcoRI, BamHI, Xbal and PvuII 
sites to those present in wt HSV DNA sequence (data not
shown) . Plasmids were digested with BamHI and Xbal and
tested for their ability to rescue the mutation of tsl233
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Figure 14
Map location of the tsl233 mutation.
The EcoRI, BamHI, Xbal and PvuII cleavage sites in the 
region where tsl233 lesion lies are given. The solid Xbal 
and PvuII lines represent the fragments which rescued the 
tsl233 mutation. The 152bp cross hatched box represents 
the region common to Xbal f and PvuII k ' .
EcoRI o Fragment
PvuII 
EcoRI fcr* i
BamHI BamHI Xbal
132bp ! 517bp ! 392bp \ 450bp
i Pvuii ! 
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p o l y l i n k e r  c l o n i n g  s i t e .
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Ori
Vector pUC8 
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Amp
pGX200 fs1233 
pGX201 fs1233 
pGX203 Rev 1 
pGX204 Rev 2
7?* EcoRI
Figure 15
A diagram representing the EcoRI o fragment taken from 
tsl233, tsl233 revl,or tsl233 rev2 and cloned into the 
EcoRI site of pUC8 polylinker. Numbers on top of the 
fragment represent the size of the four fragments obtained 
from a BamHI-Xbal double digest. The 392bp fragment was 
used in sequencing analysis.
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DNA in a marker rescue experiment (table 9) . The two 
mutant clones, pGX200 and pGX201 failed to rescue tsl233 
lesion, whereas pGX203 and pGX204 both gave positive values 
in the marker rescue test. These results confirmed that 
the correct fragment had been cloned in each case.
3.2 GENE UL33 IS REQUIRED FOR DNA ENCAPSIDATION
The first part of this section deals with the 
identification of the gene responsible for the defect in 
tsl233, while the subsequent parts of the section deal with 
attempts to identify the gene product of this gene.
3.2.1 Tsl233 lesion maps within UL33
The 392bp fragment common to Xbal f and BamHI b' in 
each of the following plasmids pGX200, pGX203 and pGX204 
was ligated into M13mpl8 and M13mpl9 DNA cleaved with Xbal- 
BamHI. These two bacteriophage DNAs have the polylinker 
cloning sequence in opposite orientations to one another. 
The ligated DNA was transfected into competent JM101 
bacteria and bacteriophage forming white plaques were 
isolated. Bacteriophage ssDNA was prepared and sequenced 
using the chain termination method of Sanger. The 
nucleotide sequence of the tsl233 BamHI-Xbal cloned 
fragment was identical to the sequence in the corresponding 
cloned fragment from wt virus except for a single bp change 
at residue 69210 where a transversion from an A to a T had 
occurred (figure 16 refer to tsl233 A and T tracks). 
Sequence analysis of the BamHI-Xbal from the two 
ts*revertant clones revealed that these DNAs each had an
TABLE 9
Marker rescue of tsl233 using pGX74, 
pGX200r pGX201r pGX203r pGX204
Clones
/Fragment used
Efficiency of plating 
NPT/PT X 103
Rescue
pGX74 digested with 
BamHI-Xbal 
Unseparated fragments 
Separated frag obtained 
from a BamHI-Xbal dig.
392bp frag.
0.20
0.30
+
+
517bp <0.02 -
187 4bp " <0.02 -
2505bp " <0.02 -
pGX200 digested with 
BamHI-Xbal 
Unseparated fragments
<0.02 -
pGX201 digested with 
BamHI-Xbal 
Unseparated fragments
<0.02 -
pGX203 digested with 
BamHI-Xbal 
Unseparted fragments 
Separated frag obtained 
from a BamHI-Xbal dig.
392bp frag.
0.35
0.20
+
+
460bp <0.02 -
517bp <0.02 -
2822bp " <0.02
—
pGX204
digested with 
BamHI-Xbal 
Unseparetd fragments 
Separated frag obtained 
from a BamHI-Xbal dig.
142bp frag.
0.20
<0.02
+
392bp 0.12 +
517bp <0.02 -
3140bp " <0.02 -
None <0.02 -
Table 9
Marker rescue of tsl233 using pGX74r pGX200, pGX201f
PGX203, pGX204
Vector
pGX74 contain HSV-1 17syn* EcoRI o fragment. pACYC184 
PGX200 " tsi233 " " . pUC8
pGX201 " tsl233 " " . "
pGX203 " tsi233 revl " " . "
PGX204 " tsl233 rev2 " " . "
The insert in pGX204 is in opposite orientation. When 
the clones are digested with BamHI-Xbal, four 
fragments are obtained which contain the vector 
sequences attached to the 450bp fragment and 132bp 
fragment. For the sizes of the fragment refer to 
figure 15.
Ts1233 Revl Rev2
Figure 16
A portion of the autoradiograph of a DNA sequencing gel. 
Sequence products were separated on a 6% denaturing 
polyacrylamide gel containing 9M urea. The base pair 
change in tsl233 is indicated by TTT (thymine), whereas 
both the revertants shows the presence of adenine (A 
track).
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identical sequence to that of wt virus DNA (Figure 16 refer
to tsl233 revl and rev2 tracks A and T ) .
As mentioned previously, within the 152bp region 
lie the 5' ends of two genes transcribed in opposite 
directions. One of the genes, UL32, encodes a 65,000 mw 
polypeptide, and the other, UL33, encodes a 14,000 mw 
polypeptide. DNA sequence analysis of 11syrf virus 
(figure 17) has shown that residue no. 69210 lies 50 bp 
downstream from the ATG initiation codon of gene UL33 
(McGeoch et al. , 1988), and therefore tsl233 lesion must
lie in gene UL33 (figure 18).
3.2.2 Production of polyclonal antibodies against UL33
gene product
DNA sequence and electron microscopy analyses 
showed that tsl233 contained a ts mutation in UL33 which 
affected virus assembly at the NPT. The next step was to
identify the gene product of UL33 to obtain further
information about the function and role of this protein. 
Antisera raised against synthetic oligopeptides,
representing small portions of the amino acid sequence of a 
protein, have been extremely useful in identifying the
product of a gene whose DNA sequence is available 
(Palfreyman et al., 1984; Frame et al. , 1986; McLean et
al., 1987; Parris et al. , 1988). It was therefore decided 
to make antisera using two synthetic oligopeptides, one of 
which was directed towards the amino terminus and the other
of which was specific to the carboxy terminus. The two
oligopeptides were chosen because of the high success rate
Translation of: UL33
|m A G R £ G R T R Q Rl T L R D T I P D 19*
ATG GCT GGG CGG GAG GGG CGC ACG CGC CAG CGA ACT TTA CGG GAC ACA ATC CCC GAC 69217
C A L R S Q T L E S L D A R Y V S R D 38
TGC GCG CTG CGG TCC CAG ACC CTG GAG AGT CTA GAC GCG CGC TAC GTC TCG CGA GAC 69274
G A H D A A V H F E D M T P A E L E V 57
GGC GCG CAT GAC GCG GCC GTC TGG TTC GAG GAT ATG ACC CCC GCC GAG CTG GAG GTT 69331
V F P T T D A K L N Y L S R T Q R L A 76
GTC TTC CCG ACT ACG GAC GCC AAG CTG AAC TAC CTG TCG CGG ACG CAG CGG CTG GCC 69388
S L L T Y A G P I K A P D D A A A P Q 95
TCC CTC CTG ACG TAC GCC GGG CCT ATA AAA GCG CCC GAC GAC GCC GCC GCC CCG CAG 69445
T P D T A C V H G E L L A A K R E R F 114
ACC CCG GAC ACC GCG TGT GTG CAC GGC GAG CTG CTC GCC GCC AAG CGG GAA AGA TTC 69502
A A V I N |R F L D L H Q I L R G | - 130
GCG GCG GTC ATT AAC CGG TTC CTG GAC CTG CAC CAG ATT CTG CGG GGC TGA 6955:
-  A M I N O  A C I D  C O M P O S I T I O N
Ala 19 14.6%
Gly 6 4.6%
His 3 2.3%
Asn .2 1.5%
Lys 3 2.3%
Val 6 4.6%
Pro 7 5.4%
Phe 4 3.1%
Gin 5 3.8%
Arg 1.4 10.8%
Leu 15 11.5%
Cys 2 1.5%
Tyr 3 2.3%
Ser 5 3.8%
Asp 11
4PinCD
H e 4 3.1%
Met 2 1.5%
Trp 1 0.6%
Thr 11 8.5%
Glu 7 5.4%
A p p r o x i m a t e  M o l e c u l a r  W e i g h t  =  1 4 4 3 6 . 4 9
Figure 17
The EcoRI o fragment showing 152bp region were the 5' end 
of two genes map. HSV-1 17syit sequence is compared to 
tsl233 sequence. Bold letters represent the thymidine 
nucleotides observed in the sequencing results. The 
underlined region represents the change in the amino acid 
sequence from an isoleucine to asparagine. The crossed- 
hatched region is where the tsl233 mutation was located by 
marker rescue.
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Figure 18
Translation of gene UL33 (McGeoch et al. , 1988). The
diagram shows the nucleotide and amino acid sequence of 
this gene and its predicted mw. The (*) at residue 69210 
represents the position of the mutation in tsl233. The 
boxes indicate the amino acid sequence of the two peptides 
synthesised.
T y r o s i n  w a s  a d d e d  t o  t h e  3 ' e n d  a n d  5 ' e n d  o f  t h e  f i r s t  
a n d  s e c o n d  o l i g o p e p t i d e  r e s p e c t i v e l y  t o  f a c i l i t a t e  
c o u p l i n g  t o  c a r r i e r  p r o t e i n .
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with antisera raised against oligopeptides specific to the 
ends of the protein. Antisera often contained antibodies 
which cross reacted with the intact protein and the regions 
contained amino acid sequence that were able to be 
synthesised easily on the oligopeptide synthesiser (H. 
Marsden, personal communication). The first peptide 
represented the first 11 amino-acids from the amino- 
terminus of gene UL33, and the other represented the last 
11 amino-acids from the carboxy-terminus of gene UL33 
(Figure 18) . The oligopeptides were coupled to either BSA 
or p-galactosidase, and injected into rabbits (table 10) 
(also refer to section 2.12.1).
Antibodies made against BSA were removed by passing 
the sera through a column containing BSA linked to CNBr 
activated Sepharose 4B (Section 2.12.2, 2.12.4). A radio­
immunoassay was performed prior to and after BSA antibody 
isolation to check that BSA antibodies had been removed 
(data not shown).
Figures 19a, and 19b represents results of the 
radio-immunoassays of serum from animals injected with the 
carboxy-terminal peptide coupled to p-galactosidase. 
Antisera from post-immune bleeds reacted to the antigen 
(peptide) coating the microtitre wells and gave high [123I] 
counts in comparison to preimmune serum, suggesting that 
the antisera raised against the peptides were recognising 
the antigen. Similar results were obtained with both 
peptides coupled to BSA from which BSA antibodies had been 
removed (data not shown).
TABLE 10
The Injection protocol of UL33 peptides coupled to
p-galactosidase
Peptide
code
Peptide
representing
injections
peptide/ml
1 2 3 4 5
20988
The first 11 
A.A from the 
NHZ-terminus
* / 150yg
* * * / tv
20994
The last 11 
A.A from the 
COOH-terminus
* * * * * «f
* * * * * It
/ : no injections were given due to the death of animals 
* : injection
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Figure 19
The graphs represent the results obtained from radio­
immunoassay experiment using sera from two animals injected 
with the carboxy terminal peptide coupled to p- 
galactosidase. The pre-immune serum is the first bleed. 
Post immune bleeds were obtained before booster injection 
with the peptide.
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3.2.3 Detection of antibodies using western blots
All antisera prepared by coupling peptide to either 
BSA or p-galactosidase were tested on western blots (as 
described in section 2.12.5, 2.12.6). None of the antisera 
reacted specifically with a virus-infected cell protein 
band (figure 20) , suggesting that the oligopeptide 
antibodies did not recognise UL33 gene product immobilised 
on nitrocellulose.
3.2.4 Immunoprecipitation of UL33 gene product
Since the oligopeptide antisera did not react with 
a virus-specific polypeptide on a protein blot, 
immunoprecipitation experiments were performed to determine 
whether antibodies specific to UL33 gene product could be 
detected by this method. Oligopeptide antisera were 
incubated with extracts of [38S]-methionine labelled virus- 
infected cell polypeptides and the antibody-antigen 
complexes precipitated by binding to protein A sepharose. 
The bound protein was eluted and analysed on SDS 6-15% 
polyacrylamide gradient gels. The antisera raised against 
oligopeptides coupled to BSA did not appear to contain 
antibodies which immunoprecipitated a virus-specific 
polypeptide suggesting that the oligopeptide antibodies did 
not recognise UL33 gene product. Further experiments were 
performed using IgG purified from one of the antisera by 
fast protein liquid chromotography. Although purified IgG 
reacted with the oligopeptide in a radioimmunoassay, no 
virus-specific polypeptides were selectively precipitated 
from virus-infected cell extracts. However, one of the
peptide code
moc M s y n
20988 20994 20988 20994
A1 B1 A2 B2 A1 B1 A2 B2 A1 B1 A2 B 2 A1 B 1 A2 B2
t
f
/
_______
Figure 20
Immunoblot experiment using anti-carboxy terminal peptide 
serum, carried out as described in section 2.12.5 and 
2.12.6. The A track represent the [33S]-methionine of 
labelled mock-infected (moc i) or wt virus-infected cell 
polypeptides (17syn* ) transferred to nitrocellulose. The B 
track represent the reaction of antiserum bound to [123I] 
protein A with mock-infected or wt virus infected cell 
polypeptides. Sera obtained from two rabbits were diluted 
either 1/10 (A1 and Bl) or 1/100 (A2 and B2) . Bands seen
on the [12 * 1 3 track represents non-specific reaction 
between the serum and mock- or virus-infected cells.
124
antisera raised against the carboxy-terminus peptide 
coupled to p-galactosidase showed a weak reaction with a 
protein of around 14,000 MW in immunoprecipitation 
experiments (Figure 21).
3.2.5 Nucleocapsid and virion polypeptide profiles of
HSV-1 , HSV-2, and the HSV-l/HSV-2 recombinant
BX1(31-1)
A monoclonal antibody to V m w 155 reacted not only 
with free V m w 155 but also with V m w 155 present in capsids, 
providing cell extracts were prepared using a mild 
solubilising buffer which did not disrupt capsids. Thus in 
immunoprecipitates five capsid proteins, as well as V m w 155 
were detected. The genomic region specifying the low mw 
capsid protein V m w 12 was determined by analysis of HSV- 
l/HSV-2 recombinants, taking advantage of the observation 
that V m w 155 antibody immunoprecipitated capsids. V m w 12 was 
shown to map between 0.44-0.52 mu (J.W. Palfreyman, 
personal communication). This region of the genome 
contained coding sequences of genes UL32 to UL36. Only two 
of these genes, UL33 and UL35, however, specify low mw 
polypeptides. The HSV-l/HSV-2 recombinant BX1(31-1) has 
HSV-2 sequence spanning UL33 gene (figure 22) (Marsden et 
al., 1978). Since the recombinant induces V m w 28 with a mw 
intermediate between HSV-1 and HSV-2 counterparts, it is 
likely that the crossover site on the right hand side lies 
within gene UL34 which encodes V m w 28. The crossover site 
on the left hand side is probably located within UL32. The 
recombinant BX1(31-1) should therefore specify an HSV-2
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Figure 21
Autoradiograph of immunoprecipitates, using UL33 anti- 
carboxy terminus peptide antibody. Mock-infected cells or 
cells infected with wt virus-, or tsl233 were incubated at 
31° or 39° for 9h, labelled with [3 5 S]-methionine for lh 
and harvested. Immunoprecipitation was performed as 
described in section 2.12.7 and the immunoprecipitates were 
analysed on a 6-15% polyacrylamide gradient SDS gel. The 
polypeptide recognised by the oligopeptide antisera raised 
against the carboxy terminus (rabbit 20994) is marked. 
Track 1 represent mock-infected cell extracts, track 2 
represent wt virus-infected extracts, tracks 3 and 12 mock- 
infected extracts with preimmune sera taken from either 
rabbit no. 20988 or 20994, track 4, 8, 13, and 17 represent 
extracts of wt virus-infected cells at 31° , tracks 5, 9, 14 
and 18 represent extracts of tsl233-infected cell at 31° , 
tracks 6, 10, 15, 19 of extracts of wt virus-infected cells 
at 39°, tracks 7, 11, 16, 20 of extracts of tsl233 virus-
infected cells at 39° with either sera from rabbit 20988 
(tracks 3-11) , or sera taken from rabbit no.20994 (tracks 
12-20) .
K b p /  M A P  C O O R D I N A T E S
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HSV-2 HSV-2
Figure 22
The structure of BX1(31-1).
The regions where a crossover has occurred in BXK31-1) are 
denoted by a cross hatched area. The upper line represents 
HSV-1 sequences and the lower line represents HSV-2 
sequences. The HSV-1 EcoRI sites and the position of genes 
UL32, 33, 34 and 35 are also included.
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UL33 gene and an HSV-1 UL35 gene. An experiment was 
carried out to determine whether UL33 gene product was a 
capsid protein. Nucleocapsids and virions were purified 
from cells infected with either wt HSV-1 17syn* virus, wt 
HSV-2 HG52 virus or the recombinant virus BX1 (1-31). The 
method of purification was essentially the same as that 
described by Gibson and Roizman (1972) (refer to section 
2.13). Capsids and virions, labelled with [3aS]- 
methionine, were analysed on SDS 6-15% polyacrylamide 
gradient gels. Figure 23 shows an autoradiograph of virion 
and capsid profiles of HSV-1, HSV-2 and the recombinant. 
The recombinant BX1(31-1) appeared to specify a 12,000 mw 
capsid protein of the same mobility on SDS polyacrylamide 
gels as HSV-1 wt virus. These results suggest that UL33 
does not encode a capsid protein.
3.3 UL33 GENE EXPRESSION
Antisera raised against synthetic oligopeptides 
representing the carboxy-terminus and amino-terminus of 
UL33 either failed to give a specific reaction with UL33 
gene product or only weakly recognised the protein. 
Therefore, the main objective for expressing the protein 
was to use the expressed protein to make antisera specific 
for UL33 gene product. Two different techniques were used 
during the course of this study in an attempt to identify 
the gene product of gene UL33.
Capsids
Apparant
MW X 103 1 2 3 4 5
Virions 
6 7
Figure 23
Autoradiograph of polypeptide profile obtained from [3SS]- 
methionine labelled capsids and virions prepared according 
to Gibson and Roizman (1972) . Polypeptides were separated 
on a 6-15% polyacrylamide SDS gel.
Lanes 1 and 2 represent mock-infected and wt virus-infected 
cell extracts respectively.
Lanes 3 and 6 represent 11 syn* capsids and virions
respectively.
Lane 4 and 7 represents BX1(31-1) recombinant capsids and 
virions respectively.
Lane 5 and 8 represents HG52 capsids and virions
respectively.
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3.3.1 Cloning and expression of intact UL33 in bacterial
expression vector
Initially, intact UL33 gene was inserted into 
bacterial expression vector. Two vectors, pKK240-ll which 
contains the tac promoter, and pKK233-2 which contains the 
trc promoter (trp-lac fusion promoter with a 17bp consensus 
spacing between the trp -35 region and the lacUV 5-10 
region) followed by JacZ ribosome binding site -10 region, 
an ATG initiation codon and a transcription terminator 
were used. PKK233-2 has been shown to express high levels 
of HSV-1 gD (Amann and Brosius, 1985) . The ATG codon in 
the vectors is located within a unique Ncol site which, 
when digested with Ncol, exposes a 4bp overhang containing 
the ATG codon. Since sequencing data of HSV-1 genome has 
shown that the ATG initiation codon of UL33 (McGeoch et 
al., 1988) coincides with an Ncol site, the 472bp Ncol 
fragment containing the coding sequence of gene UL33, was 
cloned into the Ncol site of pKK233-2 and pKK240-ll and 
transfected into E. coli strain W3110 lacl* . Recombinant 
clones were screened with various restriction endonucleases 
to check that the correct sequence had been cloned and to 
determine the orientation of the insert. Cultures of 
bacteria containing the clones with the insert in the 
correct orientation were prepared and expression in duced 
from tac or trc promoter by the addition of IPTG. The 
plasmid pcT15, containing the N-terminal deletion mutant of 
the bacteriophage A cl repressor inserted into pKK233-2, 
was used as a control. This truncated repressor protein is 
stable in E. coli and expressed at high levels (Amann and
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Brosius, 1985). Polypeptides from the bacteria were 
analysed by SDS PAGE. The protein profiles of the bacteria 
containing the recombinant plasmids were similar to these 
of bacteria containing the expression vector. No novel 
protein of the size around the predicted mw for UL33 
polypeptide was detected when the recombinant bacteria were 
treated with IPTG. Bacteria carrying pcI15, however, 
expressed high levels of a 26,000 mw, mutated cl repressor 
when culture were treated with IPTG, confirming that the 
expression assay was working (Figure 24).
3.3.2 Expression of gene UL33 under IE-Vm w 175 control
Since the attempt to express gene UL33 in a 
prokaryotic expression system did not reveal any novel 
protein it was decided to express UL33 in a eucaryotic 
expression system. Enhanced expression of a gene can be 
obtained by placing the gene of interest under IE gene 
regulation in the HSV-1 virus tsK. This mutant has a 
defect in Vm w 175 (Davison et al. , 1984), and as a
consequence overproduces IE proteins, and fails to induce 
other classes of viral proteins at the NPT (Preston, 1979a; 
1979b).
3.3.2.a Cloning and insertion of UL33 into the IE
expression vector p23 „
The-
The IE expression vector p23 consists of/vMwl75 
promoter and regulatory region inserted into^cloned HSV-1 
TK gene. A brief description of the construction of this 
plasmid is given here. The plasmid pGX153 contains the
pKK233-2 pKK240-10
Figure 24
Comassie brilliant blue stain of a protein gel. Gene UL33 
was cloned into pKK233-2 and pKK240-10. Bacterial cultures 
containing the clones were assayed as described in section 
2.14. Polypeptides were separated on a 12.5%
polyacrylamide SDS gel.
(-) without IPTG added 
(+) with IPTG added
Tracks l r 2, 11 and 12 represent bacteria carrying the
plasmid pcJ.
tracks 3, 4 , 13 and 14 represent bacteria carrying
pKK233-2 and pKK240-10 without any insert.
Tracks 5, 6, 7, 8 represent bacteria carrying pKK233-2
containing UL33 inserted in the correct orientation 
required for expression.
Track 9 and 10 represent bacteria containing UL33 inserted 
in the opposite orientation.
Tracks 15, 16 , 17, 18 represent bacteria carrying pKK240- 
10 containing UL33 in the correct orientation.
Tracks 19, 20 represents bacteria carrying pKK240-10 
containing UL33 in the opposite orientation. Expressed pcJ 
is marked.
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HSV-1 BamHI p fragment inserted into the BamHI site of
pAT153. An Xhol site was created within the coding
sequences of TK in BamHI p by insertion of an Xhol
oligonucleotide linker at the SstI site (Fisher and
Preston, 1986). The mutated plasmid was referred to as
pGX166. A 360bp BamHI-Hindlll fragment, containing the
the.
promoter and upstream regulatory sequences of/vnwl75 gene, 
was derived from the plasmid A494#23 constructed by Dr. C. 
M. Preston (see figure 25). This fragment was treated with 
Klenow in the presence of all four dNTPs to create a blunt 
ended fragment and inserted into pGX166, cleaved with Xhol 
and treated with Klenow in the presence of dNTPs. The Xhol 
site was recreated by the ligation of the filled in BamHI 
site from the 360bp fragment with the filled in Xhol site 
from pGX166. Similarly, the Hindlll site was created at 
the other end of the inserted fragment. The plasmid 
containing the 360bp BamHI-Hindlll fragment was referred to 
as p23 and generously supplied by Dr. C. M. Preston.
Since the EcoRI o fragment did not contain any 
suitable restriction endonuclease sites for cloning the 
UL33 gene into the Xhol site in p23, the 555bp EcoRI-Smal 
fragment, containing UL33, was subcloned from pGX74 (this 
plasmid contains the EcoRI o of HSV-1 11 syn* ) into EcoRI- 
Smal cleaved pUC8 (figure 26). Two clones, referred to as 
pGX215 and pGX216, were isolated and digested with various 
restriction endonucleases to check that the correct 
fragments had been inserted. PGX215 was linearised with 
EcoRI, and the EcoRI site was filled in with T4 DNA 
polymerase in the presence of 200yM dGTP, dCTP (1 unit per
X  Xhol linker
TK
IE-Vmw175 promoter 
from plasmid A494#23
■ I  Hindi II filled
pGX153 Xhol
Vector pAT 153
Xhol IE-Vmw175
promoter
pGX166
P23
Figure 25
Diagram showing the construction of p23 vector into which 
the UL33 gene was inserted. An Xhol linker was inserted 
into an SstI site and the IE V m w 175 promoter and regulatory 
sequences cloned into the Xhol site to give p23 (for 
details of the construction method refer to the text).
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Pvull Smal
a i
• a
-0— 0
Smal-EcoRI Fragment
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X \
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pGX216 J 
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|— — So— j>-- (Sp>
polylinker cloning site
Xhol
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Figure 26
A diagram showing the construction of pIE-UL33 used for 
inserting UL33 into TK gene of tsK virus. The EcoRI-Smal 
fragment containing UL33 gene was sub-cloned from pGX74 
(contains the wt virus EcoRI o) into pUC8. The Sall-Xhol 
fragment was subcloned from pGX224 into Xhol cleaved 
phosphatased p23. The resulting clone was pIE-UL33 (for 
further details on the construct refer to section 3.3.2a.
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Ug plasmid DNA) in a final concentration of IX T4 
polymerase buffer. The linearised plasmid was then treated 
with 10 units of calf intestinal phosphatase. The 
phosphophatased treated plasmid DNA was ligated to Xhol 
phosphorylate oligonucleotide linker d(pCCGCTCGACGG) and 
transfected into competent DH1 bacteria. Two clones 
containing the Xhol linker, pGX223 and pGX224, were 
isolated and the presence of restriction endonuclease sites 
checked. The Xhol-Sall fragment (Sail site is present in 
the polylinker cloning site of pUC8 vector) from pGX224 was 
ligated into Xhol cleaved, phosphatased p23 plasmid. 
Isolated clones (referred to as pIE-UL33) were digested 
with various restriction endonucleases to confirm the 
correct fragment had been cloned and to determine the 
orientation of the insert.
3.3.2.b Selection and isolation of a TK“ recombinant virus 
containing gene UL33 under IE-Vm w 175 gene 
regulation
HSV, lacking a functional TK gene, will grow in the 
presence of 5-bromo-2'-deoxycytidine (referred to as
BCdR). In cells infected with wt virus, however, the TK 
phosphorylates this compound converting it into a toxic 
drug which interferes with viral DNA replication. BCdR was 
therefore used to select TK- recombinants containing UL33 
gene under IE gene regulation. BHK cells were cotransfected 
with tsK and pIE-UL33 DNA as in marker rescue experiments. 
When extensive CPE had developed, cells were harvested, and 
progeny virus titrated on duplicate sets of BHK cell
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monolayers in 30mm dishes. After incubation for 45min at 
31°, the first set was overlaid with Eagle's medium 
containing new born calf serum, and BCdR. The second set 
was overlaid with Eagle's medium containing both new born 
calf serum, and human serum. Plates were incubated for 3 
days at 31° . Thereafter cells of the first set were 
harvested into medium while the second set was stained with 
Giemsa stain and plaques counted. Virus progeny from the 
first set of plates were titrated on BHK cells and well 
isolated virus plaques picked and virus titrated. Virus 
was plaque purified three times, and large scale virus 
stocks prepared. Virus DNAs labelled with [32P] were 
prepared using the Lonsdale technique as described in 
section (2.10) and the viral DNAs analysed with BamHI, Xhol 
and Kpnl. Figure 27 represents an autoradiograph of 
separated restriction endonuclease fragments of tsK and two 
isolated recombinant viruses VIE-(UL33-1) and VIE-(UL33-2) 
following digestion with either BamHI or Xhol enzymes. The 
recombinant virus DNAs lacked BamHI p fragment and 
contained instead two smaller BamHI fragments. This was 
expected since the Xhol-Sall fragment inserted into the 
Xhol site of p23 contained a BamHI site from the polylinker 
of pUC8 (compare track 2,3 to track 1). The Xhol f 
fragment in tsK (track 1) was not present in the two 
recombinants. Instead two smaller fragments appeared, 
consistent with the presence of an Xhol site within Xhol f 
(track 2 and 3). Thus, these results suggested that the 
gene UL33 linked to IE-3 promoter had been recombined 
successfully intoATK gene of tsK.
BamHI 
1 2 3
Xhol 
4 5 6
BamHI P
Figure 27
Autoradiograph showing restriction endonuclease digests of 
viral DNA labelled in vivo with [32P]. BamHI (lane 1-3) 
and Xhol (lanes 4-6) digestion of tsK (lane 1, 4) and two 
separate recombinant viruses (lane 2, 3, 5, 6). The
location of the BamHI p and Xhol f in tsK is indicated by 
the left hand arrows (lane and 4) . The novel fragments in 
the two recombinantsare indicated by right hand arrows.
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3.3.2.C UL33 expression by the recombinant virus
BHK cells were infected with recombinant virus or 
tsK at the PT and the NPT. Virus-infected cells were 
labelled with [33S]-methionine, and the proteins separated 
on SDS 6-15% polyacrylamide gradient gels. Results 
obtained from the autoradiographs revealed that the two 
recombinant viruses each fail to induce TK (about 39,000 mw 
protein) at the PT. In addition, more than one band was 
detected under IE conditions at the NPT, one with a mw 
slightly higher than the predicted MW of UL33 and the other 
band was about 35,000-30,000 (figure 28). However,
subsequent experiments using a recombinant virus containing
"tine.
/( V m w 1 7 5  p r o m o t e r  a n d  u p s t r e a m  r e g u l a t o r y  s e q u e n c e s  i n s e r t e d  
iWe
into/TK gene of tsK is showed that this virus induced a 
similar sized band of about 16,000 mw. Therefore, it was 
concluded that UL33 was probably not expressed under these 
conditions.

Figure 28
Autoradiograph of polypeptides induced at 31° and 38.5° in 
BHK cells infected with tsK or VIE-(UL33-1) or VIE-(UL33-2) 
or in mock infected cells. Virus-infected cells were 
labelled with [3 5 S]-methionine for lh at 4 hpi and 
harvested. Protein samples were analysed on a 6-15% 
gradient SDS PAGE. Numbers represents apparant mw of IE 
polypeptides. Track 1 represents wt virus-infected cell 
extracts, tracks 2 and 6 represent mock-infected cell 
extracts, tracks 3 and 7 tsK infected cell extracts at 31° 
and 39° respectively, tracks 4 and 8 of VIE(UL33-1) virus- 
infected cells at 31° and 38.5° respectively and tracks 5 
and 9 represent VIE(UL33-2) virus-infected cells at 31° and 
38.5° respectively. TK band in tsK (track3) is marked. 
The two bands mentioned in the text are marked. Below is a 
longer exposure of the same area where the induced 16,000mw 
protein is marked.
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3.4 DISCUSSION
In the previous sections a DNA positive mutant of 
HSV-1 tsl233 has been characterised. The lesion of tsl233 
was shown to lie in gene UL33. When work on tsl233 was 
initiated no mutations had been assigned to UL33 and no 
information was available about the function of the gene. 
The analysis of this mutant suggests that gene UL33 is 
required for the assembly of nucleocapsids and may be 
important for cleavage and encapsidation of HSV DNA since 
tsl233 failed to package DNA into capsids at the NPT.
3.4.1 DNA processing in wt virus, tsl233 and tsl201 
infected cells
Electron microscopic analysis of virus-infected
cells and Southern blot analysis of total viral and
c e l l 7extracts
encapsidated DNA present in fcsl233-inf ected-4 at the NPT and 
PT revealed that tsl233 failed to package DNA at the NPT. 
More than 99% of the DNA synthesised by tsl233 was endless 
at the NPT. This finding is consistent with the 
information obtained from the analysis of ts mutants of PRV 
and HSV which have encapsidation defects and suggests that 
viral DNA is cleaved as it is inserted into the capsid 
(Ben-Porat and Veach, 1980; Ladin et al.,1980; Preston et 
al., 1983; Addison, 1986; Sherman and Bachenheimer, 1987).
Tsl233 did not cleave DNA when mutant-infected 
cells were downshifted from the NPT to the PT in the 
presence of cycloheximide and therefore, the effect of 
tsl233 mutation could not be reversed upon shift down of 
virus-infected cells to 31° . Some cleavage of tsl201
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concatemeric DNA, however, occurred following transfer of 
the mutant infected cells from 39° to 31° in the presence
of cycloheximide, although not as much as reported
previously (Addison, 1986). One explanation for this 
result is that some of the tsl201 mutant protein remains 
non-functional after transfer to 31° or the conformation of 
the mutant protein has been altered in such a way at 39° 
that it does not work as efficiently as the wt virus 
protein at 31° . Another explanation is that at the NPT all 
of the tsl201 DNA was present in an endless state and 
therefore, unless DNA cleavage was very efficient, there 
should not be as much viral DNA cleaved in tsl201-infected 
cell sample as in the wt virus-infected cell samples.
Although mutant and wt viruses packaged DNA
efficiently at 31° , only about 8% of the DNA synthesised by 
the wt virus was cleaved and packaged at 39° . This
observation is consistent with other work showing that wt 
11 syn* virus packaged DNA less efficiently at a NPT of 
38.5° than at the 31° (Addison, 1986). This result suggests 
that there may be more thermolabile proteins involved in 
encapsidation.
DNA +ve mutants from five different complementation 
groups (tsF18, tsl208, tsl201, fcsl203, tsN20) fail to
encapsidate viral DNA at the NPT (Schaffer et al. , 1987). 
One of the mutants, belonging to complementation group 
1-13, has not been characterised in detail. The mutations 
in viruses belonging to the other complementation groups, 
however, have been assigned to specific genes. Mutants 
with defects in UL6, UL26, UL28, UL32, and UL33, all
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produced large numbers of partially-cored capsids at the 
NPT, whereas the mutant tsl208, with a defect in UL25, 
produced only low numbers of capsids at 39° . It is 
therefore, likely that UL25 is not directly involved in DNA 
encapsidation. With the exception of tsl201 defect, which 
could be reversed when mutant virus-infected cells were 
shifted to the PT in the presence of cycloheximide, the 
effect of mutation in all the other packaging deficient 
mutants was irreversible. The internal structure of the
from Of
partially-cored tsl201 capsids seemd to differ/those/other 
mutants, although no information on the internal sructure 
of tsN20 and tsF18 is available. In contrast to tsl201 
partially-cored capsids, tsl233 produced capsids at the NPT 
which had a small core structure similar to those seen in 
tsl203-infected cells at the NPT.
Effect of UV light-induced mutation in tsl233
As indicated previously, tsl233 was isolated from a 
UV-mutagenised wt virus stock. This section deals with 
UV-induction of the mutation in tsl233 DNA and the effect 
the lesion exerts on the protein. UV-induced mutagenesis 
has been intensively studied in other organisms such as 
lambda phage, Escherichia coli and, therefore, these 
systems have been used as general models for explaining the 
nature of mutation in this study, although it should be 
emphasised that the analysis of larger numbers of 
UV-induced mutations in HSV is vital for increasing our 
knowledge regarding the concepts of UV mutagenesis and 
understanding the nature of the repair mechanism
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employed by HSV.
The mechanism of UV-induced lesion
UV light is known to induce a number of different
classes of mutations ranging from base substitutions
(including single, tandem double-base substitution) ,to
frameshift$, deletions, and insertions (Wood and Hutchinson,
1984; Wood et al, , 1984; Miller, 1985; Schaaper et al, ,
1987). However, the identity of the major cause of the
premutational DNA lesions after UV irradiation is
uncertain, and is thought to be one of two photoproducts.
Cyclobutane dipyrimidine dimer is the product which has
been widely implicated in UV mutagensis, and around two-
thirds or more of the mutations in lambda phage are thought
to be caused by this product (Hutchinson et al. , 1988).
The second less frequent candidate is pyrimidine-pyrimidone
[6-4] photoproducts (referred to as [6-4]) and these are
defined as a series of products derived from unstable four-
membered rings formed after the photo-induced addition of a
carbonyl or imino group from one pyrimidine in a DNA strand
to the 6 position in the 5,6 double bond of an adjacent
pyrimidine. This product has been implicated as a cause
of premutational DNA in bacteriophage lambda (Wood et al., 
"the
1984) and in /( E.Coli lacl gene (Gilkman et al., 1986; 
Schaaper et al., 1987) .
The damaged DNA is excised and mutations result from 
errors in repair synthesis. Among the base substitutions, 
transitions predominate over transversions and form the 
largest class of mutations. 85% of base substitutions are
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found at sequences of two or more adjacent pyrimidines, 
leading to the conclusion that UV-mutagenesis is a targeted 
event at sites of dipyrimidine damage, either of
cyclobutane or the [6-4] type in E.Coli lacl gene (Schaaper 
et al. 1987). Results obtained from previous studies
showed that transversion normally occurred at pyr-pyr*,
rather than at pur-pyr*-pyr (* represent the mutated
Ypyrimidine) sites in a lambda phage cl gene (Wood et al. ,
■the
1984), and / l acl gene of E. coli (Miller, 1985). In
comparison with the data of site specificity of UV-induced
the
base substitution in&E. Coli lacl gene and lambda phage, it 
is concluded that the mutation in tsl233 has occured as a 
result of a targeted event at a pur-pyr*-pyr and is
consistent with the nature of induction of the mutation by 
UV-light in other systems. However, since transversions 
are much less frequent than other base substitutions a 
wider statistical analysis on the occurance of such 
mutations in HSV is required to support this conclusion.
UL33 protein conformation
As mentioned earlier the lesion in tsl233 is caused
by a base pair transversion of A.T to T.A which results in
the substitution of isoleucine with asparagine at amino
acid position 17 in the proposed UL33 gene product. Since
this change affects the ability of the virus to produce DNA
containing capsids at the NPT, it is reasonable to assume
that the lesion affects an important functional domain in
UL33 protein. To assess the impact of the mutation on the
the
UL33 protein structure, the predicted secondary structure ofV
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UL33 gene product was determined using the Chou-Fasman 
computer programme Chou and Fasman (1978). This programme 
calculates the probability of a residue type adopting one 
of the structural states, a-helices (characterised by 
intra-molecular hydrogen bonding between peptides on the 
same polypeptide chain), 3~sheet structures (inter- 
molecular hydrogen bonding), and reverse or 3-turns (also 
known as coil regions which cause the polypeptide to fold 
on itself by approximately 180°). The most striking 
difference observed between the predicted wt virus UL33 
protein structure and that of tsl233 is the formation of a 
new 3~turn at the position of the lesion near an a-helix 
pole (figure 29 and 30) . Since tsl233 grows well at 31° , 
it is possible that this change does not affect the 
conformation of the protein at the PT, but higher 
temperatures (39°) cause an alteration in the secondary 
structure of the protein and as a consequence the protein 
becomes non-functional. It is possible that/ altered 
protein is more stable than it was in its possible original 
configuration This idea provides an explanation for
the observation that the effect of the tsl233 lesion was 
unable to be reversed when mutant- infected cells were 
transferred from the NPT to PT in the presence of 
cycloheximide.
The position of the lesion in tsl233 is located at 
the a-helix pole, and it is interesting to note that the 
thermostability of the T4 lysozyme has been increased by 
amino-acid substitutions at the dipoles (Nicholson et al.,
1988) . Since the the accuracy of prediction of the Chou

Figure 29
Predicted secondary structure of UL33 protein.
The structure is based on Chou and Fasman computer 
programme which predicts helices, sheets and turns 
according to Chou and Fasman (1978).
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Figure 30
Predicted secondary structure of tsl233 UL33 protein.
The structure is based on Chou and Fasman computer 
programme which predicts helices, sheets and turns 
according to Chou and Fasman (1978). (see figure 29)
The position of the mutation within the secondary structure 
is indicated by an arrow.
H e l i c e s  a r e  s h o w n  w i t h  a  s i n e  w a v e  (AAA), b e t a  
s h e e t s  w i t h  a  s h a r p  s a w - t o o t h  w a v e  ( ) . t u r n s
w i t h  1 8 0  d e g r e e  t u r n s ,  a n d  c o i l s  w i t h  a  d u l l  
s a w - t o o t h  w a v e ,  h y d r o p h i l i c i t y  ( 0  ) a n d
h y d r o p h o b i c i t y  ( <) ) a r e  s u p e r im p o s e d  o v e r  t h e  w a v e .
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and Fasman programme is about 50-60% other explanations for 
the observation that the effect of/tsl233 lesion at the NPT 
is irreversible may exist, for example the protein could be 
unstable and degraded at the NPT, or alternatively the 
mutant protein at NPT might form a different structure to 
the wt protein upon transfer to the PT. Crystallographic 
analyses of UL33 protein would be of great help in 
determining the effect of the lesion on the protein 
conformation.
P o l y c l o n a l  a n t i b o d i e s
Anti-peptide antibodies have been extremely useful 
for isolating and characterising gene products. Factors 
such as the length of the peptide, hydrophilicity, amino 
acids present in the oligopeptide, their location in the 
native molecule, and even the secondary and tertiary 
configuration of the peptide are thought to be
important factors in generating protein-reactive 
antipeptide antibodies.
Two peptides were used in this study, one 
representing the carboxy-terminus (11 amino acids) and the 
other the amino-terminus (11 amino acids) of UL33. These 
peptides were chosen for several reasons. First, the 
carboxy-terminal and amino terminal regions of many 
proteins are relatively free to rotate and might be more 
exposed and free to react with antibodies than other 
regions of the molecule. Second, these peptides are 
reasonably hydrophilic. It was thought that antigenic 
regions are primarily hydrophilic regions on the surface of
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the protein molecule, and often contain charged and polar 
residues. Not all hydrophilic regions, however, are 
antigenic and not all antigenic regions are hydrophilic. 
Nevertheless, many investigators have been able to raise 
antisera against short peptides that recognise native 
proteins and the majority of such short epitopes were shown 
to correspond to regions in the protein that possess a high 
segmental mobility (Tainer et al. , 1984). Another reason
for choosing a resonable hydrophilic peptide is that the 
peptide is more likely to be soluble and therefore, more 
easily coupled to a carrier protein. One possibility for 
not obtaining a specific antibody could be that the length 
of the peptides chosen was not long enough to give an anti­
protein immune response since this depends entirely on the 
probability that the free peptide would adopt the 
conformation that the identical sequence would assume in 
the native protein. Several studies have reported that not 
all antisera raised against peptides generated antibodies 
specific to the native protein (Tanaka et al. , 1985). The 
optimum length for an immunogenic oligopeptide likely to 
produce a positive antiseram has been estimated to be 
between 10-15 amino acids (Palfreyman et al., 1984).
Alternatively, it is possible that the weak response of the 
carboxy-terminus antipeptide antisera to putative UL33 gene 
product was due to other factors, for example, very small 
quantities of the gene product may be present in virus- 
infected cells and since the protein is low in methionine, 
UL33 gene product may not be easily detected even with a 
potent antiserum if the virus infected cell polypeptides
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were labelled with [33S)-methionine.
UL33 Gene expression
The bacterial plasmid vector pKK233-2 has been 
useful for the expression of high levels of foreign 
proteins from both prokaryotes and eukaryotes (Amann and
Brosius, 1985). The reason for the failure to detect the
vJi'tk
putative UL33 gene product/this expression system is not 
known. The protein could be unstable or toxic.
Alternatively, a mutation which affected gene expression 
could have been induced during the cloning of this gene
into pKK233-2. The possibility that gene UL33 contains 
more than one intron can not be dismissed, especially since 
no transcripts have been characterised in the region where 
UL33 gene is located. It is, however, unlikely because RNA 
splicing is rare in HSV and, with one exception restricted 
to IE transcripts. Furthermore, a homologue of UL33 has 
been identified in VZV.
The UL33 gene was also placed under IE gene
tine
regulation and inserted into/TK gene of tsK. The results 
of this experiment were difficult to interprete because 
more than one novel protein band could be detected by SDS- 
PAGE when the recombinant virus was grown under IE
conditions. One explanation for the presence of the high 
mw protein band is that the protein was modified or the 
promoter was altering the expression working on an adjacent 
open reading frame. It should be mentioned that in certain 
cases inversion can occur between sequences inserted in/TK
gene and the endogenous gene provided the sequences
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inserted into the TK gene are in opposite orientation to 
the original sequence. In view of difficulty in 
interpreting the results of expression of UL33 in tsK 
alternative methods of expressing UL33 gene product are 
required.
The functional role of UL33 gene product
U.
Although^tsl233 mutant failed to package DNA at the 
NPT, the effect of the mutation of was irreversible, and
tu
therefore, it is not possible to conclude that/UL33 gene 
product is directly involved in DNA packaging. Tsl233 may 
produce abberrant capsids at the NPT which are unable to 
encapsidate DNA or the DNA may have been modified.
Several polypeptides have been implicated in the 
assembly of capsids. Vm w 155 is clearly an important 
component of capsids since the hexameric capsomeres and 
probably the pentamer capsomeres are composed of this 
protein (refer to section 1.8.1, on capsid proteins), and 
ts mutants with lesions in Vm w 155 have a capsid-negative 
phenotype at the NPT (Bone and Courtney, 1974; Schaffer et 
al., 1974; Weller et al. , 1987). Like Vm w 155 ts mutants,
the UL38 ts mutant HSV-1 A44ts2 fails to produce capsids at 
the NPT (Pertuiset et al., 1989). This finding suggests
that UL38 gene product is also an essential component of 
capsids, and recent results have shown that the capsid 
protein Vm w 50 (VP19C) is encoded by UL38 (F.J. Rixon, 
personal communication). Clearly, Vm w 155 and Vm w 50 are 
integral capsid proteins.
The correct processing of UL26 gene product is
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probably important for assembly of partially-cored capsids 
since the mutant tsl201f which has a defect in UL26 f 
produces capsids at the NPT that have a larger internal 
structure than the capsids produced at the NPT by packaging 
mutants with defects in other genes (Preston et al. , 1983; 
Sherman and Bachenheimer, 1988).
Nucleocapsid purification experiments suggested 
that UL33 protein is probably not the 12,000 mw capsid 
protein. The possibility that UL33 gene product is a 
virion non-capsid protein, possibly a tegument protein, 
which interacts with other structural proteins during 
assembly of capsids could not be ruled out, and in tsl233- 
infected cells at NPT such a protein was unable to interact 
with capsid proteins. Evidence obtained from electron 
microscopy favours the pathway of capsid assembly in which 
DNA is packaged into preformed nucleocapsids. No empty 
capsids were found in tsl233 infected cells at the NPT, 
therefore, demonstrating that empty capsids are probably 
derived from full or partially-cored capsids. This finding 
is consistent with the results obtained from the analysis 
of DNA +ve ts mutants of PRV and HSV, together with pulse- 
chase experiments showing that empty, coreless capsids are 
breakdown products of full, DNA-containing capsids (Ladin 
et al. , 1980; 1982; Addison, 1986; Rixon et al. , 1988;
Sherman and Bachenheimer, 1988).
The use of oligopeptides in preparing antisera 
directed against UL33 gene has not been fruitful to the 
extent of identifying the UL33 gene product, and since it 
was shown that the mutation in tsl233 was irreversible, the
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functional role of the gene product could only be based on 
speculations in this situation. Work by Ladin et al. 
(1982) on PRV ts capsid- mutants suggested that the 
accumulation of the 35,000 mw polypeptide (equivalent to 
p40) was probably controlled by more than one viral gene 
product. Since the mutant tsl233 processed UL26 gene 
product normally at the NPT, the processing of UL26 gene 
product is not determined by UL33. Subsequent work has 
shown that the processing of this gene product does not 
depend on the presence of capsids since ts mutants that 
fail to make capsids at the NPT process p40 normally (V. 
Preston, personal communication). It is possible that the 
product of gene UL33 is required at a step leading to DNA 
encapsidation such as the anchoring of DNA into capsids 
(Poffenberger and Roizman, 1985), or it is a scaffolding 
protein required for the maintainance of the capsid. 
Alternatively, since it is thought that cleavage and 
packaging are linked together, UL33 protein could possibly 
be part of the postulated DNA complex mentioned by Diess et 
al. (1986) which binds and moves randomly along the DNA 
(See section 1.7.5). Recently it was shown that nuclear 
extracts of HSV-1 infected cells contain factors which 
formed two virus specific protein complexes with the a 
sequence (Chou and Roizman, 1989). The first complex, was 
composed of two proteins, one of which was thought to be 
the product of gene UL36 (MW 336,000), which is known to be 
important for the release of DNA from the capsids into the 
cytoplasm (Batterson et al.,1983), and the other, an 
unidentified protein with an approximate MW of 140,000.
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The second complex contained a polypeptide which, on the 
basis of apparent mw of the protein, its enzymatic activity 
and reaction to a monoclonal antibody appeared to be the 
viral-encoded DNase. Since the binding of this DNase to 
viral DNA does not appear to be sequence specific, it was 
suggested that the DNase interacted with another protein 
that bound in a sequence specific manner to the a sequence 
and enabled the DNase to selectively cleave at the a
sequence (Chou and Roizman, 1989). Although there is no 
evidence that the complexes are involved in DNA 
encapsidation, it is possible that other proteins such as 
UL33 gene product might be a component of this protein 
complex and interact with the DNase and the lesion in
fcsl233 could possibly affect a binding domain between UL33
gene product and the other protein.
3.5 FUTURE PROSPECTS
The main objective of characterising HSV-1 ts 
mutants is to identify the gene product in which the ts 
lesions are localised and determine the functions of the 
gene of interest. In this study the HSV-1 tsl233 mutant 
was shown to have a lesion in gene UL33. However, attempts 
to identify the gene product have been hampered by the 
production of weak antibodies to UL33 gene product and 
failure to express the gene in procaryotic expression 
systems. Oligopeptide antisera raised against synthetic 
oligopeptides specific for a small portion of the amino 
acid sequence of a protein have been used extensively to 
identify gene products. This technology, however,is still
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at an early stage, and it would be interesting to use new
developments in this field for preparing antibodies, such
as longer peptides chosen from different regions or the use
have shown that
of branched peptides since preliminary studiesTa stronger 
immune response is obtained with branched peptides than 
with ordinary peptides (H.S.Marsden, personal
communication). An alternative approach to the use of
synthetic oligopeptides for raising antisera is a modified 
gene-fusion system developed by Lowenadler et al. (1987).
Synthesis of oligodeoxynucleotides, representing short 
stretches of coding sequences of the protein of interest, 
are inserted into a prokaryotic expression vector to yield 
a fusion protein containing the peptide linked to a 
modified protein A carrier. Using a coupled
excretion/expression vector system, the fusion protein is 
execreted in large amounts into the medium and is easily
purified. This technique has several advantages over the 
traditional immunisation with a synthetic peptide 
chemically conjugated to a carrier protein. In particular, 
oligonucleotides encoding upto 50 amino acids can be
synthesised. A synthetic peptide of this size would be 
difficult to produce. In addition peptide sequences which 
are difficult to synthesise should be able to be expressed 
in this system. Other gene fusion systems have been 
developed for the purpose of raising antisera. The 
advantage of these systems is that larger portions of the 
protein of interest can be expressed and therefore there is 
a great chance that the antiserum specific to the fusion 
protein will r e a c t  with the intact protein. An alternative
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approach would be to use a eucaryotic expression system, 
for example, the insect baculovirus vector or vaccinia 
virus for expression of larger amounts of the protein. 
Once an antiserum has been obtained to this protein further 
experiments could be designed to study the role of this 
protein, for example to determine whether it is a DNA-
binding protein, whether it is a virion protein and if so, 
its location in the virus particle using immunoelectron
microscopy on purified virions and capsids. It would also
be interesting to see whether this protein interacts with
other proteins to form complexes.
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4.1 FURTHER CHARACTERISATION OF THE UL26 GENE PRODUCT 
AND THE HSV-1 MUTANT, TS1201, WHICH FAILS TO 
PROCESS UL26 GENE PRODUCT AT THE NPT
4.1.1 Introduction
Genetic analysis of HSV-1 ts mutants have led to 
the identification of several genes involved in DNA 
encapsidation and capsid assembly (See section 1.9.3). 
However, the precise role of each of these gene products is 
still obscure. Tsl201, a DNA positive mutant of HSV-1 
11syn* , has been widely characterised, and its mutation 
localised in UL26. This mutant fails to package DNA and 
process p40 the product of UL26, to its lower mw forms at 
the NPT. The correct processing of the protein could be 
achieved, however, when mutant-infected cells were shifted 
from the NPT to the PT (Preston et al. , 1983; Addison,
1986) . Recent studies have shown that p40 is transiently 
associated with partially-cored capsids and is not a major 
component of full capsids or mature virions (Rixon et al. , 
1988) . The aim of the work presented in this section was 
to extend the characterisation of the mutant tsl201 and to 
investigate the processing of p40 to the lower mw species.
4.1.2 Marker rescue of the lesion in tsl201 with a 673 bp 
fragment obtained from BamHI u
Previous marker rescue experiments showed that the 
tsl201 lesion lies within a 673bp region BamHI-Sall 
fragment at the right hand end of BamHI u (Preston et al. ,
148
1983). The 3' end of gene UL25 and the 5' end of gene UL26 
are located within this part of the genome (McGeoch et al., 
1988) . The failure of tsl201 to process p40 to its lower 
mw forms at the NPT together with the finding that two 
mutants, tsl204 and tsl208, which contain lesions within 
UL25 complement tsl201 suggested that the tsl201 lesion 
mapped within UL26. The 673 bp BamHI-Sall fragment from 
pGX56 (this plasmid contains 11 syn* BamHI u), pGX198 
(BamHI u of tsl201) , and pGX208 (BamHI u of tsl201 rev2) 
(figure 31) were tested for their ability to rescue the 
mutation in fcsl201 before being sub-cloned into M13mpl8 and 
M13mpl9 DNA. The results (Table 11) revealed that only the 
wt virus fragment rescued the lesion in tsl201. These data 
confirmed that the tsl201 mutation mapped in BamHI u. In 
addition, the results suggested that the mutation 
responsible for the ts* phenotype of tsl201 rev2 did not 
lie in BamHI u.
4.1.3 The lesion in tsl201 lies 89 bp downstream from the
amino-terminus of gene UL26
The 673bp BamHI-Sall fragments from pGX198 and 
pGX208 were ligated to M13mpl8 and M13mpl9 DNA, cleaved 
with BamHI-Xbal and transfected into JM101 competent 
bacteria. White plaques, containing the insert, were 
isolated and ssDNA prepared and sequenced using the chain 
termination method (see section 2.9). The nucleotide 
sequence of the BamHI-Sall fragment from the mutant and the 
revertant was compared to that of 17 syn* wt virus. The 
sequence in both the mutant and revertant was identical to
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Figure 31
Diagram showing the position of the tsl201 mutation within 
HSV genome as defined by marker rescue. The cross hatched 
box (673bp) BamHI-Sall (small) fragment containing the 5' 
end of two genes UL25 and UL26. This fragment was taken 
from tsl201 and fcsl201 rev2# sub-cloned into M13mpl8 and 
M13mpl9 and used for sequencing analysis.
TABLE 11
Summary of marker rescue of tsl201
Marker rescue using 
clones digested with 
BamHI-SalI< * >
Efficiency of 
plating NPT/PT X103 Rescue
pGX56
{11 syn* BamHI u) 
Unseparated fragments 0.818 +
Separated BamHI-Sall frag 
Small fragment 0.615 +
Large " <0.02 -
PGX198
(tsl201 BamHI u) 
Unseparated fragments <0.02 _
Separated BamHI-Sall frag 
Small fragment <0.02 -
Large fragment <0.02 -
pGX208
(tsl201 rev2 BamHI u) 
Unseparated fragments <0.02 —
Separated BamHI-Sall frag 
Small fragment <0.02 -
Large fragment <0.02 -
None <0.02 -
(*) The small fragment is the 673bp fragment obtained from 
a BamHI-Sall digest of BamHI u.
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that of wt virus except for a single bp change observed in 
the nucleotide sequence of the mutant and the revertant 
corresponding to residue 50897 of the HSV-1 17syn* 
nucleotide sequence (figure 32, refer to the A track of 
tsl201 and rev2). Sequencing results obtained were 
consistent with the results of the marker rescue experiment 
showing that tsl201 rev2 BamHI-Sall fragment failed to 
rescue the lesion in the mutant and confirmed that the 
reversion event was located outside the 673bp Bamhl-Sall 
fragment. Since residue 50897 was shown to be located 89 
bp from the 5' end of UL26, it was concluded that tsl201 
lesion lies in UL26 (figure 33).
4.1.4 Cloning gene UL26 (kpnl t)of t,sl201 rev2 and rev3
The results of marker rescue experiments and 
sequence analysis of tsl201 DNA and tsl201 rev2 DNA 
revealed that the ts* revertant for growth retained the bp 
change of the mutant. However, tsl201 rev2 and a number of 
other revertants were originally isolated at 38.5°. The wt 
virus, tsl201 rev2, and another ts* revertant tsl201 rev3 
were therefore titrated at different temperatures to check 
whether the revertant viruses were ts at temperatures 
higher than 38.5° . Results of the titration revealed that 
tsl201 rev2 was slightly ts at 39° but at 39.5° had an 
eopNPT/pT of <0.0002. Tsl201 rev3, however, was only 
slightly ts at 39° and 39.5° (table 12). The Kpnl t 
fragments, containing the whole nucleotide sequence of gene 
UL26 and part of the sequences of gene UL25, were isolated 
from Kpnl digested tsl201 rev2 and rev3 virus DNAs and
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Figure 32
Portion of autoradiographs of DNA sequencing gels. 
Sequence products were separated on a 6% denaturing 
polyacrylamide gels containing 9M urea.
A) Shows the base pair alteration in tsl201 (arrow) in the 
adenine track.
B) Shows the same base pair retained in tsl201 rev2 
(arrow).
Translation o f : HSV-1 Gene UL26
Im A A~ 3
GCCCCCCGACCGTTGCGCCTTTTTTTTTTTCGTCCACCAAAGTCTCTGTGGGTGCGCGC ATG GCA GCC 50817
■n A p r  n r ]  I m e e p l p d r a v p i I  21
GAT GCC CCG GGA GAC CGG ATG GAG GAG CCC CTG CCC GAC AGG GCC GTG CCC ATT 50871
B  a i t l H  X U y v A G F L A L Y ^ D S G D S G E L A  39
TAC GTG GCT GGG TTT T T G GCC CT G T AT  GAC AGC GGG GAC T CG GGC GAG T T G GCA 50925
L D P D T V R A A L P P D N P L P I  57
TTG GAT CCG GAT ACG GTG CGG GCG GCC CTG CCT CCG GAT AAC CCA CTC CCG ATT 50979
N V D H R A G C E V G R V L A V V D  75
AAC GTG GAC CAC CGC GCT GGC TGC GAG GTG GGG CGG GTG CTG GCC GTG GTC GAC 51033
D P R G P F F V G L I A C V Q L E R  93
GAC CCC CGC GGG CCG TTT TTT GTG GGG CTG ATC GCC TGC GTG CAG CTG GAG CGC 51087
V L E T A A S A A I F E R R G P P L  111
GTC CTC GAG ACG GCC GCC AGC GCT GCG ATT TTC GAG CGC CGC GGG CCG CCG CTC 51141
S R E E R L L Y L I T N Y L P  S V S  129
TCC CGG GAG GAG CGC CTG TTG TAC CTG ATC ACC AAC TAC CTG CCC TCG GTC TCC 51195
L A T K R L G G E A H P D R T L F A  147
CTG GCC ACA AAA CGC CTG GGG GGC GAG GCG CAC CCC GAT CGC ACG CTG TTC GCG 5124 9
H V A L C A I G R R L G T I V T Y D  165
CAC GTC GCG CTG TGC GCG ATC GGG CGG CGC CTC GGC ACT ATC GTC ACC TAC GAC 51303
T G L D A A I A P F R H L S P A S R  183
ACC GGT CTC GAC GCC GCC ATC GCG CCC TTT CGC CAC CTG TCG CCG GCG TCT CGC 51357
BamHI d'
E G A R R L A A E A E L A L S G R T  201
GAG GGG GCG CGG CGA CTG GCC GCC GAG GCC GAG CTC GCG CTG TCC GGG CGC ACC 51411
W A P G V E A L T H T L L S T A V N  219
TGG GCG CCC GGC GTG GAG GCG CTG ACC CAC ACG CTG CTT TCC ACC GCC GTT AAC 51465
N M M L R D R W S L V A E R R R Q A  237
AAC ATG ATG CTG CGG GAC CGC TGG AGC CTG GTG GCC GAG CGG CGG CGG CAG GCC 51519
G I A G H T Y L Q A S E K F K M W G  255
GGG ATC GCC GGA CAC ACC TAC CTC CAG GCG AGC GAA AAA TTC AAA ATG TGG GGG 51573
A E P V S A P A R G Y K N G A P E S  273
GCG GAG CCT GTT TCC GCG CCG GCG CGC GGG TAT AAG AAC GGG GCC CCG GAG TCC 51627
T D I P P G S I A A A P Q G D R C P  291
ACG GAC ATA CCG CCC GGC TCG ATC GCT GCC GCG CCG CAG GGT GAC CGG TGC CCA 51681
I V R Q R G V A L S P V L P P M N P  309
ATC GTC CGT CAG CGC GGG GTC GCC TTG TCC CCG GTA CTG CCC CCC ATG AAC CCC 51735
V P T S G T P A P A P P G D G S Y L  327
GTT CCG ACA TCG GGC ACC CCG GCC CCC GCG CCG CCC GGC GAC GGG AGC TAC CTG 51789
W I P A S H Y N Q L V A G H A A P Q  345
TGG ATC CCG GCC TCC CAT TAC AAC CAG CTC GTC GCC GGC CAT GCC GCG CCC CAA 51843
P Q P H S A F G F P A A A G S V A Y  363
CCC CAG CCG CAT TCC GCG TTT GGT TTC CCG GCT GCG GCG GGG TCC GTG GCC TAT 51897
G P H G A G L S Q H Y P P H V A H Q  381
GGG CCT CAC GGT GCG GGT CTT TCC CAG CAT TAC CCT CCC CAC GTC GCC CAT CAG 51951
Y P G V L F S G P S P L E A Q I A A  399
TAT CCC GGG GTG CTG TTC TCG GGA CCC AGC CCA CTC GAG GCG CAG ATA GCC GCG 52005
L V G A I A A D R Q A G G Q P A A G  417
TTG GTG GGG GCC ATA GCC GCG GAC CGC CAG GCG GGC GGT CAG CCG GCC GCG GGA 52059
D P G V R G S G K R R R Y E A G P S  435
GAC CCT GGG GTC CGG GGG TCG GGA AAG CGT CGC CGG TAC GAG GCG GGG CCG TCG 52113
E S Y C D Q D E P D A D Y P Y Y P G  453
GAG TCC TAC TGC GAC CAG GAC GAA CCG GAC GCG GAC TAC CCG TAC TAC CCC GGG 52167
E A R G A P  R G V D S  R R A A R H  S 471
GAG GCT CGA GGC GCG CCG CGC GGG GTC GAC TCC CGG CGC GCG GCC CGC CAT TCT 52221
P G T N E T I T A L M G A V T S L Q  489
CCC GGG ACC AAC GAG ACC ATC ACG GCG CTG ATG GGG GCG GTG ACG TCT CTG CAG 52275
BamHI e'o e l a h m r a r t s a p y g m y t  507
CAG GAA CTG GCG CAC ATG CGG GCT CGG ACC AGC GCC CCC TAT GGA ATG TAC ACG 52329
P V A H Y R P Q V G E P E P T T T H  525
CCG GTG GCG CAC TAT CGC CCT CAG GTG GGG GAG CCG GAA CCA ACA ACG ACC CAC 52383
P A L C P P E A V Y R P P P H S A P  543
CCG GCC CTT TGT CCC CCG GAG GCC GTG TAT CGC CCC CCA CCA CAC AGC GCC CCC 52437
Y G P P Q G P A S H A P T P P Y A P  561
TAC GGT CCT CCC CAG GGT CCG GCG TCC CAT GCC CCC ACT CCC CCG TAT GCC CCA 52491
A A C P P G P P P P P C P S T Q T R  579
GCT GCC TGC CCG CCA GGC CCG CCA CCG CCC CCA TGT CCT TCC ACC CAG ACG CGC 52545
A P L P T E P A F P P A A T G S Q P  597
GCC CCT CTA CCG ACG GAG CCC GCG TTC CCC CCC GCC GCC ACC GGA TCC CAA CCG 52599
E A S N A E A G A L V N A S S A A H  615
GAG GCA TCC AAC GCG GAG GCC GGG GCC CTT GTC AAC GCC AGC AGC GCA GCA CAC 52653
BamHI g' ,-------------------------------------
V D V D T t A R A A D L F V S O M M G  633
GTG GAC GTT GAC ACG GCC CGC GCC GCC GAT TTG TTC GTC TCT CAG ATG ATG GGG 52707
~~a1 R - 635
GCC CGC TGA TTCGCCCCGGTCTTTGGTACCATG 52761
Figure 33
Translation of gene UL26 (McGeoch etal., 1988). The (*) at 
residue 50897 denotes the position of the base pair alteration 
in tsl201. The (boxes) represent the amino acid sequence of the 
peptide synthesised and used for preparing antipeptides antibody, 
Below is a comparison between wt and tsl201 sequence and the 
change in the amino acid sequence (bold). The amino acid 
composition of UL26 is also given.
HSV-1 17syn+ seq. 5' GCCCTGTATGACAGC 3'
CGGGAGATACTGTCG
Tsl201 seq. 5' GCCCTGTTTGACAGC 3'
CGGGACAAAGTGTCG
Change in amino acid sequence:
Tyrosine < » Phenylalanine
U L 2 6  A M I N O  A C I D  C O M P O S I T I O N
Ala 102 16.1% Val 37 5.8% Leu 47 7.4% lie 16 2.5%
Gly 57 9.0% Pro 86 13.5% Cys 8 1.3% Met 11 1.7%
His 20 3.1% Phe 12 1.9% Tyr 23 3.6% Trp 4 0.6%
Asn 11 1.7% Gin 21 3.3% Ser 39 6.1% Thr 31 4.9%
Lys 5 0.8% Arg 46 7.2% Asp 28 4.4% Glu 31 4.9%
Approximate Molecular Weight = 66466.92
TABLE 12
Efficiency of plating (EOP1,PT/PT ) of HSV-1 syif , 
tsl201 rev2 and tsl201 rev3 at various NPT temperatures
eopN p T /p T 
Virus
NPT= 38.5° NPT= 39° NPT= 39.5°
HSV-1 17syn+ 0.64 0.33 0.31
tsl201 rev.2 0.61 0.01 <0.0002
tsl201 rev.3 0.73 0.09 0.06
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cloned into the Kpnl site of pUC18 (figure 34). Two 
chimeric plasmids, one containing Kpnl t of tsl201 rev2 
(referred to as pGX209) and ^ other containing tsl201 rev3 
(referred to as pGX210), were isolated. These clones were 
checked for the presence of various restriction 
endonuclease sites to confirm that the correct fragment had 
been cloned.
4.1.5 Marker rescue of the lesion of tsl201 with cloned
Kpnl t
Separated restriction endonuclease fragments were 
used in marker rescue experiments to determine the location 
of the reversion to wt virus temperature-sensitivity in 
tsl201 rev2 and rev3. Initially, plasmids pGX142 (contains 
wt virus Kpnl t), pGX209 (contains tsl201 rev2 Kpnl t) and 
pGX210 (contains tsl201 rev3 Kpnl t) were digested with 
Kpnl or BamHI and tested for their ability to marker rescue 
the lesion of fcsl201. A high level of rescue was obtained 
with all three plasmids digested with Kpnl. No significant 
level of rescue, however, was obtained with the Kpnl t of 
tsl201 rev2 clone, digested with BamHI (table 13). 
Separated fragments obtained from BamHI digests of cloned 
Kpnl t from pGX142, pGX209, and pGX210 were used in marker 
rescue experiments. The results revealed that the wt virus 
BamHI u fragment from pGX142 was able to rescue the lesion 
in fcsl201 as expected but, interestingly, wt virus BamHI d' 
also rescued the ts mutation albeit at a lower efficiency. 
Tsl201 rev2 BamHI u from pGX209 failed to rescue the 
lesion, which is consistent with previous findings showing
B a m H I  s i t e s - - - - - - - - - - - - - - - - - -
B a m H I  f r a g m e n t s  B a m H I  u B a m H I  c T B a m H I  e ’ j B a m H I  g
I?-Kpnl
p o l y l i n k e r  c l o n i n g  s i t e
Lac z
Lac i
Vector pUC18
Ori
Amp
pGX209 1S1201 Rev .2 
pGX210 ls1201 Rev.3
Figure 34
A diagram representing the Kpn t fragment containing the 
whole UL26 gene and part of UL25 of tsl201 rev2 and tsl201 
rev3 cloned into Kpnl site of pUC18. Four BamHI fragments 
are obtained with a BamHI digest. The BamHI fragments were 
used in marker rescue experiments.
TABLE 13
Summary of marker rescue of tsl201 with different 
Kpnl and BamHI fragments from cloned Kpnl t of wt, 
tsl201 rev2, and rev3 viruses
fragments obtained from 
HSV-1 cloned Kpnl t( * >
Efficiency of 
plating NPT/PT X103 Rescue
PGX142
(contains 17syn* Kpnl t) 
digested with Kpnl 30.00 +
BamHI u fragment 8.66 +
d ' 0.49 +
•• e H <0.02 -
.. g <0.02 -
pGX209 (contains tsl201 
revertant 2 Kpnl t) 
digested with Kpnl 40.00 +
digested with BamHI 0.63 +
BamHI u fragment <0.02 -
d' <0.02 -
" e ' " <0.02 -
g <0.02 -
pGX210 (contains tsl201 
revertant 3 Kpnl t) 
digested with Kpnl 70 . 0 0 +
BamHI u fragment <0 .02 -
.. d , 3.76 +
e' <0.02 -
g <0. 02 -
None <0. 02 -
(*) When clones are digested with BamHI, four fragments 
are obtained. The sequences of the vector are attached to
BamHI u and BamHI g.
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that the ts1201 lesion within BamHI u was retained in
tsl201 rev2 DNA (Sections 4.1.2; 4.2.3). It was also clear 
from marker rescue data that tsl201 rev3 DNA also retained 
fcsl201 mutation in BamHI u. The BamHI c?' fragment from 
pGX210 rescued tsl201, suggesting that the reversion event 
in fcsl201 rev3 mapped within BamHI d' (table 13) . None of 
BamHI fragments from Kpnl of tsl201 rev2 rescued the
mutation and, therefore, it is likely that the second site 
reversion lies close to a BamHI site in tsl201 rev2.
4.2 PROCESSING OF UL26 GENE PRODUCT
4.2.1 Isolation and detection of antibodies against UL26
gene products
In immunoblotting experiments, six UL26 gene 
product have been identified in HSV-1 infected cell 
extracts, using a monoclonal antibody specific to UL26 gene 
product (Braun et al. , 1984b). When HSV-1 infected cell
mRNA was translated in vitro, two specific gene products 
were detected in immunoprecipitation experiments using a 
monoclonal antibody to UL26 gene product. This result 
suggests that either there are two primary in vitro 
translational products of UL26 gene or there is some 
processing occurring in the in vitro translational assay. 
Analysis of the predicted sequence of UL26 gene has shown 
that there is a second potential AUG codon 27 residues from 
the first methionine amino acid and therefore, it is likely 
that there are two primary translational products 
(V. Preston, personal communication). When wt virus 
infected cells were pulse-labelled with [33S]-methionine,
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several gene products of higher apparant mw than in vitro 
translated products were made, suggesting that there is a 
rapid modification of the UL26 gene product. If the [33S]- 
methionine was removed from the medium and incubation of 
virus-infected cells continued for a further 4-5h, lower mw 
products were formed (Preston et al. , 1983). It has been
proposed that those low mw forms result from proteolytic 
cleavage (Gibson and Roizman, 1972; Braun et al. , 1984b).
In addition evidence from the work by Braun et al. (1984b) 
suggests that some of UL26 gene products are 
phosphorylated. It is clear that there is multiple 
processing of UL26 gene product (s). To confirm that there 
are two translation products and to investigate the 
processing of UL26 gene product, three synthetic 
oligopeptides, specific to different regions of/UL26 gene, 
were synthesised for the purpose of raising antibodies 
against these peptides. An oligopeptide representing the 
first 9 amino-acids, an oligopeptide representing the 
following 12 amino-acids from the amino-terminus and an 
oligopeptide representing 14 amino-acid from the carboxy- 
terminus were prepared (figure 33) . A tyrosine was added 
to the ends of the carboxy terminal peptide and to the end 
of the oligopeptides specific to the amino terminus to 
facilitate coupling to p-galactosidase. Interestingly, the 
two peptides which were made against the amino terminus 
dissolved easily in borate buffer in comparison to the 
carboxy terminus peptide which left traces of what appeared 
to be undissolved impurities, and since the amount of 
purity of this peptide was 66% as measured by the HPLC
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(Miss Ania Owsianka, personal communication), it was
decided to use twice the amount of the carboxy terminus
peptide. All three peptides were coupled to (S-
galactosidase, emulsified in adjuvent, and injected into 
rabbits (table 14) as described in section 2.12.1. Sera 
were collected before each injection and after the final 
injection. Antibodies specific to the injected peptides
were detected by radioimmunoassay. Figure 35 shows [123I] 
counts obtained from radioimmune assay using sera from 6 
rabbits injected with one of the three peptides. Preimmune 
sera gave background counts when compared to sera isolated 
from rabbits injected with peptides. Thus, it is clear 
that all the sera contained antibodies which recognised the 
antigen against which they were raised.
4.2.2 Detection of UL26 gene product by western blotting 
Virus-infected cell extracts, labelled with [33S]- 
methionine, were separated by SDS PAGE, and transferred to 
nitrocellulose strips (refer to section, 2.12.5). The 
strips were incubated in different dilutions of serum, 
washed, dried and autoradiographs prepared as described in 
section (2.12.6). Analysis of autoradiographs revealed the 
following: Sera from rabbits injected with the two
oligopeptides specific to the amino terminal end of UL26 
gene product gave too weak a reaction to be of any use, 
while sera from the two rabbits injected with carboxy- 
terminus oligopeptide reacted strongly with an HSV-1 11 syn* 
specific polypeptide band (figure 36) . No polypeptide of 
this mw was detected in radiolabelled mock-infected cell
TABLE 14
T h e  i n j e c t i o n  p r o t o c o l  o f  U L26 p e p t id e  c o u p le d  t o
p - g a la c t o s id a s e
Peptide
code
Peptide
representing
no.
of
injection
purity% peptide/ml
147
9 A.A from the 
First AUG
methionine 
at NH2 -terminus
5 86% 150pg
148
12 A.A from the 
second AUG 
methionine 
at NH2 -terminus
«t 89% 150pg
149
14 A.A from 
the
COOH-terminus vt 66% 300ug
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Figure 35
The graphs shows the results obtained from radio­
immunoassay experiment using sera from animals injected 
with either the first amino terminus (A and B) or second 
amino terminus (C and D) or the carboxy terminus (E and F) 
peptides coupled to 3-galactosidase. The pre-immune serum 
was the first bleed. Post immune bleeds were obtained 
prior to booster injection with the peptide.
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Figure 36
Immunoblots of HSV-infected cell polypeptides labelled with 
[39S]-methionine at 9hpi and harvested at 20hpi.
Polypeptides were separated on 12.5% polyacrylamide SDS gel 
and transferred to nitrocellulose strips. Different
dilutions were used (1: 1/10 and 2: 1/100) for each
antisera. Sera taken from six rabbits were tested as
described in sections 2.12.5 and 2.12.6. [128I]
autoradiographs were aligned with [39S]-methionine
autoradiographs.
Rabbits, 20995 and 20996, were injected with peptide 147
representing the first 9 amino acids at the amino terminus. 
Rabbits, 20997 and 20998, were injected with peptide 148
representing 12 amino acids from the amino terminus 
following peptide 147.
Rabbits, 20999 and 21000, were injected with peptide 149
representing the carboxy terminus. The strong bands in the 
[129I] track represent a specific reaction with a protein 
of 40,000mw.
154
extracts (figure 37). Sera taken from one rabbit at 
different time intervals after injection with the carboxy- 
terminus peptide were compared to the monoclonal antibody 
5010B, specific to p40. The results showed (figure 38) 
that antibodies in preimmune serum gave no specific 
reaction whereas all sera obtained after the first
injection contained antibodies which recognised a specific 
polypeptide band with a mw of approximately 40,000, similar 
to that detected by the monoclonal antibody. These
findings are also supported by the results obtained from 
radioimmune assay for the detection of antibodies after 
each injection (fig 35, E and F) . Thus, the polyclonal 
antibody against the carboxy-terminus of UL26 gene product 
appeared to be recognising UL26 gene products.
4.2.3 Evidence that the antibody is specific to UL26 gene
product (P40)
To confirm that the polyclonal antibodies, raised 
against the carboxy terminus of the predicted primary UL26 
gene product were reacting specifically with UL26 gene 
product, high concentrations of the carboxy terminus
peptide were included in the immune precipitation reaction. 
If the antipeptide antibody was recognising UL26 gene 
products then the peptide should competitively inhibit 
immunoprecipitation of UL26 gene products. When [33S]- 
methionine labelled virus-infected cell extracts were 
incubated with the antibody, a band of a around 40,000 mw 
was immuno-precipitated. The addition of lOpg of peptide 
to 50pl (106 cpm) of virus-infected cell extract caused a

Figure 37
Immunoblots of mock-infected cells treated as described in 
the legend to figure 36.
ft III »  M U M
Figure 38
Immunoblot experiment using antisera, taken at different 
time intervals after the initial injection with the carboxy 
terminal peptide 149, specific to p40. Mock-infected (MI) 
and 11 syn*-infected (17) cell polypeptides labelled with 
[3 9 S]-methionine , were separated on a 12.5% polyacrylamide 
SDS gel, transferred to nitocellulose strips and incubated 
either with a monoclonal antibody 5010B, specific to p40 or 
with anticarboxy terminus antisera. Tracks indicated by 
the arrows represent reaction of antisera, bound to [12SI] 
protein A, to p40. The remaining tracks show either mock- 
infected (MI), or 17syn*-infected cell polypeptide labelled 
with [39S]-methionine.
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reduction in the intensity of the immunoprecipitated 
polypeptide band detected on SDS polyacrylamide gel 
(figure 38), while the addition of lOOyg of peptide 
completely inhibited immunoprecipitation of 40,000 mw 
polypeptide by the antipeptide antibody (figure 39) . 
Therefore, it was concluded that the antibodies raised 
against the carboxy-terminus were specific for UL26 gene 
product.
4.2.4 UL26 gene product is processed at the carboxy
terminus
To investigate whether the UL26 gene product is
processed at the carboxy-terminus, wt virus- and fcsl201
virus-infected cells, grown at the NPT or PT, were labelled
with [38S]-methionine for 15 min at 5hpi and either
harvested or incubated for a further 5h in culture medium
lacking [38S]-methionine prior to harvesting. Cell
extracts were prepared and incubated either with monoclonal
antibody (ma) specific for p40 (5010B) or with polyclonal
antibody directed against the carboxy-terminus of p40.
Antibody-antigen complexes were bound to protein A
sepharose, washed, eluted and analysed by SDS PAGE.
and 41
Autoradiographs of immune precipitates (figure 4(r) revealed 
that in the 31° and 39° pulse-labelled virus-infected cell 
extracts, the polyclonal antibody recognised similar high 
mw species of UL26 gene product to those immuno- 
precipitated by ma5010B. In the 31° virus-infected cell 
samples, which had been incubated for 5h after being 
labelled with [38S]-methionine, the polyclonal antibody
Pre-immune Post-immune
i--------- 1-i--------------1
17syn+
Ml 0 10ug 100ug
Figure 39
Immunoprecipitation with an antipeptide antisera. Proteins 
labelled with [35S]-methionine were precipitated from MI 
(lane 1) and HSV-1 infected cell extracts with either 
preimmune (lane 2) or post-immune sera (lane 3-5). Anti 
carboxy terminus serum was incubated in the presence of 0, 
lOug and lOOug of peptide 149 (lane 3-5). Arrows represent 
p40. Dotted arrow indicates break down products of p40.
chase
Figure 40
Autoradipgraph of immuneprecipitates of p40 from BHK 
infected at the 31° with wt virus (track 4, 7, 8, 10f 13 
and 14), or tsl201 (track 5, 6, 11, 12). Virus-infected or 
mock- infected cells were pulse-labelled at 6hpi with 
[3sS]-methionine and either harvested immediately (pulse) 
or after incubation for a further 5h in EFCi o (chase). 
Immunoprecipitation was performed as described insection
2.11.2 using a ma5010B, specific to p40 (tracks 6, 8, 12, 
14) or with an antipeptide antibody against the carboxy 
terminus (tracks 5, 7, 11, 13). Mock-infected cell
extracts (tracks 3 and 9) and wt-infected cell extracts 
(tracks 4 and 10) were incubated with control non-immune 
rabbit serum instead of the antisera. Tracks 1 and 2 
represents whole cell extracts of mock-infected cells and
11syn*-infected cells, respectively. The polypeptides were
analysed on a 8% polyacrylamide SDS gel.
Solid arrows represent high mw forms of p40.
dotted arrows " low " " " " .
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failed to recognise the low mw processed forms of UL26 gene
(fig 40) (fig 41) 
product detected by ma5010B^ At 39°/tsl201 is unable to
process the UL26 gene product to its lower mw forms
(Preston et al. , 1983) and therefore, only the high mw
species of UL26 gene product were detected by ma5010B in
the 39° tsl201-infected cell sample incubated for 5h at 39°
after removal of [33S]-methionine. The same high mw forms
were detected by the polyclonal anti-oligopeptide antibody
in this extract and in wt virus infected cells treated in
the same manner, whereas both high and low mw species in
wt-virus infected cell sample were recognised by ma5010B
(figure 41) . Information from this experiment suggests
that UL26 gene product is processed at the carboxy-terminus
and that this step results in the formation of lower mw
forms. Ibl201 clearly has a block in processing at the
carboxy terminus of UL26 gene product.
chase
Figure 41
Autoradiograph of immuneprecipitates of p40 from BHK 
infected at the 39° with wt virus (track 4, 7, 8 r 10, 13 
and 14), or tsl201 (track 5, 6, 11, 12). Virus-infected or 
mock- infected cells were pulse-labelled at 6hpi with 
[38S]-methionine and either harvested immediately (pulse) 
or after incubation for a further 5h in EFCi o (chase). 
Immunoprecipitation was performed as described insection
2.11.2 using a ma5010B, specific to p40 (tracks 6, 8, 12, 
14) or with an antipeptide antibody against the carboxy 
terminus (tracks 5, 7, 11, 13). Mock-infected cell
extracts (tracks 3 and 9) and wt-infected cell extracts 
(tracks 4 and 10) were incubated with control non-immune 
.rabbit serum instead of the antisera. Tracks 1 and 2 
represents whole cell extracts of mock-infected cells and 
11 syn*-infected cells, respectively. The polypeptides were 
analysed on a 8% polyacrylamide SDS gel.
Solid arrows represent high mw forms of p40. 
dotted arrows " low " " " " .
157
4.3 DISCUSSION
In this study the UL26 gene has been further
characterised together with the HSV-1 mutant tsl201. 
Sequence analysis of the lesion of fcsl201 confirmed that 
the mutation mapped in gene UL26. Interestingly, both ts* 
revertants analysed retained the tsl201 mutation, although
they had an eopNpT ipT similar to that of wt virus T of
38.5° . At 39° or 39.5° , however, these revertants showed 
some imprairment of growth. Experiments with anti­
oligopeptide antibodies, specific to UL26 carboxy-terminus, 
showed that the UL26 gene product undergoes processing at 
the carboxy terminus.
Map location of tsl201 lesion
Previous work located the tsl201 lesion to within a 
673bp BamHI-Sall fragment at the right hand end of BamHI u 
(Preston et al., 1983). This result has been confirmed
during this study by sequencing the corresponding fragment
from tsl201. The mutation was located 89bp downstream from 
the first AUG initiation codon at residue 50897. The
change in the nucleotide sequence results in the
substitution of a tyrosine fey phenylalanine at position 30 
from the first methionine amino acid in gene UL26. The
nucleotide sequence of tsl201 rev2 was identical to that of 
tsl201 in this region. Marker rescue data showed that 
tsl201 rev3 also retained the tsl201 mutation. It was
clear both from the temperature-sensitivity of tsl201 rev2 
and tsl201 rev3 at 39° and 39.5° , and from the results of
marker rescue experiments that these viruses had second
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site reversions in different places within / UL26 gene. 
Interestingly, a low level of rescue of tsl201 lesion was 
obtained when wt virus BamHI d' fragment was used in marker 
rescue experiments. This result suggested that tsl201 may 
also have a mutation within BamHI d'. Since this work was 
done, cloned BamHI u and two independent BamHI d' clones 
from wt virus were screened for the ability to rescue the 
tsl201 lesion. Cells transfected with tsl201 and BamHI u 
yielded progeny virus with a high proportion of ts* virus, 
whereas cells transfected with the mutant and either of the 
BamHI d' clones gave progeny virus with a relatively low 
proportion of ts* virus. The resulting ts* progeny were 
analysed for temperature-sensitivity at 38.5° and 39.5°. 
Surprisingly, all the ts* virus formed plaques at 39.5° as 
efficiently as wt virus (V. Preston, personal 
communication). This result indicates that tsl201 probably 
has a single ts mutation but it will be necessary to 
sequence the entire UL26 gene of the mutant to confirm 
this.
The nature of tsl201 mutation
The mutant, fcsl201 (Preston et al., 1983), was 
derived from the multiple mutant 1 7 tsJC116 (Coates, 1982) 
which was isolated from a UV-mutagenised wt HSV-1 17syn. 
As indicated in this study the transversion occurred at a 
single pyrimidine (thymine on the complementary strand) 
(figure. 33). Studies on the mechanism of UV-induced 
mutations in E.coli lacl gene has shown that one third of 
the mutations occured at single pyrimidines, and their
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origin cannot be explained by a targeted event at a
cyclobutane dimer or a [6-4] dipyrimidine photoproduct.
These mutations therefore could have resulted from other,
less frequent, photodamages (Schaaper et al., 1987). The
tsl201 mutation could also havearisen asaconsequence of a
similar untargeted event, and in this respect, differs from 
%e.
^tsl233 mutation (chapter 3) which can be explained on the
basis of a targeted photodamage event occuring at a purine-
■ttie
pyrimidine-pyrimidine. It is possible that/tsl201 mutation 
could have arisen in 17 tsJC116 virus as a consequence of 
errors during excision-repair.
The effect of tsl201 mutation on protein conformation
The Chou and Fasman computer program (Chou and 
Fasman, 1978) was used to determine whether the mutation in 
tsl201 affected the secondary structure of gene UL26. 
Interestingly, the the mutation in UL26 is located in a 
region predicted to form a p-sheet (figure 42, 43) . The
mutation induces a turn in the protein. Such an effect on 
the protein struc ture might result in a thermolabile 
protein.
Use of polyclonal antibodies specific to UL26 gene product 
As mentioned earlier in section (4.2.1), three 
peptides were selected from different regions of UL26 to 
raise oligopeptide antibodies. Although the antisera 
isolated from rabbits all contained antipeptide antibodies. 
Only the oligopeptide antibodies specific to the carboxy 
terminus gave a strong specific reaction with p40. One
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Figure 42
Predicted secondary structure of UL26 protein.
The structure is based on Chou and Fasman computer 
programme which predicts helices, sheets and turns 
according to Chou and Fasman (1978). (see figure 29)

Figure 43
Predicted secondary structure of tsl201 UL26 protein.
The structure is based on Chou and Fasman computer 
programme which predicts helices, sheets and turns 
according to Chou and Fasman (1978) . (see figure 29) .
The position of the mutation within the secondary structure 
is indicated by an arrow.
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reason both peptides directed against the amino terminus
did not show a strong specific reaction to p40 is that the
length of the two peptides (9 and 12 amino acids) was not 
long enough to induce antibodies that react with UL26 gene 
product.
Processing of UL26 gene product
Previous work by Braun et al. (1984b) has 
demonstrated that the UL26 gene product (ICP35 or p40) 
consists of a family of polypeptides with a mw ranging 
between 39,000 to 55,000. Cell fractionation experiments 
suggested that higher mw forms are cytoplasmic precursors 
of the nuclear forms of the protein. Work on tsl201, 
however, has shown that in fact all forms of UL26 gene 
product are present in the nucleus (Rixon et al., 1988).
In immunoprecipitation experiments using a polyclonal 
antibody raised against the carboxy terminus of UL26 gene 
product, the antisera only recognized the high mw forms of 
UL26 gene product in virus-infected cells in contrast to 
the monoclonal antibody 5010B, which recognised all forms 
of UL26 gene product. This result demonstrates that the 
low mw forms are produced by a processing step at the 
carboxy terminus. Recently it has been shown that the 
mature lower mw forms of the homologous protein, known as
the assembly protein, in CMV are produced by proteolytic
cleavage at the carboxy terminal end of the protein. The 
precursor contained a single cysteine residue, 32 amino 
acid residues from the carboxy terminus of the assembly 
protein, while the mature form did not contain the cysteine
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(Robson and Gibson, 1989). This suggests that 32 or more 
amino acids are removed from the carboxy terminus. It is 
likely on the basis of work on CMV, that the processing at 
the carboxy terminus of UL26 gene protein is proteolytic 
cleavage. It is not known whether a separate 
endoproteinase is required for cleavage of UL26 gene 
product as is the case for cleavage of structural proteins
in adenovirus (G.Kemp, p.c., in press), or whether the UL26
gene product itself is responsible for this step. It is 
interesting to note that the lesion in fcsl201 is located 
within the amino terminal end of the protein yet clearly 
has an effect on processing at the carboxy terminus. 
Certain glycoproteins in HSV including gD and gG have been 
shown to undergo proteolytic cleavage at the amino 
terminus. Removal of the signal peptide is important for 
transfer of the glycoprotein through the membrane 
(Eisenberg et al., 1984; Balachandran and Hutt-Fletcher,
1985). To date, there is no evidence that any structural 
protein other than UL26 gene product is cleaved.
Comparison of UL26 gene product with homologues of EBV, VZV
and CMV
The bestfit computer programme was used to compare
the amino acid sequence of UL26 gene with the amino acid
sequence of the homologous proteins of EBV, VZV and CMV.
The results showed that the HSV protein is more related to
the VZV and EBV homologues than to the assembly protein
(table 15) . Interestingly, the HSV UL26 gene product had
ike
more amino acids in common with^VZV homologue than i EBV
XTABLE 15
Comparison between UL26 gene and the counterpart 
genes in other viruses based on bestfit computer program
Virus HSV-1 EBV VZV CMV
gene UL26 Bvrf2.EBV 33.VZV APcDNA-1
no. of A.A. 635 605 605 310
%Similarity
HSV-1 / 39.69 52.79 32.48
EBV / 35.38 33.98
VZV / 33.22
CMV /
A.A. : amino acid
APcDNA-1 : assembly protein (Robson and Gibson, 1989)
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counterpart protein. One striking difference between HSV,
EBV, VZV and CMV proteins is that the CMV protein is almost
half the size of the HSV, EBV and VZV proteins and the best
matched sequences of CMV assembly protein are predominantly
in the carboxy-terminal portion of the protein (data at the 
end of the thesis 
X  ). It is interesting to note that the cysteine at
position 134 in the UL26 amino acid is conserved between
HSV-1, EBV, and VZV. Whether this amino acid is of any
functional significance, remains to be determined.
Functional role of UL26 gene products
The processing of UL26 gene product has been linked 
to DNA encapsidation (Preston et al. , 1983). However, it
is not known exactly how this protein is involved in this 
process. Contradictory results have been obtained 
regarding the association of the gene products with the 
capsids depending on the techniques used. From the 
analysis of purified capsids, it was suggested that UL26 
gene products were associated with full capsids but not 
empty (Gibson and Roizman, 1972; 1974) , and results of
surface iodination experiments suggested that the presence 
of the processed form of ICP35 on the surface of full 
capsids prevented the iodination of the major capsid 
protein (Braun et al. , 1984b). However, recent studies
using immuno-electron microscopy clearly showed that UL26 
gene products are transiently associated with partially 
cored capsids but not full capsids (Rixon et al. , 1988;
Sherman and Bachenheimer, 1988). In support of these
results are findings obtained by Newcomb et al. (1989)
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using scanning transmission electron microscopy to measure 
the masses of light and intermediate capsids of equine 
herpes virus 1. Their results suggested that a 46,000 mw 
protein was present in intermediate capsids and not empty 
capsids. Recently, a new technique known as the Ar+ plasma 
etching technique has been used to locate UL26 gene product 
within capsids. Intact capsids are exposed to low energy 
which degrades the outermost polypeptide before the 
internal ones (Newcomb and Brown, 1989). The results 
suggested that UL26 gene product was localised inside the 
capsid cavity in partially-cored HSV-1 capsids and not on 
the outside. It would be interesting to expose capsids 
produced at the NPT by the mutant fcsl201 to low energy to 
determine the exact location of unprocessed forms of UL26 
gene products.
4.4 Future prospects
The UL26 gene product of tsl201 and tsl201 rev2 and 
rev3 have been cloned. It would be interesting to 
determine the second site reversions in the revertant 
viruses UL26 genes and to investigate by sequence analysis 
whether tsl201 has any mutations in the region of UL26 gene 
encoded within BamHI d'. Since tsl201 rev2 is ts at 39.5° , 
it would also be interesting to determine whether the virus 
processes UL26 gene products normally at 39.5° and whether 
it has an encapsidation defect like fcsl201.
It is unclear from the literature whether UL26 gene 
products are DNA binding. It would be interesting to find 
out whether the products of UL26 have the ability to bind
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DNA or interact with other structural proteins.
Evidence that there are two primary translational 
products has been obtained from the analysis of in vitro 
transitional products. Further studies are required to 
show that these primary translational products exist and to 
determine whether they are both functional.
Although work in this thesis has clearly shown that 
the UL26 gene product undergoes processing at the carboxy 
terminus, it remains to be determined that this 
modification is proteolytic cleavage.
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408 R Q A G G Q P A A G D P G V R G S G K R R R Y E A G P S E S Y C D Q D E P D A D Y P Y Y P G E A R G  457 
I I I  I I I  I I I I  I I  I I I I I I I I I
388....................P P P P V P P Y Y G S H L R A D Y V P A P S R S N K R K R D P E E D  E E G G G  426
458 APRGVDSRRAARHSPGTNETITALMGAVTSLQQELAHMRARTSAPYGMYT 507 
I I  I I I  I I I I I I I
427 LFPGEDATLYRKDIAGLSKSVNELQHTLQALRRETLSYGHTGVGYCPQQG 47 6
508 P V A H Y R P Q V G E P E P T T T H P A L C P P E A V Y R P P P H S A P Y G P P Q G P A S H A P T P  557
I I I I I I I I I I I I I I I I  I I
477 P C Y T H S G P Y G F Q P H Q S Y E V P R Y V P H P P P P P T S H Q A A Q A Q P P P P G T Q A P E A  52 6 
558 P Y A P A A C P P G P P P P P C P S T Q T R A P L P T E P A F P P A A T G S Q P E A S N A E A G A L  607
I I  I I I I I I I I I  I I I I
527 H C V A E S T I P E A G A A G . N S G P R E D T N P Q Q P T T E G H H R G K K L V Q A S A S G V A Q  575 
608 V N A S S A A H V D V D T A R A A D L F V S Q M M G A R  635
I I I  I I I I I I
57 6 SKEPTTPKAKSVSAHLKSIFCEELLNKR 603
B E S T F IT  o f :  U L 2  6 X 3 3 . V Z V
gap Weight: 5.000
Length Weight: 0.300
Percent Similarity: 52.7 97
9 RMEEPLPDRAVPIYVAGFLALYDSGDSGELALDPDTVRAALPPDNPLPIN 58 
I I  I I I I I I I I I I I I  I I I I  I I I I  I I I I  I I I I I I  
1 MAAEADEENCEALYVAGYLALY.SKDEGELNITPEIVRSALPPTSKIPIN 49
59 VDHRAGCEVGRVLAWDDPRGPFFVGLIACVQLERVLETAASAAIFERRG 108 
I I I I I I I I I I  I I I I I I I I I I  I I  I I I I I I I  I I  l l l l l .
50 IDHRKDCWGEVIAIIEDIRGPFFLGIVRCPQLHAVLFEAAHSNFFGNRD 99
109 PPLSREERLLYLITNYLPSVSLATKRLGGEAHPDRTLFAHVALCAIGRRL 158 
I I  I I I I  I I  I I  I I  I I I  I I  I I  I I  I I I  I I I I I I I I I I I I 
100 SVLSPLERALYLVTNYLPSVSLSSKRLSPNEIPDGNFFTHVALCWGRRV 149
159 GTIVTYDTGLDAAIAPFRHLSPASREGARRLAAEAELALSGRTWAPGVEA 208 
I I I  I I I I I I I I I I I I  I I I  I I  I I  I I
150 GTWNYDCTPESSIEPFRVLSMESK..ARLLSLVKDYAGLNKVWKVSEDK 197
20 9 LTHTLLSTAVNNMMLRDRWSLVAERRRQAGIAGHTYLQASEKFKMWGAEP 258
I I I I I I I I II I I I I I I III I I I I I I I II lllll I I
198 LAKVLLSTAVNNMLLRDRWDWAKRRREAGIMGHVYLQASTGYGLARITN 2 47
259 VSAPARGYKNGAPESTDIPPG....... SIAAAPQGDRCPIVRQRGVAL 300
II III III III II I I I  I
248 VNGVESKLPNAGVINATFHPGGPIYDLALGVGESNEDCEKTVPHLKVTQL 297
301 S P V L P P M N P V P T  S G T P A P A P P G D G S Y L W IP A S H Y N Q L V A G H A A P Q  345
I I I I  I I I I I I I  I I I I I I I I I  I I
2 98 CRNDSDMASVAGNASNISPQPPSGVPTGGEFVLIPTAYYSQLLTGQTKNP 347
346 P Q P H S A F G F P A A A G S V A Y G P H G A G L S Q H Y ....................P P H V A H Q Y P G V L F S G  389
II I I I I I I I I I I I I I
348 QVSIGAPNNGQYIVGPYGSPHPPAFPPNTGGYGCPPGHFGGPYGFPGYPP 397
390 PSPLEAQIAALVGAIAADRQAGGQPA....AGDPGVRGSGKRRRYEAGPS 435 
I I I I I I I I I I I I I I I I I  I I  I I I  I I I  I
398 PNRLEMQMSAFMNALAAERGIDLQTPCVNFPDKTDVRRPGKRDFKSMDQR 447
436 E...SYCDQDEPDADYP...YYPGEA...RGAPRGVDSRRAARHSPGTNE 476 
I I I I I  I I I I I I I I I I I I I I  I I  I I
448 ELDSFYSGESQMDGEFPSNIYFPGEPTYITHRRRRVSPSYWQRRHRVSNG 497
477 TITALMGAVTSLQQELAHMRARTSAPYGMYTPVAHYRPQVGEPEPTTTHP 526
I I I  l l l l l  I I  I I
498 QHEELAGWAKLQQEVTELKSQNGTQMPL.....................  52 6
527 ALCPPEAVYRPPPHSAPYGPPQGPASHAPTPPYAPAACPPGPPPPPCPST 57 6
I I
527 ............................... SHHTNIPEGTRDPRISILL 545
577 QTRAPLPTEPAFPPAATGSQPEASNAEAGALVNASSAAHVDVDTARAADL 62 6 
I I I  I I I  I I I I I I I I I I
546 KQLQSVSGLCSSQNTTSTPHTDTVGQDVNAVEASSKAPLIQGSTADDADM 595
627 FVSQMMGAR 635 
I l l l l l  
596 FANQMMVGR 604
B E S T F IT  o f : 3 3  . V z v  X B v r f  2  . E B V
G a p  W e i g h t :  5.000
L e n g t h  W e i g h t :  0.300
P e r c e n t  S i m i l a r i t y :  35.385
9 NCEALYVAGYL..ALYSKDEGELNITPEIVRSALPPTSKIPINIDHRKDC 5 6 
I II I I I I I I I I I I l l l l l  I II I I I I
3 QAPSVYVCGFVERPDAPPKDACLHLDPLTVKSQLPLKKPLPLTVEHLPDA 52 
57 WGEVIAIIEDIRGPFFLGIVRCPQLHAVLFEAAHSNFFGNRDSVLSPLE 10 6
I I I I I I I I I  l l l l l  II I II I I  I I
53 PVGSVFGLYQSRAGLFSAASITSGDFLSLLDSIYHDCDIAQSQRLPLPRE 102 
107 RALYLVTNYLPSVSLSSKRLSPNEIPDGN . . . . FFTHVALCWGRRVGTV 152
I I I I I I I  I I  I I I I I I I I I I I I I I I I
103 P K V E A L H A W L P S L S L A S L H P D IP Q T T A D G G K L S F F D H V S IC A L G R R R G T T  152
153 VNYDCTPESSIEPFRVLSMESKARLLSLVKDYAGLNKVWKVSEDKLAKVL 202
II I I I  II I I I
153 A V Y G T D L A W V L K H F S D L E P S IA A Q IE N D A N A A K R E S G C P E D H P L P L T K . L  201
203 LSTAVNNMLLRDRWDVVAKRRREAGIMGHVYLQASTGYGLARITNV.... 248 
I I I I  I I I I I I I I I I I  I I I I I I I I 
202 IAKAIDAGFLRNRVETLRQDRGVANIPAESYLKASDAPDLQKPDKALQSP 251
249 ....NGVESKLPNAGVINATFHPGGPIYDLALGVGESNEDCEKTVPHLKV 294 
I I I I I I I I I I I II
252 PPASTDPATMLSGNAGEGATACGGSAAAGQDLISVPRNTFMTLLQTNLDN 301
295 T Q L C R N D S D M A S V A G N A S N IS P Q P P S G V P T G G E F V L IP T A Y Y . . . S Q L L T  341 
I II I I  I I I I I I I I I
302 K P P R Q T P L P Y A A P L P P F S H Q A IA T A P S Y G P G A G A V A P A G G Y F T S P G G Y Y A  351
342 G Q T K N P Q V S IG A P N N G Q Y IV G P Y G S P H P P A F P P N T G G Y G C P P G H F G G P Y G  3 91 
I I I I  I I I I I I  I I II I
352 G P A G G D P G A F L A M D A H T Y H P H P H P P P A Y F G L P G L F G P P P P V P P Y Y G S H L R  401
392 F P G Y P P P N R L E M Q M S A F M N A L A A E R G ID L Q T P C V N F P D K T D V R R P G K R D F  4 41 
l l l l l  I I I I I I I I I I I
402 A D Y V P A P S R S N K R K R D P E E D E E G G G L F P G E D A T L Y R K D IA G L S K S V N E L Q  451
442 K S M D Q R E L D S F Y S G E S Q M D G E F P S N IY F P G E P T Y IT H R R R R V S P S Y W Q R R  4 91 
II I I I  II I I I I I I l l l l l
452 H T L Q A L R R E T L S Y G H T G V G ........................Y C P Q Q G P C Y T H S . . . . G P Y G F Q P H  490
492 H R V S N G Q H E E L A G W A K L Q Q E V T E L K S Q N G T Q M P L S H H T N IP E G T R D P R I  541
I I I I I I II I I
491 QSYEVPRYVPHPPPPPTSHQAAQAQPPPPGTQAPEAHCVAESTIPEAGAA 5 40
542 SILLKQLQSVSGLCSSQNTTSTPHTDTVGQDVNAVEASSKAPLIQGSTAD 5 91
I I  I I I  I I I
541 GNSGPREDTNPQQPTTEGHHRGKKLVQASASGVAQSKEPTTPKAKSVSAH 5 90
592 DADMFANQMMVGRC 605 
I I I I I I I 
591 LKSIFCEELLNKRV 604
B E S T F IT  o f :  U L 2  6 X CMV ( A P c D N A - 1 )
Gap Weight: 5.000
Length Weight: 0.300
Percent Similarity: 32.468
316 PAPAPPGDGSYLWIPASHYNQLVAGHAAPQPQPHSAFGFPAAAGSVAYGP 365 
I I  I I I I I l l l l l  I I I I
2 SHPMSAVATPAAS TVAP SQAP LALAHDGVYLPKDAFF SLIGASRP LAEAA 51
366 H G A G L S Q H Y P P H V A H Q Y P G V L F S G P S P L E A Q IA A L V G A IA A D R Q A G G Q P A  415
I I  I I I I I  I I I I  I I I I I I I I  I I
52 GARAAYPAVPPPPA..YPVMNYEDPSSRHFDYSAWLRRPAYDAVPPLPPP 99
416 A G D P G V R G S G K R R R Y E A G P S E S Y C D Q D E P D A D Y P Y Y P G E A R G A P R G V D S R  465 
I I I  I I I  I I I  I l l l l l  I 
100 P V M P . M P Y R R R D P M M E E A E R A A W E R G Y A P S A Y D H Y V N N G S W S R S R S G A L K  148
4 66 R A A R H S P G T N E T IT A L M G A V T S LQQE LA H M R A R T S A P Y G M Y T P V A H Y R PQ 515
I l l l l l  I I  I I I I I I I
149 RRRERDASSDEEEDMSFPGEADHGKARKRLKAHHGRDNNNSGSDAKGDRY 198
516 VGEPEPTTTHPALCPPEAVYRPPPHSAPYGPPQGPASHAPTPPYAPAACP 565
I I I  I I I I I I I I I I I I
199 DDIREALQELKREMLAVRQIAPRALLAPAQLATPVASPTTTTSHQAEASE 2 48
5 66 P G P P P P P C P S T Q T R A P L P T E P A F P P A A T G S Q P E A S N A E A G A L V N A S S A A H  615
I I II I I I I l l l l l  I
2 49 P Q A S T A A A A S P S T A S S H G S K S A E R G W N A S C R V A P P L E A V N P P K D M V D L N  2 98
616 VDVDTARAADL 626 
I I I 
2 99 RRLFVAALNKM 30 9
B E S T F I T  o f : CMV (APcDNA-1) XBvrf2.EBV
Gap Weight: 5.000
Length Weight: 0.300
Percent Similarity: 33.981
1 MSHPMSAVATPAAS TVAP SQAP LALAHDGVYL......... PKDAFFSL 40
II I l l l l l  I I I I l l l l l  I I I  I
2 62 LSGNAGEGATACGGSAAAGQDLISVPRNTFMTLLQTNLDNKPPRQTPLPY 311
41 IGASRPLAEAAGARAAYPAVPPPPAYPVMNYEDPSSRHFDYSAWLRRPAY 90 
I I I I I I II I I I I I I I  I II
312 AAPLPPFSHQAIATAPSYGPGAGAVAPAGGYFTSPGGYYAGPAGGDPGAF 361
91 D A V P P L P P P P V M P M P Y R R R D P M M E E A E R A A W E R G Y A P S A Y D H Y V N N G S W S  140 
I I I  I I I I I I  I I  I I  I I I
3 62 LAMDAHTYHPHPHPPPAYFGLPGLFGPPPPVPPYYGSHLRADYVPAPSRS 411
141 RSRSGALKRRRERDASSDEEEDMSFPGE . ADHGKARKRLK.........  17 9
I I I I  I I I  I I I I I I I
412 N K R K R D P E E D E E G G G L F P G E D A T L Y R K D IA G L S K S V N E L Q H T L Q A L R R E T  4 61 
180 ...A H H G R D N N N S G S D A K G D R Y D D IR E A L Q E L K R E M L A V R Q IA P R A L L A P  22 6
I I I I I I I I  I I I  I
4 62 L S Y G H T G V G Y C P Q Q G P C Y T H S G P Y G F Q P H Q S Y E V P R Y V P H P P P P P T S H Q A  511
227 A Q L A T P V A S P T T T T S H Q A E A S E P Q A S T A A A A S P S T A S S H G S K S A E R G W N  27 6 
l l l l l  I I I II I I I
512 A Q A Q P P P P G T Q A P E A H C V A E S T IP E A G A A G N S G P R E D T N P Q Q P T T E G H H R  561
2 77 ASCRVAPPLEAVNPPKDMVDLNRRLFVAALNKM 30 9 
I I I  II II I I I I
5 62 GKKLVQASASGVAQSKEPTTPKAKSVSAHLKSI 594
BESTFIT of: 3 3 . V z v  X CMV ( A P c D N A - 1 )
Gap Weight: 5.000
Length Weight: 0.300
Percent Similarity: 33.221
2 99 RNDSDMASVAGNASNISPQPPSGVPTGGEFVLIPTAYYSQLLTGQTKNPQ 348 
I l l l l l  I I I  I I I I I I I
1 M S H P M S A V A T P A A S T V A P S Q A P L A L A H D G V Y L P K D A F F S . . L I G A S R P L A  48
349 V S IG A P N N G Q Y IV G P Y G S P H P P A F P P N T G G Y G C P P G H F G G P Y . G F P G Y P P  397 
II I I I I I I I I I I I I I I I
49 E A A G A R A A Y P A V P P P P A Y P V M N Y E D P S S R H F D Y S A W L R R P A Y D A V P P L P P  98
398 P N R L E M Q M S A F M N A L A A E R G ID L Q T P C V N F P D K T D V R R P G K R D F K S M D Q R  447 
I I I  I I I  I I I I  I I I
99 P P V M P M P Y R R R D P M M E E A E R A A W E R G Y A P S A Y D H Y V N N G S W S R S R S G A L K  14 8
448 E L D S F Y S G E S Q M D G E F P S N IY F P G E P T Y IT H R R R R V S P S Y W Q R R H R V S N G  497 
I I  I I  I I I I  I I I  I I  I I I  I I I I
149 R  R R E R D A S S D E E E D M S F P G E A D H G K A R K R L K A H H G R D N N N S G S D A  193
4 98 Q H E E L A G W A K L Q Q E V T E L  K S Q N G T Q M P L S H H T N IP E G T R D P R IS  542
I I I  I I I  I I  I I I I I I
194 K G D R Y D D IR E A L Q E L K R E M L A V R Q IA P R A L L A P A Q L A T P V A S P T T T T S H Q  243 
543 IL L K Q L Q S V S G L C S S Q N T T S T P H T D T V G Q D V N A V E A S S K A P L IQ G S T A D D  592
I I  I I I I  I I I  I I I  I I
244 AEASEPQASTAAAASPSTASSHGSKSAERGWNASCRVAPPLEAVNPPKD 293
593 ADMFANQMMVG 603 
I I I I I 
2 94 MVDLNRRLFVA 304
